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Colorectal adenocarcinoma is the third most common cancer and the fourth most fre-
quent cause of death due to cancer worldwide. Yearly almost one million new cases 
occur global, with 492000 related deaths.[1] In developed countries it is the second 
most common tumour, with a lifetime risk of 5%, but its incidence and mortality are 
currently decreasing.[2;3] Surgery is the cornerstone of therapy when the disease is 
confi ned to the bowel wall. This results in 70 to 80% of patients who can be resected 
with curative intent.[4] After curative surgery the fi ve-year survival rate for patients 
with localised disease is 90%, decreasing to 65% in case of metastised disease in the 
lymph nodes. Adjuvant radiation therapy, chemotherapy, or both are benefi cial in 
selected patients. For colorectal cancer the TNM staging system remains the gold 
standard for prognostication of the disease relying entirely on morphological and 
histopathological appearance of the tumour. Classifi cation of tumours into these 
TNM stages with distinct clinical courses enables clinicians to defi ne treatment. How-
ever, tumours with similar histopathological characteristics may have different clini-
cal outcome and responsiveness to therapy.[5] Therefore, a detailed diagnosis would 
allow a more individualised treatment that may avoid unnecessary morbidity and 
increase survival. Despite these optimised treatment strategies for colorectal cancer 
patients, early detection of colorectal cancer will increase survival most. Colorectal 
cancer is optimal to employ early detection, as precancerous and early cancerous 
lesions are well defi ned in a multistep sequence of genetic alterations that result in 
the transformation of normal mucosa to a precursor adenoma and ultimately to car-
cinoma. Thus, given the natural history of the malignancy, early diagnosis appears to 
be the most appropriate tool to reduce disease-related mortality.[6-8]
BIOMARKERS IN COLORECTAL CANCER
Biomarkers are molecules that indicate the presence of cancer in the body. Most 
biomarkers are based on abnormal presence, absence or alterations in genes, RNA, 
proteins and metabolites. Since the molecular changes that occur during tumour de-
velopment can take place over a number of years, some biomarkers may be used to 
detect colorectal cancer early. Furthermore, they might be used to predict prognosis, 
monitor disease progression and therapeutic response. Gion et al. classifi ed different 
circulating biomarkers according to their clinical application.[9] These candidate bio-
markers however, are frequently found in relatively low concentrations amid a sea 
of other biomolecules, so biomarker research and possible diagnostic tests depend 






ments. Ideally, biomarkers should be specifi c for the disease and easy accessible, 
such as serum, plasma or urine, to increase their clinical applicability.
Carcinoembryonic antigen (CEA) is the best-characterised serologic tumour marker 
for monitoring colorectal cancer. However, its use as a population based screening 
tool for early detection and diagnosis of the disease is hindered by its low sensitivity 
and specifi city. Fletcher showed that for screening purposes in a normal population, 
a cut-off concentration of 2.5 µg/L CEA would yield a sensitivity of 30-40%. Based 
on these data he calculated that there would be 250 false positive tests for every true 
positive test, i.e. a patient with cancer. Furthermore, 60% of the cancers would not 
be detected.[10-13]
Faecal occult-blood testing (FOBT) is another biomarker for which clinical trials 
have shown evidence of a decreased risk of death correlated with increased detec-
tion of the disease. This approach is a non-invasive option that limits the need 
for follow-up colonoscopy to patients with evidence of bleeding. Neoplasms bleed 
intermittently, however, allowing some to escape detection with faecal occult-blood 
testing. Annual retesting is therefore necessary but is still insuffi cient, detecting only 
25 to 50% of colorectal cancers and 10% of adenomas. The specifi city of FOBT is also 
limited by frequent false positive reactions to dietary compounds, medications, and 
gastrointestinal bleeding from causes other than colorectal cancer.[14-17] However, 
population screening for colorectal cancer based on FOBT is already implemented 
in several countries, including a trial in the Netherlands. The expectation is that 
even though the techniques still has its fl aws, a population screening for colorectal 
cancer will decrease mortality with 15-20%.[14] This can be attributed to the fact 
that colorectal cancer develops as a multistep sequence of precancerous and early 
cancerous lesions over a relatively long period of time. However, these early stages 
of the disease can only be detected by screening. Furthermore, scientifi c evidence 
clearly shows that, in the case of CRC, early detection and treatment leads to more 
benefi t than treatment that has started later. These reasons among other Wilson and 
Jungner’s criteria, that also apply for colorectal cancer, are explain that a population 
based screening trial has started in the Netherlands, although the technique still has 
some limitations.[18] 
BREAST CANCER
With over 1 million new cases in the world each year, breast cancer is the com-
monest malignancy in women and comprises 18% of all female cancers.[19] In 2005, 
breast cancer caused 502,000 deaths (7% of cancer deaths; almost 1% of all deaths) 
worldwide. The most recent data from the Surveillance, Epidemiology, and End 
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Results (SEER) program of the National Cancer Institute indicate that the lifetime 
probability of developing invasive breast cancer is one in nine.[20] Despite increas-
ing incidence rates, annual mortality rates from breast cancer have decreased over 
the last decade (2.3% per year from 1990 to 2002).[21] The effect of reduction due 
to early diagnosis of breast cancer has been outlined with patients’ data by the 
Surveillance, Epidemiology, and End Results program in a competing-risk analysis 
calculating probabilities of death from breast cancer and other causes according 
tot stage, race and age at diagnosis.[22] Reasons for the decline in mortality rates 
in western Europe, Australia and the Americas include widespread mammography 
screening, precise diagnosis, and increased number of women receiving tailor made 
treatment- including extensive use of tamoxifen and the use of chemotherapy.
[23] There are many risk factors for breast cancer, including age and gender, race, 
lifestyle and dietary factors, reproductive and hormonal factors, family history and 
genetic factors, exposure to ionizing radiation and environmental factors. Although 
many epidemiological risk factors have been identifi ed, the cause of any individual 
breast cancer is often unknown. In other words, epidemiological research informs 
the patterns of breast cancer incidence across certain populations, but often not in 
a given individual. 
Once the diagnosis of breast cancer is established, the choice of initial treatment 
depends upon the stage or extent of disease. Although initial treatment decisions 
are made on the size and appearance of the primary tumour and the presence 
of palpable axillary nodes, the surgical and pathological fi ndings are used to de-
termine the pathologic disease stage, which dictates the prognosis and need for 
adjuvant systemic therapy. The most important are the status of the draining axillary 
lymph nodes, tumour size, whether the tumour expresses hormone receptors and/
or the protein HER2, and a woman’s age or menopausal status. Up to one-third of 
women with non-palpable axillary lymph nodes will be found to harbour metastases, 
while one-third of those with palpable nodes will be pathologically free of nodal 
involvement. In women with breast cancer who are younger than 50 years of age, 
chemotherapy increases their 15-year survival rate by 10%; in older women the 
increase is 3%.[24] However, chemotherapy has a wide range of acute and long-term 
side effects that substantially affect the patient’s quality of life.[25] As it is not pos-
sible to accurately predict the risk of metastasis development in individual patients, 
nowadays more than 80% of them receive adjuvant chemotherapy, although only 
approximately 40% of the patients relapse and ultimately die of metastatic breast 
cancer. Therefore, many women who would be cured by local treatment alone, 
which includes surgery and radiotherapy, will be ‘over-treated’ and suffer the toxic 






Women who have oestrogen sensitive (ER positive) tumours receive some form 
of hormonal therapy to block the cancer-promoting effect of oestrogen.[27] The use 
of tamoxifen was shown to signifi cantly reduce the risk of recurrence and increase 
ten year survival in women with ER positive and ER unknown status tumours and its 
gradual widespread use is one of the main factors associated with the dramatic fall 
in mortality during the late twentieth century.[28;29] Most postmenopausal women 
receive tamoxifen for fi ve years. Trials are ongoing to establish even more effective 
drugs and regimens for pre- and postmenopausal patients, taking into account side-
effects as well as survival times. The ATAC trial recently reported its early results 
comparing anastrazole alone, anastrazole plus tamoxifen, and tamoxifen alone for 
postmenopausal women and has shown the benefi ts of anastrozole over tamoxifen 
in disease-free survival in early breast cancer.[30] In premenopausal women oestro-
gen production may be stopped by surgery (removing the ovaries), radiotherapy or 
drugs that reversibly suppress the ovaries (LHRH analogues). 
In a recent meta-analysis, a mortality reduction of 38% (age <50 years) and 20% (age 
50-69 years) with chemotherapy is shown, followed by a further reduction of 31% 
from tamoxifen. When combined together, the fi nal mortality reductions would be 57% 
and 45%, respectively 57% reduction for women younger than 50 years of age and for 
those of age 50–69 years.[24] Moreover, breast cancer patients with the same stage of 
disease can have markedly different treatment responses and overall outcome. 
DIAGNOSIS AND BIOMARKERS IN BREAST CANCER
The procedures most commonly used in breast-cancer diagnosis is mammography, 
and to a lesser extent ultrasonography, MRI, and PET. In addition, physical examina-
tion remains important because a certain proportion (11%) of breast cancers is not 
seen on mammography.[31] Mammography remains the most important diagnostic 
tool in women with breast tissue that is not dense and is used in many coun-
tries as a population based screening in woman older than 50 years. The effect of 
breast screening in terms of breast cancer mortality reduction persists after long-term 
follow-up. A recent meta-analysis of seven randomised trials – concluded that there 
was a 15-20% reduction in risk of death from breast cancer in women attending 
mammography.[32] The effect of mammography screening is age-dependent and the 
highest effect is seen in women aged 55-69 years. This effect was not seen in woman 
under the age of 50, probably because of the higher density of the breast tissue.
[33] Thus, after menopause, mammography is generally the best method to discover 
tiny, non-palpable lesions. By contrast, ultrasonography is the most effective pro-
cedure to diagnose small tumours in women with dense breast and to differentiate 
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solid lesions from cystic lesions.[34] Although mammography can identify suspicious 
micro calcifi cations, it is not good at distinguishing between breast densities and 
has diffi culty in identifying certain lobular invasive carcinomas, Paget’s disease of 
the nipple, infl ammatory carcinoma, and particularly peripheral, small carcinomas.
[35] MRI is mainly used as a problem-solving method after conventional diagnostic 
procedures. The technique is highly sensitive and mainly used for the screening of 
high-risk, BRCA-positive patients. It is also useful for identifi cation of primary foci in 
non-palpable lesions and axillary metastases with no evidence of a primary focus, 
and for assessment of response to neoadjuvant chemotherapy.[36] Although MRI 
has good diagnostic accuracy, the rate of false-positive cases is still high and MRI 
fi ndings cannot be a sole indication for breast surgery.[37] PET is presently used to 
discover undetected metastatic foci in any distant organ and can assess the status of 
axillary nodes in the preoperative staging process.[38] 
Currently, mammography remains the most important diagnostic tool since serum 
tumour markers play no role of importance in the diagnosis of breast cancer due to 
a lack of sensitivity and specifi city. Consequently, a major focus of present research 
is the identifi cation of new biomarkers and drug targets to improve (early) detec-
tion and treatment; since early detection and more individualised treatment would 
benefi t the individual patient and avoid unnecessary morbidity.
A NEW DIAGNOSTIC PARADIGM: CLINICAL PROTEOMICS
Proteomics is the large-scale study of proteins, particularly their presence, structure 
and functions. The term ‘proteomics’ was coined to make an analogy with genomics, 
the study of the genes. Proteomics is often considered the next step in the study of 
biological systems, after genomics. It is more complicated than genomics, mostly 
because while an organism’s genome is rather constant, a proteome differs from cell 
to cell and constantly changes through its biochemical interactions with the genome 
and the environment. However, this functional state of a cell is very interesting for 
research goals and especially in oncogenesis. Clinical proteomics is referred to as 
mass spectrometry based proteomics using easy accessible body fl uids.
Mass spectrometry is an analytical technique used to measure the mass-to-charge 
ratio of ions. It is most generally used to fi nd the composition of a physical sample 
by generating a mass spectrum representing the masses of sample components. The 
mass spectrum is measured by a mass spectrometer. Matrix-assisted laser desorption/
ionisation (MALDI) is a soft ionisation technique used in mass spectrometry, allowing 
the analysis of biomolecules which tend to be fragile and fragment when ionised by 






(normally a nitrogen laser). A matrix is used to protect the biomolecule from being 
destroyed by direct laser beam and to facilitate vaporization and ionisation. The type 
of a mass spectrometer most widely used with MALDI is the TOF (time-of-fl ight mass 
spectrometer), mainly due to its large mass range. These mass spectrometers use an 
electric fi eld to accelerate the ions through the same potential, and then measures 
the time they take to reach the detector. If the particles all have the same charge, 
then their kinetic energies will be identical, and their velocities will depend only on 
their masses. Lighter ions will reach the detector fi rst, as shown in fi gure 1. The TOF 
measurement procedure is also ideally suited to the MALDI ionisation process since 
the pulsed laser takes individual ‘shots’ rather than working in continuous operation. 
MALDI-TOF instruments are typically equipped with an “ion mirror”, defl ecting ions 
with an electric fi eld, thereby doubling the ion fl ight path and increasing the resolu-
tion. First, a sample has to be introduced into the ionisation source of the instrument. 
Once inside the ionisation source, the sample molecules are ionised, because ions 
are easier to manipulate than neutral molecules. These ions are extracted into the 
analyzer region of the mass spectrometer where they are separated according to 
their mass-to-charge ratios (m/z). The separated ions are detected and this signal 
is sent to a data system where the m/z ratios are stored together with their relative 
abundance for presentation in the format of an m/z spectrum.
Proteomic pattern diagnostics is a recent and potentially revolutionary approach 
for early disease detection, prognostication, and monitoring in oncology. The use of 
proteomic technologies might benefi t biomarker discovery and treatment modalities: 
serum protein profi ling for early disease detection and molecular signal mapping to 
instigate pharmocoproteomic therapeutic interventions.[39] Thus, several authors hy-
pothesised that proteomic patterns generated with mass spectrometry are correlated 







Figure 1. Schematic version of MALDI-TOF mass spectrometry principle.  
Sample molecules are ionised with a laser source. Then an electric field is used to accelerate the ions 
in a flight tube. The detector measures their flight time. If the particles all have the same charge, then 
their kinetic energies will be identical, and their velocities will depend only on their masses. The 












Figure 1. Schematic version of MALDI-TOF mass spectrometry principle. 
Sample molecules are ionised with a laser source. Then an electric  eld is used to accelerate the ions in a  ight tube. The detector measures their 
 ight time. If the particles all have the same charge, then their kinetic energies will be identical, and their velocities will depend only on their 
masses. The smaller ones (red) will reach the detector earlier than the heavier ones (green).
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presence of disease. New types of bioinformatic pattern recognition algorithms were 
used to identify patterns of protein changes in order to discriminate cancer patients 
from healthy individuals with promising results. 
Petricoin and his co-workers were the fi rst to state that fi nding a single disease-
related biomarker is like searching for a needle in a haystack; each entity has to be 
separated and identifi ed individually.[40;41] Moreover, they postulated that the blood 
proteome constantly changes as a consequence of the perfusion of the diseased 
organ adding, subtracting, or modifying the circulating proteome. These differences 
might be the result of proteins being abnormally produced or shed and added to 
the serum proteome, clipped or modifi ed as a consequence of the disease process, 
or subtracted from the proteome owing to disease-related proteolytic degradation 
pathways. Therefore, protein pattern diagnostics would provide an easy and reliable 
tool for detection of cancer. The advantages of the proteomic pattern approach were 
stressed in several papers. In addition to the high sensitivity and specifi city, cost-
effectiveness, easy accessibility of body fl uid and especially the high-throughput, 
ultimately allowing application in future screening studies, were mentioned.[42;43] 
Next to these hopeful voices, soon critical notes were made on analytical reproduc-
ibility and the use of the so-called black box approach, lacking identifi cation of 
discriminating proteins.[44]
CLINICAL PROTEOMICS IN ONCOLOGY
Cancer is known to be the consequence of genetic alterations. A gene, however, 
is only potential information that must be put into a functional form. The DNA is 
transcribed into RNA before translation into protein, the functional manifestation 
of the genetic code. During the transformation of a healthy cell into a neoplastic 
cell, including alterations in expression, activity, localization and differential protein 
modifi cation, changes also occur in the protein level. Identifying and understanding 
these changes is the underlying theme in cancer proteomics.[45]
In 2002 several studies discriminated patients with various cancers from healthy 
subjects on the basis of presence/absence of multiple low-molecular-weight serum 
proteins using SELDI-TOF mass spectrometry technologies.[42;46-48] The authors 
hypothesised that proteomic patterns are correlated with biological events occurring 
in the entire organism and are likely to change in the presence of disease. New 
types of bioinformatic pattern recognition algorithms were used to identify patterns 
of protein changes in order to discriminate cancer patients from healthy individuals 
with promising results. Several studies have shown that biomarkers can be identi-






proteins.[41;42;46-49] Furthermore, different profi les may be associated with varying 
responses to therapeutics and other clinically relevant parameters and may also serve 
as prediction for treatment outcome. 
Although serum protein patterns showed high sensitivity and specifi city as an 
early diagnostic tool in several studies, critical notes have been made on biological 
variation, pre-analytical conditions and analytical reproducibility of serum protein 
profi les that would make it diffi cult to differentiate a normal from a pathological 
and/or malignant status.[50] In addition, the reproducibility of serum protein profi les 
has been questioned, which however relates more to the bioinformatical analysis of 
the measured protein profi les than the capturing and measuring techniques itself.
[51-53] Thus, if proteomics spectra are ultimately to be applied in a routine clinical 
setting, collection and processing of the data will need to be subject to stringent 
quality control procedures.[54] 
OUTLINE OF THIS THESIS
Given the natural history of colorectal and breast cancer, early diagnosis appears to 
be the most appropriate tool to reduce disease-related mortality.[6;7] Currently, there 
is no early diagnostic test with high sensitivity, specifi city and positive predictive 
value, which can be used as a routine screening tool. Therefore, there is a need for 
new biomarkers for both types of cancer that can improve early diagnosis, monitor-
ing of disease progression and therapeutic response and detect disease recurrence. 
Proteomic expression profi les generated with mass spectrometry have been suggest-
ed as potential tools for the early diagnosis of cancer and other diseases. Because it 
is still in its infancy, many problems have to be overcome before clinical proteomics 
can be transferred form bench to bedside. Chapter 2 gives an insight in the differ-
ent fi elds of translational research in colorectal cancer by our group. In chapter 3
reliability of human serum protein profi ling using MALDI-TOF mass spectrometry 
is analysed. We present a pipeline for pre-processing, statistical data analysis and 
presentation of MALDI-TOF spectra. This novel analysis method was used to assess 
the effect of variable pre-analytical conditions on human serum protein profi les, and 
their effect on reproducibility. In line with the logistic conditions in a routine clinical 
setting, the effects of sample handling and storage, and also circadian rhythm factors 
on the serum protein profi les were analysed. In chapter 4 and 5 the feasibility of 
mass spectrometry based protein profi ling for the discrimination of colorectal cancer 
patients from healthy individuals was assessed. In addition to standardizing technical 
factors and biological variations, we performed blinded tests and employed a ran-
domised block design experimentation to minimize impact of potential confounding 
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factors and to avoid bias. Especially, validation of our classifi er, as a possible pitfall, 
was given much attention. Therefore, we performed a linear discriminant analy-
sis with double cross-validation to separate cancer patients from healthy subjects. 
Chapter 6 reports on results from an identical designed protein profi ling study for 
the detection of breast cancer. In chapter 7 a fi rst validated study on the detection 
of breast cancer based on mass spectrometry generated protein profi les is described. 
In this study the same randomised blocked design and double cross validation is 
used, however the classifi er was validated in an independent set of new patients 
and controls. Finally, the results and conclusions of all above mentioned studies 
and especially the current status of clinical proteomics in cancer are discussed in 
chapter 8. 
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Chapter 2
Translational research in 
prognostic pro ling in 
colorecTal cancer
M.E.de Noo, G.J. Liefers, R.A.E.M. Tollenaar. 







There is a widening gap between basic research and clinical practice, particularly 
for colorectal cancer. In recent years, many have expressed concerns regarding the 
disconnection between the promises of basic science and the delivery of better 
individual health. In this paper we describe some of our research in serum proteom-
ics, microarrays and minimal residual disease dedicated to this fi eld and discuss 
some of the roadblocks ahead in translational research. We conclude that transla-
tional medicine should be a collective effort for the medical community as a whole 
with adequate fi nancial support and sound, measurable outcome. Since extensive 
validation of the above mentioned research fi elds is necessary, adequate funding is 
required. This may require some adjustments in the current funding policy because 
it involves non-innovative studies. Furthermore, the pool of researchers/clinicians 
capable of performing translational research must be increased. Additionally, there 
should be an enhanced participation of patients in clinical trials and an optimiza-
tion of the effi ciency of these trials using validated surrogate markers. Only when 
these conditions are fulfi lled will the ‘post-genomic’ era of biomedical research have 
unprecedented opportunities to innovate and improve therapy for cancer.
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INTRODUCTION
There is a widening gap between basic research and clinical practice particularly for 
colorectal cancer. Over the last decades our molecular knowledge on the genesis 
of colorectal cancer has increased dramatically. Despite this increase our treatment 
of patients remains largely the same: ‘en-bloc’ removal of the primary tumour and 
draining lymph nodes when possible, staging according to standard Dukes’ or TNM 
classifi cation systems and adjuvant treatment with cytotoxic drugs and/or radiation 
therapy. Despite mounting evidence of abundant heterogeneity of both clinical 
course of disease and responsiveness to therapy, ‘tailor-made’ medicine is an item in 
review papers and editorials instead of every-day-practice.
The paradigm for the translation of new information has been conceptualised 
by some as a highway. A ‘translational highway’ running from basic biomedical 
research to individualised patient care with improved health as a result (Figure 1). 
In recent years many have expressed concerns regarding the disconnection between 
the promise of basic science and the delivery of better health.[1] In a special com-





















Figure 1. Current biomedical research places high priority on defining molecular mechanisms of disease with 
the ultimate aim of improving health of the individual patient (hypothesis driven). However, part of the failure 
to translate hypotheses derived from complex experimental models into improved patient care can be 
explained by the fact that many of these hypotheses do not translate to human pathology. It is therefore pivotal 
for successful translational medicine to promote research based on clinical observations and corresponding 
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innovations in health care as postulated by Rogers.[2] One of the obstacles he men-
tions, is that apart from lack of knowledge about the expected consequences of 
innovations or the perceived benefi t, these innovations must resonate with currently 
felt needs and beliefs. Other factors associated with perceptions of an innovation 
are the complexity the proposed innovation, trial ability (testing the change on a 
small scale) and observability (watching others trying the change fi rst), as shown 
in table 1. For colorectal cancer the ‘needs and beliefs’ are evident. First, the prog-
nostic information from our standard classifi cation system needs refi nement. This is 
exemplifi ed by the fact that despite of lack of evidence of residual disease in Dukes’ 
B colorectal cancer patients, 30% die of recurrent disease within fi ve years. Second, 
there is a need for tools that allows us to predict or monitor therapy response to 
avoid unnecessary morbidity. And third there is a need for new molecular targets 
that allows the development of cancer specifi c drugs that lack the side effects of 
current cytotoxic chemotherapeutics.
In this paper we would like to describe some of our research dedicated to this fi eld 
and discuss some of the roadblocks ahead.
PROTEOMICS
Cancer is often described as a genetic disease. A gene alone, however, is only poten-
tial information that must be put into a functional form. The DNA is transcribed into 
RNA before translation into protein, the manifestation of the genetic code. During 
the transformation of a healthy cell into a neoplastic cell, including alterations in 
expression, activity and localization and differential protein modifi cation, changes 
occur in the protein level. Identifying and understanding these changes is the under-
lying theme in cancer proteomics.[3]
Table 1.  Factors associated with perceptions of an innovation
Perception of an innovation that in uences the rate of spread
Perceived bene t of the change
Compatibility with beliefs and needs of potential adopters
Complexity of the proposed innovation
Trialability (testing the change on a small scale)
Observability (watching others try the change  rst)
Adapted from: E.M. Rogers, Di usion if innovations, 4th ed. New York, NY: Free Press 1995
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Proteomic pattern diagnostics is a recent and potentially revolutionary approach 
for early disease detection, prognostication, and monitoring in oncology. The use of 
proteomic technologies might benefi t biomarker discovery and treatment modalities: 
serum protein profi ling for early disease detection and molecular signal mapping to 
instigate pharmocoproteomic therapeutic interventions.[4]
Several studies have shown that biomarkers can be identifi ed on the basis of 
the presence/absence of multiple low-molecular-weight serum proteins using mass 
spectrometry technologies such as SELDI-TOF and MALDI-TOF.[5-9] Patterns of these 
peptides can be correlated to biological events occurring in the entire organism 
and are likely to change in the presence of disease. In oncology new types of 
bioinformatic pattern recognition algorithms have been used to identify patterns of 
protein changes in order to discriminate cancer patients from healthy individuals.
[10] Furthermore, different profi les may be associated with varying responses to 
therapeutics and other clinically relevant parameters and may also serve as predic-
tion for treatment outcome. Although serum protein patterns showed high sensitivity 
and specifi city as an early diagnostic tool in several studies, critical notes have been 
made on biological variation, pre-analytical conditions and analytical reproducibility 
of serum protein profi les that would make it diffi cult to differentiate a normal from 
a pathological and/or malignant status.[11] In addition, the reproducibility of serum 
protein profi les has been questioned, which however relates more to the bioinfor-
matical analysis of the measured protein profi les than the capturing and measuring 
techniques itself.[12-14] Thus, if proteomics spectra are ultimately to be applied in a 
routine clinical setting, collection and processing of the data will need to be subject 
to stringent quality control procedures.[15] 
In a recently submitted study we assessed the reproducibility of our MALDI-TOF 
protein profi ling procedure after capture and elution of serum peptides with C8 
magnetic beads. Corresponding to the logistical conditions in a routine clinical set-
ting, the effects of sample handling and storage, and also individual factors on the 
serum protein profi les were analysed. The reproducibility of the used capturing 
technique with C8 magnetic beads and MALDI-TOF analysis is acceptable and satis-
factory for large discriminating studies. The time of blood collection and the number 
of freeze-and-thaw cycles had no infl uence on serum protein profi les. However, 
sample handling prior to serum centrifugation did have considerable effect on serum 
protein profi les. All together, we have shown in this study that effects of handling 
and storage procedures on serum protein profi les lie within acceptable limits. To 
prevent bias in classifi cation studies we stress the importance of a standardised 
collection of all blood samples, from the point of sample handling and storage 
until freezing the samples. Although the importance of homogeneity and uniformity 






excluded in a clinical setting. The most important issues for discriminating studies 
at this moment are a standardised and well-documented sample collection and a 
thorough study design. Further research for the statistical data-analysis is needed. 
Due to the lack of discriminating profi les, serum protein profi ling is not ready for 
introduction in a routine clinical setting. Nevertheless, based on the present data and 
these of Villanueva et al. [16], we feel that the methodology can be standardised to 
a level which allows application as a diagnostic and prognostic tool. Therefore, we 
are now in the process of carrying out a study to determine whether serum protein 
profi les can differentiate colorectal cancer patients from individuals with benign 
bowel disorders and healthy subjects. Further, identifi cation and functional analysis 
of these discriminating proteins will render new insights on tumour development 
and environmental responsiveness.
MICROARRAYS (PROGNOSTIC FACTORS)
Over the last decades, numerous molecular factors with prognostic and predictive 
value have been described. Specifi cally loss of heterozygousity (LOH) of chromo-
some 18q and microsatellite instability (MSI) have been repeatedly implicated both 
as prognosticators as well as predictive for 5-fl uorouracil based chemotherapy.[17] 
Despite multiple studies with large number of patients and unequivocal outcome 
data these markers have not yet found their way into routine treatment planning for 
patients with colorectal cancer. One of the reasons for this may be that the observed 
differences are studied retrospectively, which diminishes the expected benefi t of 
using these markers in clinical decision making. Furthermore, with respect to the 
triability, it takes a tremendous amount of work for potential adopters to prospec-
tively validate these markers. Also, the use of a single marker disregards the biologi-
cal complexity of tumour development. New techniques, such as cDNA microarray 
analysis enable the parallel monitoring of expression levels of thousands of genes. 
Current cDNA microarray protocols are based on the Southern blot technique in 
which labelled nucleic acid molecules are hybridised to complementary nuclear acid 
molecules attached to a solid surface such as glass. Technical innovations such as 
miniaturization and fl uorescence-based detection greatly enhance the throughput. 
A microarray consists of thousands of small spots of multiple copies of amplifi ed 
cDNA spotted on a glass microscopic slide. Each spot represents a unique sequence 
from a named gene or expressed sequence tag (EST) and one slide can hold up to 
10,000 probes. As a target for analysis, total RNA or mRNA from two cell populations 
is used (e.g. cell lines, clinical samples and animal models). Fluorescent marker dyes 
such as Cy3 and Cy5 are incorporated into target cDNA. The labelled cDNA from the 
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two cell populations of interest are mixed with a labelled control sample and hy-
bridised to the probes on the glass slides. The array is scanned using confocal laser 
microscopy. After excitation and emission of fl uorescence, signals can be measured 
and displayed. This results in a matrix of thousands of green, red and yellow spots. 
When, for example, a gene is equally expressed in test and control samples, both 
the red and green fl uorescent signals will be equally strong and will be visualised as 
a yellow dot. Consequently, in the case of differential expression, the red to green 
ratio will shift. Following hybridisation and scanning, large amounts of data are 
available for processing. A variety of software tools are available which can help to 
measure fl uorescent signal ratios, exclude artefacts and normalize data. 
In a small, unpublished series of rectal cancer patients we have tested the hypoth-
esis that microarray analysis could distinguish between patients with and without 
liver metastases. In collaboration with the Institute of Medical Sciences, University of 
Tokyo, Japan, we analysed tumour RNA from 20 rectal cancer patients; 12 patients 
with liver metastases and 8 patients without. RNA was extracted from fresh frozen 
tissue samples using laser capture micro dissection (LCM). After amplifi cation and 
labelling, probes were hybridised to a microarray consisting of 9,216 genes. After 
scanning, the differential expression ratio for each gene was determined.
Data were analysed according to the ‘leave-one-out’ methodology as described. 
The resulting set of 30 genes could correctly predict the presence of liver metastases 
in 10 out of 12 patients. These data are currently being validated in a larger series. 
However these preliminary data show that, as in many other tumours, cDNA mi-
croarrays are promising new tools for the prognostication of patients with colorectal 
cancer.
For the translation of these experimental techniques into standard care, some of 
the roadblocks ahead can be easily envisioned. First the proposed superiority over 
our standard classifi cation system must be (repeatedly) demonstrated in large groups 
of patients. To achieve this, tissue banks with fresh frozen tissues and serum must 
be established for validation studies. With adequate funding, these tissues can be 
collected from patients who are randomised in clinical trials and made available to 
the research community. International initiatives from the NCI and EORTC underline 
this view.
Secondly, the introduction and acceptance of prognostic gene sets would be more 
anticipated when experiments show a causal role of each of the genes in the clinical 
course of the disease. Microarray data are therefore by no means endpoints. Rather, 








Detection of metastatic cells by molecular techniques has been reported to increase 
the sensitivity over standard pathological examination. Metastatic cells can be found 
in histopathological negative lymph nodes, bone marrow and blood of colorectal 
cancer patients. Many of the published papers indicate a poor prognosis in patients 
with molecular detected metastases in all of the mentioned sites. Despite this, mo-
lecular techniques are not routinely used in the staging of patients.
The prognosis for colorectal cancer patients whose lymph nodes are not involved 
(stage II) is good. Five-year survival rates approximate 70%. In the Netherlands, 
adjuvant chemotherapy, therefore, is not considered standard care. Our group 
studied 26 stage II patients to detect micro metastases in lymph nodes by reverse-
transcriptase-PCR of carcinoembryonic antigen (CEA) mRNA in microscopic negative 
lymph nodes. Overall, micro metastases could be detected in one or more lymph 
nodes from 14 patients (54%). These patients fared signifi cantly worse than the 
patients without micrometastases. In this study, survival dropped from 75% to 36% 
based on the presence of micrometastatic disease. When only cancer-related deaths 
were considered, survival dropped from 91% to 50% respectively. The relative risk 
for cancer related death associated with the presence of micrometastases was 11.7 
(95% C.I.: 1.2-106.9; P=0.03).[18] 
This study is one of the fi rst to relate micrometastatic disease to patient outcome 
and provides a rationale for the selection of patients who might benefi t from adju-
vant therapy. Since our publication others have confi rmed these fi ndings but there 
has been no massive introduction or these techniques into daily practice. The reason 
for this is that the pivotal question whether the prognosis of patients ‘upstaged’ by 
molecular techniques improves after adjuvant treatment remains unanswered. The 
perceived benefi t for this innovation therefore may be low and is subject of ongoing 
investigation by our group and others. A second reason for the lack of adoption of 
these techniques is that they are complex and time consuming. Sentinel node (SN) 
biopsy has been introduced to minimize the extent of surgery and to enable assess-
ment of minimal residual disease (MRD) without compromising accurate staging or 
survival.[19] For colorectal cancer the SN concept could be used to limit the number 
of nodes amenable for detailed molecular analysis. We are currently in the process of 
evaluation of micrometastases in sentinel nodes from colorectal cancer patients.
Another area of research is MRD detection in bone marrow. Viable cancer cells can 
be found in bone marrow from 20-40% of patients with colorectal cancer. This phe-
nomenon correlates with an adverse prognosis. We have tested different methods for 
MRD detection, including automated microscopy and RT-PCR and preliminary results 
indicate prognostic relevance of these tests for different stages of colorectal cancer.
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[20] Not all cancer cells that can be found in bone marrow are clinically relevant 
since they are present even in patients that never relapse. Experimental studies in 
breast cancer show that tumours consist of heterogeneous populations of cells with 
distinct tumorigenic potential.[21;22] 
Minimal residual disease may arise from tumorigenic or non-tumorigenic cancer 
cells. Only when tumorigenic cancer cells metastasize, clinically relevant metastasis 
will occur.[23] Support for this theory comes from observations that disseminated 
minimal residual cancer cells from patients with and without overt distant metastasis 
are genotypically different.[24] Therefore the development of diagnostic tools that 
allow for the prospective identifi cation of tumorigenic minimal residual cells may 
have therapeutic signifi cance for patients with solid tumours. This will be one of the 
research goals for our group in the coming years. 
CONCLUSION
In the ‘post-genomic era’ of biomedical research there are unprecedented opportuni-
ties to innovate and improve therapy for cancer. These opportunities are limited by 
today’s clinical infrastructure. Efforts to validate and implement novel therapies are 
characterised by lack of funding and fragmentation. For a successful translation of 
novel biomedical discoveries to improved, individual health there are several issues 
to be addressed. First of all, translational medicine should be a collective effort for the 
medical community as a whole with adequate fi nancial support and sound, measur-
able outcome. As extensive validation of the above mentioned research fi elds is neces-
sary, adequate funding is required. This may require some adjustments in the current 
funding policy as it involves non-innovative studies. Secondly, the pool of researchers/
clinicians capable of performing translational research must be increased. Thirdly, 
there must be an enhanced participation of patients in clinical trials and we have to 
optimize the effi ciency of these trials using validated surrogate markers. Especially 
when we move towards ‘tailor-made’ medicine, evidence from large randomised trials 
(with inherently large groups of uniformly treated patients) will be more diffi cult to 
obtain. Current clinical trials must be appended with basic biomedical science studies, 
with collection of tissues for retrospective analysis. Last, we have to deal with regula-
tory and cultural aspects of the implementation of health innovations. 
For the coming years it is the goal of our group to integrate three lines of research; 
MRD detection, cDNA microarray analysis and proteomics (Figure 2). We believe 
that integrating these techniques will improve the detection and staging of colorec-






























Figure 2. Integrating the three different research techniques will result in a better understanding of the 
molecular mechanisms of colorectal cancer and will facilitate translating hypotheses derived from basic science 
into improved patient care. The combination of the different research techniques may result in earlier 















Figure 2. Integrating the three di erent research techniques will result in a better understanding of the molecular echanisms of colorectal 
cancer and will facilitate translating hypotheses derived from basic science into improved patient care. The combination of the di erent research 
techniques may result in earlier detection, prognostication and treatment monitoring of colorectal cancer.
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Protein profi ling with mass spectrometry is a promising approach for classifi cation 
and identifi cation of biomarkers. However, there is debate about measurement qual-
ity and reliability. Here we present a pipeline for pre-processing, statistical data 
analysis and presentation. Serum samples of sixteen healthy individuals are used 
to generate protein profi les with a high-resolution MALDI-TOF after isolation of 
peptides with C8 magnetic beads. Analysis of variance (ANOVA) was performed after 
binning, normalization and baseline correction of the mean spectra. Relative varia-
tions in the spectra are expressed as coeffi cient of variation (CV), which depending 
on the respective preanalytical variation parameter investigated, was found to range 
between 0.15 and 0.67 in this study. With this novel method the reproducibility 
of our protein profi ling procedure could be quantifi ed. We showed that circadian 
rhythm and the number of freeze-thaw cycles had relatively limited infl uence on 
serum protein profi les, whereas the period between collection and serum centrifuga-
tion had a more pronounced effect.
37Reliability of Human Serum Protein Pro les Generated with C8 Magnetic Beads Assisted MALDI-TOF Mass Spectrometry
INTRODUCTION
Proteomic pattern diagnostics is a recent and potentially revolutionary technology 
and approach for early disease detection, surveillance, and monitoring in oncology.
[1] In proteomics proteins and functional protein networks as well as their dynamic 
alteration during physiological and pathological processes are characterised. It is a 
potential powerful tool in the discovery of disease biomarkers, as the proteome re-
fl ects both the intrinsic genetic program of an organism and the impact of its immedi-
ate environment.[2] Human serum contains thousands of peptides, most of which are 
thought to be fragments of larger proteins, but their precise nature remains largely 
undetermined. High throughput mass spectrometry can generate a proteome/pep-
tidomic fi ngerprint of a given body fl uid, such as serum. Patterns of these peptides 
can be correlated to biological events occurring in the entire organism and are likely 
to change in the presence of disease. In oncology new types of bioinformatic pattern 
recognition algorithms have been used to identify patterns of protein changes in or-
der to discriminate cancer patients from healthy individuals.[3] Furthermore, different 
profi les may be associated with varying responses to therapeutics and other clinically 
relevant parameters and may also serve as prediction for treatment outcome. Several 
studies have shown that biomarkers can be identifi ed on the basis of the presence/
absence of multiple low-molecular-weight serum components using time-of-fl ight 
(TOF) mass spectrometry technologies such as SELDI-TOF and MALDI-TOF.[4-7] In 
general, although most studies measure serum components in a range in which 
primarily peptides and protein degradation products as well as small proteins are 
detected, the term protein profi ling is generally accepted to describe this approach. 
Although essentially imprecise, this term will also be used in this study. Petricoin et 
al. showed that patterns of low-molecular-weight serum proteins refl ect the patho-
logical state of organs. In addition, these disease-related protein patterns could be 
useful in the early detection of ovarian cancer.[8] Based on discriminating serological 
protein profi les that study showed a sensitivity of 100%, specifi city of 95% and a 
positive predictive value of 94% for the detection of ovarian cancer. 
Although serum protein patterns have shown high sensitivity and specifi city as an 
early diagnostic tool in several studies, critical notes have been made on biological 
variation, pre-analytical conditions and analytical reproducibility of serum protein 
profi les, which would make it diffi cult to differentiate a normal from a pathological 
and/or malignant status.[9] In addition, the reproducibility of serum protein profi les 
has been questioned, however more with respect to the bioinformatical analysis of 
the measured protein profi les than to the capturing and measuring techniques itself.
[10-12] Thus, if proteomics spectra are ultimately to be applied in a routine clinical 






quality control procedures.[13] In fact, some critics argue that discriminating protein 
profi les are so far based more on experimental artefacts than on real biological dif-
ferences.[14] 
There are many factors that are thought to have an infl uence on serum protein 
profi les, complicating clear and unambiguous study fi ndings. These factors include 
environmental and individual factors such as race, age, diet, smoking, stress, general 
physical condition and use of drugs, which all may infl uence serum protein profi les. 
Pre-analytical conditions of human serum also appear to infl uence protein pattern 
outcomes. So far, only a few studies have reported on the effects of different serum 
sample preparations and the use of a magnetic beads based approach to capture 
and concentrate serum proteins for MALDI-TOF mass spectrometry.[15-17] Since data 
processing and statistical analysis of protein spectra are essential elements in clinical 
proteomics, the objective of this study was to quantify the relative contributions of 
sources of variability on the protein spectra. To this end we developed a novel data 
processing pipeline, which was performed with an analysis of variance (ANOVA) of 
the spectra, after the spectra had been made comparable, reduced to common mass 
channels and the noise had been fi ltered. Strong baselines were always present in 
the spectra and had to be removed. This novel analysis method was used to assess 
the effect of variable pre-analytical conditions on human serum protein profi les, 
and their effect on reproducibility. In contrast to the above-mentioned study, we 
have chosen to primarily focus on assaying serum with C8 magnetic beads with 
hydrophobic functionality, followed by MALDI-TOF analysis. In line with the logistic 
conditions in a routine clinical setting, the effects of sample handling and storage, 
and also circadian rhythm factors on the serum protein profi les were analysed. 
MATERIAL AND METHODS
Serum samples
Blood was collected from 16 healthy adult volunteers, 8 men and 8 women, by 
antecubital venipuncture. All blood samples were drawn from the left arm while the 
volunteers were seated. Approximately 10 ml venous blood was collected in a 10 cc 
Serum Separator Vacutainer Tube (BD Vacutainer Systems, Preanalytical Solutions, 
Plymouth, UK) at three different time points throughout the day. The fi rst sample 
was drawn between 8 and 9 a.m. when all individuals had been fasting since mid-
night. The second specimen was obtained half an hour after lunch, between 1 and 2 
p.m. and the last sample between 5 and 6 p.m. Thirty minutes after collection serum 
was separated by centrifugation at 3,000rpm for 10 minutes, divided into aliquots 
(Greiner) and stored at -70ºC. The serum procurement, data management and blood 
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collection protocol were according to the guidelines of the Medical Ethical Commit-
tee of the Leiden University Medical Center. Informed consent was obtained from 
all subjects.
Protein pro ling 
To enhance signal quality magnetic beads based on hydrophobic interaction chro-
matography (MB-HIC kit, Bruker Daltonics, Leipzig, Germany) were used for sample 
preparation prior to MALDI-TOF mass spectrometry analysis. Five µl of serum was 
diluted with 10 µl binding solution and 5 µl magnetic beads were added. The solu-
tion was mixed by carefully pipetting fi ve times. After 30 seconds supernatant was 
separated from the magnetic beads in a magnetic beads separator (MBS, Bruker) 
and discarded. This was followed by three washing steps with 100 µl wash solu-
tion (MB-HIC kit, Bruker) and supernatant was discarded each time. After 1 minute 
in 10µl e lution solution (50% Acetonitrile) the magnetic beads were separated in 
the MBS from the elution solution. An amount of 1 µl of this eluate, containing 
the captured peptides/proteins, was mixed with 10 µl matrix solution and 1 µl of 
this mixture was transferred to an Anchor Chip target plate ™ (Bruker Daltonics, 
Bremen, Germany) and allowed to dry before introduction into the mass spectrom-
eter. Alpha-cyano-4-hydroxycinnamicacid (HCCA) was used as matrix (0.3 mg/ml 
in Ethanol: Acetone 2:1). Each sample was deposited onto four spots of the target 
plate. Matrix Assisted Laser Desorption Ionisation Time-Of-Flight (MALDI-TOF) mass 
spectrometry measurements were performed using an Ultrafl ex TOF/TOF instrument 
(Bruker Daltonics, Bremen, Germany) equipped with a SCOUT ion source, operating 
in linear mode. Ions formed with a N2 pulse laser beam (337 nm) were accelerated 
to 25 kV. With the employed serum preparation peptide/protein peaks in the m/z 
range of 1500 to 10,000 were measured. An independent mass spectrometer operator 
performed all measurements with blinded samples. Hereafter the entire process of 
capturing and concentrating serum proteins using C8 magnetic beads including the 
generation of readouts of the MALDI-TOF spectra will be designated as the protein 
profi ling procedure.
Data processing
All spectra were compiled, and qualifi ed mass peaks with mass-to-charge ratios (m/z) 
between 1500 and 10,000 were auto-detected. Each mass spectrum, as exported in an 
ASCII fi le, consisted of approximately 45,000 pairs of mass-to-charge values (Dalton) 
and ion counts. As we preferred to analyze the data using the intensity of the mass 
spectra per bin, the fi rst processing step was to collect and average the data in bins 
of 1 Dalton wide. To reduce noise the Whittaker smoother was applied, using second 






bin.[18] The resulting spectra generally showed strong baselines, which had to be re-
moved before further processing. We used the asymmetric least squares algorithm as 
described in the appendix of Eilers 2004 [19]; fi gure 1 shows a typical example. The 
intensity scale of the baseline-corrected spectra was un-calibrated. To normalize the 
spectra we divided each mass spectrum by the median of the intensities. We consider 
this to be more robust than normalization on the average (or equivalently, the area 
under the curve), as the median is less sensitive to spurious large peaks. While this 
is an ad-hoc solution, we hope to fi nd relatively stable regions in the spectra, so that 
we can normalize on medians over these regions in further research. 
Statistical data analysis
To quantify the effects of experimental conditions, variability between individual 
persons and noise, we applied analysis of variance (ANOVA). Consider, as an ex-
ample, an experiment in which we have Р subjects, Т storage times and С storage 
temperatures points. For each combination of subject and time we have measured 
a spectrum. First, we concentrate on only one, arbitrary, mass channel. We have 
PTC measurements, which we indicate by Урtс. The ANOVA model assumes that 










Figure 1.  MALDI-TOF spectrum before and after baseline correction. 
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fect of storage time t, γс is the effect of storage temperature s and eрtс is random varia-
tion. The values of μ and the vectors α, β and γ that minimize the sum of the squares 
of the elements of e are the so-called least squares estimates and the standard result 
of ANOVA. If all combinations of persons, storage times and temperatures are pres-
ent, they are the averages per person (storage time, temperature) over all spectra. 
When some combinations are missing, a somewhat more complicated regression 
approach has to be used. 
The ANOVA was performed for each bin on the mass axis. This results in 1) one 
spectrum for μ, the average spectrum; 2) Р spectra of person effects; 3) Т spectra 
of time effects; 4) С spectra of storage temperature effects and a spectrum of ѕ, the 
standard deviation of the noise for each sample. The single spectra of μ and ѕ are 
easy to present and study, but the multiple spectra of the effects can be voluminous. 
We summarised them by computing standard deviations of α, β and γ per mass bin. 
The fi nal results are a plot of fi ve spectra for each of the performed experiments, 
but only shown in fi gure 3. The plot shows that, generally, the standard deviations 
increase when the overall mean increases. A simple measure of this relationship 
would be the coeffi cient of variation, like ѕ/μ or  ѕα /μ, where ѕα indicates the standard 
deviation of α. Unfortunately, this can provide wildly fl uctuating results when μ is 
near zero. Therefore, we computed сѵ = Σѕі μі /Σі μі2, which is the slope of a regression 
line through the origin in a scatter plot of ѕ vs. μ. The summation can be over the 
whole mass range; this result is reported as a number in the title of each graph of 
standard deviations for all experiments. In addition, we graphically present CV as 
computed in m/z windows 500 Dalton wide.
To investigate the infl uence of the effective bin width on computed CVs, we varied 
the smoothing parameter λ over a large range, artifi cially increasing peak width up 
to fi ve times.
EXPERIMENTS
Reproducibility
In a fi rst set of experiments both the reproducibility of repeated measurements of the 
same eluate and the reproducibility of repeated analysis of the same samples on four 
different days were determined. Serum samples of 8 randomly chosen individuals, 
drawn at one time point during the day were used. Each of these serum samples was 
processed only once, and measured 8 times with MALDI-TOF according to the stan-
dard protocol. Additionally, to determine the inter-measurement variation, protein 
profi ling from 4 of the 8 serum samples was performed on 4 consecutive days. In all 







To simulate ‘realistic’ logistical factors, the effects of sample handling and storage tem-
perature prior to serum centrifugation on serum protein profi les were studied. Serum 
samples of 4 out of the 16 randomly chosen individuals, all drawn at the same time 
point were used for this experiment. From each individual 7 aliquots were stored at 
both room temperature and the same number at 4 °C. After a period of 30 minutes, 1 
hr, 2, 4, 8, 24 and 48 hours serum samples were processed according to the standard 
protocol and protein profi les of all samples were compared for each individual.
Freeze-thaw cycles 
To determine the utility of (archival) serum banking, effects of multiple freeze-thaw 
cycles on serum protein profi les were determined. Serum, drawn at one time point, 
of 8 randomly chosen individuals was used. Serum of each individual was divided 
into 11 primary aliquots. From each serum sample one aliquot was measured within 
30 minutes after blood collection. The remaining ten sets were immediately frozen 
at -70 °C. Four hours after the initial freezing, all aliquots were removed from the 
freezer. Two aliquots of each sample were left at room temperature and the rest on 
ice for approximately 2 hours until completely thawed. Following the fi rst freeze-
thaw cycle, two samples, one thawed on ice and one at room temperature, were 
assayed. The remaining sets of aliquots were refrozen at –70 °C for 4 hours. Again 
one sample of each individual was allowed to stand at room temperature and the 
rest on ice for 2 hours until completely thawed. Subsequently, two samples were 
processed and the rest refrozen. This was repeated after respectively three and four 
freeze-thaw cycles, but all samples were thawed on ice.
Circadian rhythm 
In a last set of experiments, effects of at which moment of the day blood was drawn 
on serum protein profi les were studied by analyzing serum samples of 16 individu-
als, drawn at three different times over the day. All samples were frozen and thawed 
once and assayed on one day according to the standard protocol.
RESULTS
The data processing pipeline described above was applied to all our experiments. In a 
preliminary step the infl uence of effective bin width was studied. We found that stron-
ger fi ltering, which corresponds to increasing the effective bin width, broadens peaks in 
both mean and standard deviation spectra, but that the CV did not change much (less 
than 20%). Therefore, the subsequent experiments were analysed with bins of 1 m/z. 
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Reproducibility 
A test concerning intra-measurement reproducibility was performed by determin-
ing the coeffi cient of variation (CV) over 8 MALDI-TOF spectra for each subject, as 
shown in fi gure 2. The CV of the reproducibility within one measurement was less 
than 20% for 6 out of 8 subjects. Subject D2 and D5 showed slightly higher CV’s of 
22% and 29%, respectively.
The inter-measurement reproducibility of 4 serum samples performed on 4 dif-
ferent days is shown in table 1. The range in CV between the spectra within one 
individual (14-23%) is similar to the CV between the consecutive days after correc-
tion for differences between individuals (17-26%). However, the variation in spectra 
between the 4 consecutive days was minor, with an increase in CV on day 4 - 26% 
(Figure 3).
Sample handling 
To establish the effects of serum sample handling, an ANOVA was performed for 
effects of persons, time and temperature and residual variation (Figure 4). After cor-
rection for inter-individual differences and residual standard deviations with ANOVA, 
CV between storages at room temperature or at 4 °C was calculated to be 45 and 
50%, respectively. The CV of the samples stored for different periods of time before 
centrifugation ranged from 42% to 67% (Table 2). There was no correlation between 
the storage time and the coeffi cient of variation. 
Freeze-thaw cycles 
The effects of multiple freeze-thaw cycles on serum protein profi les were deter-
mined for 10 sets with various storage circumstances, as set 5 had to be left out of 
the analysis due to technical problems. Table 3 shows the coeffi cient of variation 
between persons for different freeze-thaw cycles. In fresh serum samples (set 1) the 
CV was highest with 64%. With the growing number of hours that serum samples 
were stored in the fridge at 4 °C, the CV decreased to a minimum of 24% after 8 
Table 1. Coe  cient of variation (CV) for inter-measurement reproducibility. The CV was determined over 4 MALDI-TOF spectra of each 
individual, all measured at consecutive days.











Figure 2.  Intra-measurement reproducibility. The CV was determined over 8 MALDI spectra of each 
individual, all processed in one run. 
Figure 2.  Intra-measurement reproducibility. The CV was determined over 8 MALDI spectra of each individual, all processed in one run.
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Figure 3. ANOVA for inter-measurement reproducibility. The CV is calculated for spectra that are 
measured on the same day, after correction for inter individual differences. 
Figure 3. ANOVA for inter-measurement reproducibility. The CV is calculated for spectra that are measured on the same day, after correction for 







gure 4. ANOVA of sample handling. From top to bottom: the average spectrum; the variation in spectra 
due to person's effect; the variation in spectra due to time effects is shown. Finally, the effects of storage 
temperature variation and the standard deviation of the noise for each sample are presented. 
Figure 4. ANOVA of sample handling. From top to bottom: the average spectrum; the variation in spectra due to person’s e ect; the variation 
in spectra due to time e ects is shown. Finally, the e ects of storage temperature variation and the standard deviation of the noise for each 
sample are presented.
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hours. The number of freeze-thaw cycles had no infl uence on the CV. All CV of sets 
6 to 11 were smaller than 28%, with exception of set 7 (thawed at room temperature 
after one cycle) with a CV of 39%. 
To get an impression of the patterns of change with freeze-thaw cycles, we applied 
the following procedure to each of the 8 subjects: 1) selected the 8 spectra of the 
reference set spectra; 2) subtracted these reference spectra from the individual spec-
tra of all sets; 3) regressed (per spectrum) the absolute value of the corresponding 
reference spectrum, to calculate a CV. The so computed CVs are presented in fi gure 
Table 2. Coe  cient of variation (CV) between storage times of venous blood before serum centrifugation, regardless the temperature of storage








Table 3. Coe  cient of variation (CV) between persons per freeze-thaw set. Each set consisted of serum samples of 8 subjects. Each set was 
stored under di erent circumstances, namely after none or 1 to 4 freeze-thaw cycles.  Sets 1 to 4 were not frozen at all, but stored at 4 ° C during 
di erent periods of time.
Set No freeze-thaw cycles Temp CV (in %)
1 0 21 ° C 64
2 0 (2 hrs) 4 ° C 40
3 0 (4 hrs) 4 ° C 39
4 0 (8 hrs) 4 ° C 24
6 1 on ice 26
7 1 21 ° C 39
8 2 on ice 28
9 2 21 ° C 25
10 3 on ice 28






5. Generally, all 8 subjects showed the same patterns per reference set, with one or 
two outliers. In contrast to the other reference sets, 6 showed a continuous increase 
in CV per extra set. Between the reference sets 7 and 10, the patterns became more 
identical and the CV was decreased over all sets. In set 11, the variation between the 
subjects increased, became more variable.
Circadian rhythm 
The effect of time variation of blood drawing on serum protein profi les is shown 
in table 4. Spectra in set 1, collected at 8 a.m. when subjects were fasting, showed 
a CV between the 8 individuals of 51%. Set 2, collected half an hour after lunch, 
and set 3, drawn at the end of the afternoon, non-fasting, resulted in 44% and 55%, 
respectively. No large difference in CV was found between the three sets. 
 
Figure 5. Coefficient of variation between the samples of one reference set and set 6 to 11. On the Y-axis 
the CV is stated . The sets of the freeze-thaw experiment, as described in table 3, are represented on the 
X-axis. 
Figure 5. Coe  cient of variation between the samples of one reference set and set 6 to 11. On the Y-axis the CV is stated . The sets of the freeze-
thaw experiment, as described in table 3, are represented on the X-axis.
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DISCUSSION
So far, in a limited number of studies, proteomics-based approaches have shown 
promising results for the generation of diagnostic profi les in serum. Substantial at-
tention was given to analyze low molecular weight protein patterns from easy-
accessible body fl uids. To qualify as a future diagnostic test, the entire procedure 
of protein profi ling should be easy to use, robust, reproducible and affordable.[15] 
High-throughput will also be essential for embedding protein profi ling in the clinical 
setting. The use of fractionation protocols, such as reversed phase magnetic beads, 
to reduce the complexity of biological samples in MALDI-TOF is needed to avoid sig-
nal suppression effects.[20] Therefore, direct analysis of serum is not feasible. In this 
study we have chosen to use the increasingly accepted C8 magnetic bead capturing 
technique, taking into consideration that only a small fraction of proteins, from the 
potential ten thousands of proteins and peptides in human serum can be analysed 
with this approach. In future studies we will evaluate capturing techniques with 
different functionalities. In our MALDI-TOF experiments we obtained ‘rich’ mass 
spectra, containing many peaks and showing much detail. Our novel data processing 
pipeline proved to be an effective tool for quality assessment. Baseline correction, 
binning and fi ltering provided uniformly structured data in which most typical arte-
facts had been removed. The ANOVA algorithm separates the sources of variation 
and provides easily understood numerical summaries of their relative strength.
There is much room for further improvement and refi nement. Calibration of the 
spectra is now based on the median over the domain of interest (1500 to 10,000 
Dalton). This is a natural, but rather arbitrary choice. It would be attractive if stable 
areas in spectra could be located on which to base calibration, or if a reliable spiking 
procedure was available. 
The ANOVA assumed an additive model for the spectral intensities, which is ac-
ceptable to compare the relative infl uence of logistical factors. However, one could 
argue that a multiplicative model might hold as well, or perhaps even better. It is not 
possible to simply take logarithms and replicate the ANOVA, as many mass channels 
Table 4. Coe  cient of variation (CV) between individuals per time point of blood collection. Each set consists of serum samples of 16 subjects, 
all drawn at time point as indicated in the table.
Set Time of blood drawing Fasting CV
1 8-9 a.m. Yes 0.51
2 13-14 p.m. No 0.44






contain negative numbers after baseline correction, caused by noise. A threshold 
may solve this problem, but overall coeffi cients of variation depend on the level of 
this threshold. 
We have analysed the data in the form of binned spectra. An alternative approach 
is to detect individual peaks and analyze peak lists.[21;22] For our purpose, quanti-
fi cation of the reproducibility and of the effects of logistical factors, this would offer 
no advantages. The experiments with increased smoothing showed only a small 
infl uence of the effective bin width on the CV. In a peak list, each peak acts like 
one ‘bin’ representing a group of highly correlated intensities around it. Whether 
we compute a local coeffi cient of variation by averaging over these individual in-
tensities or over a smaller set of representative peak heights makes little difference. 
A disadvantage of peak lists is the need for fi nding complete lists for all spectra, 
because missing peaks complicate the ANOVA. Furthermore, we used the Whittaker 
smoother to remove noise and in baseline removal.[18] Compared to wavelets, it has 
the following advantages: one has continuous control over smoothness and one very 
short Matlab function does all the work, eliminating any need for toolboxes.[22] 
With the employed statistical data analysis the intra-measurement experiments 
showed a good reproducibility. It is generally accepted that factors like matrix com-
position and ionisation suppression infl uence the quality of the MALDI spectra, 
which in turn will always result in a certain degree of variance in intensity of the 
generated spectra. This phenomenon can be seen in spectra of subject D5. All spec-
tra of this individual were of inferior quality, possibly due to ionisation suppression 
or poor matrix solvent composition.[23] Ion suppression results from the presence 
of less volatile compounds that can change the effi ciency of droplet formation or 
droplet evaporation. This in turn affects the amount of charged ion in the gas phase 
that ultimately reaches the detector and may result in lower quality spectra.[24;25] To 
minimize these infl uences, we used HCCA as a matrix and each sample was spotted 
four times. However, differences in ionisation rate and thus in peak intensity are 
intrinsic to the technique and have to be accounted for in the statistical analysis.
The inter-measurement reproducibility within one individual corresponded to the 
intra-measurement reproducibility for all 4 individuals. However, there seems to be 
a very small but acceptable day-to-day variation between the different experiments. 
Therefore, we recommend performing all experiments on one day or to correct for 
day-to-day variation. To further enhance intra and inter-measurement reproducibility 
application of robotics for sample processing is recommended. Indeed, implementa-
tion of an automated procedure on an 8-channel Hamilton STAR® pipetting robot 
(Hamilton, Martinsried, Germany) did result in a further reduction of the CV (data 
not shown).
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Ultimately, it might be advisable to include a synthetic peptide mix in the gener-
ated spectra for external calibration. In larger profi ling studies, batch effects should 
be taken into account in the design of the study. 
Moreover, it is interesting to speculate on the potential discriminating power of 
MALDI spectra. In the reproducibility experiment we found the overall CV of the er-
ror to be 0.18 and that of the person effect 0.33. This can be expressed as a reliability 
coeffi cient r = 0.332/(0.332 + 0.182) = 77%. This indicates that nearly 80% of variation 
in spectra is related to differences between persons. This is not a percentage that in-
dicates that on the basis of whole spectra discrimination between individual spectra 
will be possible. The graphs of CV as computed for windows of 500 Dalton show 
strong variations, suggesting that better discrimination could in principle be achieved 
by using selected parts of the m/z domain. Of course, our data were generated from 
healthy volunteers, so it remains to be determined how much spectra will differ 
between healthy and diseased persons. 
In this study the largest effect was observed for sample handling conditions. There 
was no correlation between the increasing number of hours before centrifugation 
and the variation between the serum protein profi les, but the overall variation was 
larger. This would already justify acceptance of a certain time range after blood 
collection and before centrifugation. Furthermore it is unlikely that in a hospital’s 
daily practice this factor could be rigorously standardised. Thus, although a standard 
time period would be ideal, we accept a delay of 0-4 hours between the moment of 
blood collection and serum centrifugation. In view of the fact that there was no large 
difference between the storage temperatures and logistical factors, leaving all blood 
samples to stand at room temperature before centrifugation seems justifi ed. 
The effect of increasing numbers of freeze-thaw cycles was small and consistent, 
with the exception of set 7, in which serum samples were thawed only once at room 
temperature. The coeffi cient of variation in this set was larger than in all other sets, 
as shown in table 3. This might be explained by the fact that protein degradation oc-
curs sooner at room temperature, as also demonstrated in sets 2-4. This phenomenon 
might be explained by proteolytic activity and the fact that hydrophobic interactions 
are strengthened, while with increasing temperature the hydrogen bonding is weak-
ened and the electrostatic interactions are not changed due to its entropic origin.[26] 
Whereas the range in coeffi cients of variation between increasing numbers of freezes 
and thaw cycles is small, fresh serum samples provided the largest variation between 
persons, almost double in comparison to other sets. Furthermore, in fresh serum 
samples the number of peaks observed was less than 50, as also reported by other 
groups.[15;27] We suggest that in this early stage of defi ning optimal parameters/
conditions for serum pattern diagnostics the use of fresh serum samples is better 






loss of proteins and peptides and thus of information. However, on the condition 
that all samples are treated according to a standard protocol, this would not be criti-
cal for a black box approach. Thus it would seem that the use of archival material 
is safe with respect to the effect of freezing and thawing; nevertheless it remains 
of paramount importance that the entire sample handling and storage procedure is 
standardised. Based on the fact that the coeffi cient of inter-group variation in refer-
ence set 8 is lower than in the other sets (Figure 5), we prefer to use serum samples 
for further studies, which have undergone two freeze-thaw cycles. Moreover, our 
choice is mainly rooted in practical and logistical reasons, as in many large hospitals; 
sample collection is centralised in the clinical chemical laboratory. 
With only minimal variation observed between protein profi les from samples col-
lected at three different time points over the day, circadian rhythm seems to have 
limited effect on individual serum protein profi les. This is an encouraging fact, as 
blood samples can be collected all over the day, which increases the future appli-
cability of serum protein profi ling in the clinic. Furthermore, there is no indication 
that fasting has any infl uence on serum protein profi les, which also facilitates future 
clinical use.
All together, we have presented a method to assess the reproducibility of a protein 
profi ling procedure using a high-end MALDI-TOF. Our appliance of ANOVA over 
the mean spectra allowed analysis of the effects of handling and storage procedures 
on serum protein profi les. The results from this study stress the importance of a 
standardised collection of all blood samples, from the moment of sample handling 
and storage until freezing the samples in order to prevent bias in classifi cation stud-
ies. Although the importance of homogeneity and uniformity within sample groups 
must be stressed, variation of such factors can not totally be excluded in a clinical 
setting. The most important issues for discriminating studies at this moment are a 
standardised and well-documented sample collection and a thorough study design. 
Based on the present data and those of Villanueva et al.[15], we feel that the method-
ology can be standardised to a level which allows application as a tool in biomarker 
discovery. Although it remains to be seen whether actual biomarkers can reliably be 
identifi ed with the current technique, we are now in the process of carrying out a 
study to determine whether serum protein profi les can differentiate colorectal cancer 
patients from individuals with benign bowel disorders and healthy subjects. To this 
end and to facilitate high-throughput studies, we developed an automated platform 
for our capturing technique with C8 magnetic beads with reverse-phase based func-
tionality and we used the MS instrument’s AutoXecute function to further enhance 
reproducibility (data not shown). In addition to large clinical studies as mentioned 
above, such a platform would also be valuable for more large-scale studies as e.g. 
inter group variance (cases versus controls) under different experimental setups.
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Serum protein profi ling is a promising approach for classifi cation of cancer versus 
non-cancer samples. The objective of our study was to assess the feasibility of mass 
spectrometry based protein profi ling for the discrimination of colorectal cancer pa-
tients from healthy individuals.
Experimental design
In a randomised block design pre-operative serum samples obtained from 66 col-
orectal cancer patients and 50 controls, were used to generate MALDI-TOF protein 
profi les. After pre-processing of the spectra, linear discriminant analysis with double 
cross-validation was used to classify the protein profi les.
Results
A total recognition rate of 92.6%, a sensitivity of 95.2% and a specifi city of 90.0% 
for the detection of CRC were shown. The area under the curve of the classifi er was 
97.3%, which demonstrates the high, signifi cant separation power of the classifi er. 
Conclusions
Double cross-validation shows that classifi cation can be attributed to information in 
the protein profi le. Although preliminary, the high sensitivity and specifi city indicate 
the potential usefulness of serum protein profi les for the detection of colorectal 
cancer. 
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INTRODUCTION
Colorectal cancer (CRC) is among the most common malignancies and remains a 
leading cause of cancer-related morbidity and mortality. It is well recognised that 
CRC arises from a multistep sequence of genetic alterations that result in the trans-
formation of normal mucosa to a precursor adenoma and ultimately to carcinoma. 
Given the natural history of CRC, early diagnosis appears to be the most appropriate 
tool to reduce disease-related mortality.[1;2] Currently, there is no early diagnostic 
test with high sensitivity, specifi city and positive predictive value, which can be used 
as a routine screening tool. Therefore, there is a need for new biomarkers for col-
orectal cancer that can improve early diagnosis, monitoring of disease progression 
and therapeutic response and detect disease recurrence. Furthermore, these markers 
may give indications for targets for novel therapeutic strategies.
Proteomic expression profi les generated with mass spectrometry have been sug-
gested as potential tools for the early diagnosis of cancer and other diseases. Differ-
ent protein profi les may be associated with varying responses to therapeutics. It has 
been postulated that on the basis of the presence/absence of multiple low-molecular-
weight serum proteins using time-of-fl ight (TOF) mass spectrometry technologies, 
such as SELDI-TOF and MALDI-TOF, biomarkers can be identifi ed.[3-6] Although 
the data from these studies are encouraging, critical notes have been made on both 
study design and experimental procedures for proteomic profi ling.[7-9] In addition, 
the importance of avoiding confounding biological variables, as well as technologi-
cal factors that may bias the results, have previously been stressed by several au-
thors.[10;11] Another recurrent topic for debate is the use of independent validation 
sets for the classifi cation of diseased versus healthy individuals. A specifi c problem 
in the discovery-based research fi eld of clinical proteomics is overfi tting. Overfi tting 
may occur in the analysis of large datasets when multivariate models show apparent 
discrimination that is actually caused by data over-interpretation, and hence give rise 
to results that are not reproducible.[9;12;13] The chance of overfi tting, however, can 
be reduced by appropriate application of validatory estimation and assessment, such 
as through application of double cross-validation, when properly implemented. 
The objective of this study was to assess the feasibility of mass spectrometry based 
protein profi ling for the discrimination of colorectal cancer patients from healthy in-
dividuals. In addition to standardizing technical factors and biological variations, we 
performed blinded tests and employed a randomised block design experimentation 
to minimize impact of potential confounding factors and to avoid bias. To minimize 
danger of overfi tting, among other reasons, we used a fairly infl exible classifi cation 
method based on fi rst-and-second order statistics only. Specifi cally, Fisher linear 










Serum samples were obtained from a total of 66 colorectal cancer patients one day 
before surgery. All patients with stage IV disease had synchronous metastatic disease 
confi ned to the liver. Colorectal cancer was histological confi rmed on surgical speci-
mens and preoperatively assessed with abdominal CT scan and carcinoembryonic 
antigen (CEA) levels. The extent of tumour spread was assessed by TNM classifi cation 
based on histological examination of the resected specimen. All stages of colorectal 
cancer were represented in the patient group. The median age of the patient group 
was 62.8 years (range 32.6-90.3) and the male to female ratio was 31/35. Patients 
were included from October 2002 till December 2004 in our Center. The control 
group consisted of 50 healthy volunteers. The median age of the healthy symptom-
free control group was 49.7 years (range 25.9-76.6) and the male to female ratio was 
21/29. The controls were included from October till December 2004 (Table 1). 
Study design 
Having identifi ed plate-to-plate and day-today variation as important potential batch 
effects, we used a randomised blocked design.[14;15] All the available 116 samples 
from both groups (controls and colorectal cancer) were randomly distributed across 
3 plates in roughly equal proportions (Table 2). For colon cancer, the distribution of 
stadia across plates was again in random fashion and in approximately equal propor-
tions (Table 3). The position on the plates of samples allocated to each plate was 
randomised as well. Each plate was then assigned to a distinct day, which completes 
the design. Analysis was carried out on 3 consecutive days, Tuesday to Thursday, 
Table 1. Patient characteristics.
CRC patients Controls
inclusion results
n = 66 63 50
Age (mean) 62.6 62.2 49.7
Age (range) (32.6-90.3) (32.6-90.3) (25.9-76.6)
Male/female ratio 34/32 31/32 21/29
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processing a single plate each day. A duplicate of this randomised blocked study was 
performed in the following week.
Serum samples
Informed consent was obtained from all patients and the Medical Ethical Committee 
approved the study. All blood samples were drawn while the patients or healthy 
controls were seated and non-fasting. The samples were collected in a 10 cc Serum 
Separator Vacutainer Tube and centrifuged 30 min later at 3000 rpm for 10 minutes. 
The serum samples were distributed into 1 ml aliquots and stored at -70 ºC until the 
experiment.[16]
Table 2. Distribution and randomisation of serum samples of colorectal cancer patients with di erent TNM stage before and after the MALDI-
TOF experiment. The distribution of stadia across plates was performed randomly and in approximately equal proportions.
Plate 1 Plate 2 Plate 3 Total
Colorectal cancer 22 22 19 63
Controls 17 17 16 50
Total 39 39 35 113
Table 3. Distribution and randomisation of serum samples of di erent groups over the three MS target plates.
TNM stage Plate 1 Plate 2 Plate 3
Inclusion I 4 4 3
II 10 10 8
III 4 4 4
IV 4 4 4
0 4 3 3
Total 26 25 22
Exclusion I 0 0 1
II 0 0 1
III 0 0 1
IV 0 0 0
0 4 3 3






Isolation of peptides 
The isolation of peptides from serum was performed using the magnetic beads, 
based hydrophobic interaction chromatography (MB-HIC) kit from Bruker, mainly 
according to the manufacturers instructions, adapted for automation on an 8-channel 
Hamilton STAR® pipetting robot (Hamilton, Martinsried, Germany). Magnetic beads 
with C8- functionality (MB-HIC8) were divided in 5-µl aliquots in a 96-well microtiter 
plate, which was placed on the magnetic beads separation device (MPC®-auto96, 
Dynal, Oslo, Norway), with the magnet down. Ten µl MB-HIC binding solution and 
5-µl serum sample were added to the beads and carefully mixed using the mixing 
feature of the robot. The sample was incubated for 30 sec and the magnet was lifted, 
followed by a 30 sec waiting interval to settle the magnetic beads. The supernatant 
was removed and the magnet was lowered again. The magnetic beads were washed 
three times with MB-HIC washing solution (also provided with the kit) lifting and 
lowering the magnet as needed. The peptides were eluted from the beads using 
10-µl 50% acetonitrile and 2-µl of this eluate was transferred to a fresh 384-well 
microtiter plate (Greiner). Most of the remaining eluate (6-µl) was transferred to an 
auto sampler vial containing 54-µl water and stored for later use. 15-µl α-cyano-4-
hydroxycinnamic acid (0.3 mg/l in ethanol: acetone 2:1) was added to the 1-µl eluate 
in the 384-well microtiter plate and mixed carefully. 1-µl of this mixture was spotted 
in quadruplicate on a MALDI AnchorChip™ (Bruker Daltonics, Bremen, Germany).
Protein pro ling 
Matrix Assisted Laser Desorption Ionisation Time-Of-Flight (MALDI-TOF) mass spec-
trometry measurements were performed using an Ultrafl ex TOF/TOF instrument 
(Bruker Daltonics, Bremen, Germany) equipped with a SCOUT ion source, operating 
in linear mode. Ions formed with a N2 pulse laser beam (337 nm) were accelerated 
to 25 kV. With this specifi c serum preparation peptide/protein peaks in the m/z 
range of 960 to 11,169 Dalton were measured. An independent mass spectrometer 
operator performed the experiments at 3 consecutive days after cleaning of the 
instrument. One week later the experiment was duplicated in exactly same order. 
Hereafter the entire process of capturing and concentrating serum proteins using C8 
magnetic beads including the generation of readouts of the MALDI-TOF spectra will 
be designated as the protein profi ling procedure.
Data processing 
All unprocessed spectra were exported from the Ultrafl ex in standard 8-bit binary 
ASCII format. They consisted of approximately 45,000 mass-to-charge ratio (m/z) 
values, covering a domain of 1160-11,600 Dalton. To increase robustness, the aver-
age of four spots was used to represent one serum sample. Subsequently, we lightly 
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smoothed the spectra using the Whittaker[17] smoother. Due to the quadratic nature 
of the TOF-equation, the high-resolution spectra were binned using a linear scaling 
at the time scale, resulting in bin widths of approximately 1 Dalton at the beginning 
of the spectrum and 3 Dalton at the end at the mass/charge scale. The resulting spec-
tra generally showed strong baseline effects. These were removed using an asym-
metric least squares algorithm. To normalize the spectra, we calculated the median 
intensity of every spectrum and subtracted it from the original spectrum. Each of the 
thus normalised spectra was then also divided by the interquartile range of intensity 
within that spectrum. We consider this more robust than normalization of the spectra 
on the average, as it is less sensitive to the most extreme intensities. Finally, prior 
to classifi cation and evaluation of error rate, the logarithm was taken of all intensity 
measurements (predominantly to ensure numerical stability of computations). 
Statistical data-analysis 
Fully validated classifi cation error rates were estimated based on a classical Fisher 
linear discriminant analysis through complete double cross-validatory joint estima-
tion and assessment of class predictions, as is further explained in appendix 1.[18-20] 
Instead of ordinary leave-one-out cross-validatory choice of k, we employ double 
cross-validation. This is an extension of leave-one-out cross-validation which com-
bines validatory ‘choice of model’ (the parameter k in this case) with ‘predictive 
assessment’ (of the same model, through use of error rate or other suitable summary 
statistic). The reason for this additional “technical complication” is that we do not 
wish to incur the bias inherent in the assessment, which would normally result 
from a model choice based on ordinary leave-one-out validation only. In a double 
cross-validatory evaluation, we remove each individual in turn from the data (just 
as in ordinary leave-one-out cross-validation), after which the discriminant rule is 
fully recalibrated and optimised for prediction on the leftover data (now of size n-1, 
where n is the total initial sample size) and using the same procedure in each case. 
The choice of the calibration rule (i.e. choice of k in this case) to classify the left-
out observation is then again based on a leave-one-out cross-validatory estimation 
(hence the name ‘double-cross’) within the leftover set of size n-1. The resulting 
classifi cation rule is then applied to the left-out datum to obtain an unbiased alloca-
tion for this sample. This procedure is then repeated across all individuals and for 
each person separately, after which we can calculate a truly unbiased estimate of the 
misclassifi cation rates on the basis of the thus validated (and calibrated) classifi ca-
tions. In other words, ‘double-cross’ is actually ‘leave-one-out cross-validation within 
leave-one-out cross-validation’ and it is precisely because of this that we can avoid 
bias in error rate estimation that an ordinary application of standard leave-one-out 







In the fi rst week three different randomised target plates were successfully mea-

















Figure 1. MALDI-TOF spectrum of a colorectal cancer patient (1a) and a healthy subject (1b) after peptide isolation with C8 magnetic beads. On 
the Y-axis the relative intensity is shown. The mass to charge ration (m/z) is demonstrated on the X-axis in Dalton.
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was performed in the second week on the same days. Figure 1 shows a raw data 
spectrum, directly obtained from the MALDI-TOF mass spectrometer. Before pre-
processing and further analysis a mean spectrum of each sample was calculated over 
all four spots that were measured for each sample. In case all four spots from one 
sample showed spectra of poor quality due to a technical problem, the sample was 
left out of the analysis. This was the case for 3 CRC patients’ samples. The above-
described pre-processing steps resulted in a sequence of 4483 normalised m/z values 
ranging from 1160 to 11,600 Dalton, for each individual. 
Detection of colorectal cancer 
Double cross-validatory analysis and evaluation carried out on the protein spectra mea-
sured in week 1, correctly classifi ed 45 of the 50 controls as not cancer. Sixty of the 63 
cancer samples were correctly classifi ed as malignant, including 9 of 10 TNM stage I pa-
tients (Table 4). The remaining 2 misclassifi ed patients had stage II disease. All patients 
with stage III and IV disease were correctly recognised as malignant within the double 
cross-validatory evaluation. These validated results thus yield a total recognition rate of 
92.6%, a sensitivity of 95.2% and a specifi city of 90.0% for the detection of CRC (Table 5). 
To analyze the actual discriminative power of the classifi er, we produced an ROC-curve 
(again based on the double cross-validatory classifi cation probabilities), visualizing the 
performance of the two-class classifi er in fi gure 2. The AUC of the classifi er was 97.6%.
Table 4. Double cross-validatory classi cation of serum samples. A positive test results assigns subjects to the CRC group and a negative to the 
controls. In the horizontal plane the actual histologically con rmed diagnosis is stated.
Test results for detection of CRC
Neg Pos Total
Controls 45 5 50
CRC patients 3 60 63
48 65 113
Table 5. Cross-validated classi cation results for the detection of CRC. TRR is the total recognition rate; Sens and Spec are sensitivity and 
speci city respectively. AUC is the estimated area under the ROC curve.
Method First week Second week
TRR Sens Spec AUC TRR Sens Spec AUC






We repeated the entire double cross-validatory evaluation executed with the week 
1 data using the duplicate measured spectra from week 2. This procedure was identi-
cal to that carried out in week 1 and used the same calibration spectra. However, 
prior to classifying each left-out datum in the outer “shell” of the double cross-
validatory procedure, we substituted the week 1 data with the corresponding mea-
sured spectra from the same sample in week 2. In this manner, we could calculate a 
double cross-validatory error rate, which takes the effect of replicate measurement of 
the spectrum (and thus also recalibration of the equipment) into account. The effect 
of classifying the remaining replicate data was that the recognition rate dropped to 
88.8%. The sensitivity and specifi city for the detection of CRC for the second week 
data was 80.6% and 97.1% respectively (Table 4). The associated AUC of this repeat 
double cross-validatory estimation on week 2 was 96.8%. 
It is of interest to evaluate bias of the double cross-validatory calculations. Hence, 
we performed a permutation exercise, which randomly permutes and reassigns 
the class labels across subjects and then repeats the entire double cross-validation 
procedure. Carrying out this procedure more than 600 times resulted in a median 
recognition rate of 50.0% (95% confi dence interval is [36.3, 72.7]). The median AUC 
was 49.4% with confi dence interval of [24.8, 64.2]. As both median recognition rates 
 
Figure 2.. 
Figure 2. ROC-curve for the double cross-validated two-group classi er. The true positive recognition rate (sensitivity) is demonstrated on the 
y-axis against the false negative recognition rate (1-speci city) on the x-axis of the classi er. 
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and AUC’s equal 50%, there is thus no substantial evidence of bias remaining within 
the cross-validatory calculation.
Having executed the above-described validatory evaluation, we can explore the 
nature of the classifi cation through a post hoc analysis. We found that the fi rst 
two principal components provide most of the between-group separation. Figure 3
shows a plot of the correlation coeffi cients, with the class indicator, which can be 
calculated from the linear discriminant weightings in the region between 1160 and 
11,600 Dalton.[20;21] The remainder of the plot is not shown, as the coeffi cients are 
effectively zero in that range. As can be seen, the classifi cation is achieved primarily 
through a contrast in peak intensities between the fi rst and second principal compo-
nent. This can also be seen from the scatter plot shown in fi gure 4: low intensities at 
the fi rst peak for cases separates cases from controls. Likewise, a small contribution 
for controls at the second peak separates controls from patients. To illustrate these 
results further, we can simply calculate the contrast between the two peak intensities 
directly across all subjects and construct a simple one-dimensional summary of the 
data, as shown in the histogram displayed in fi gure 5, which shows overlapping 
histograms of this (ad hoc) contrast for each group separately. The separation is 
clearly visible. We may also quantify the signifi cance of this difference by performing 








Figure 3. Correlation coe  cients of two  rst principal components with the class indicator. The correlation coe  cients were calculated from the 
linear discriminant weightings. The negative correlation of the  rst peak is an indicator for the control group and the positive correlation of the 









Figure 4. Scatter plot of the  rst two principle components on basis of which the classi cation patient-control group was made.
Figure 5. Histogram showing the di erence between the normalized intensities of the two most discriminating “peaks” (bins). The X-axis shows 
the di erence between the normalized intensities of the peaks. On the Y-axis the number of subjects is displayed.
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DISCUSSION
Our study supports the hypothesis that serum protein profi les can discriminate a 
normal from a malignant state of organs, in our case of the colon. Here we show 
that, based upon information in MALDI-TOF serum spectra, a classifi er could be 
constructed for the detection of CRC. This classifi er, calibrated and validated on 
spectra of week one demonstrated a sensitivity and specifi city of 95.2% and 90.0% 
respectively. Thirty-four patients out of thirty-seven with early stage disease (stage 1 
and 2) and all patients with stage 3 or 4 disease were correctly classifi ed as having 
cancer. For the misclassifi ed control subjects it was not possible to retrieve the cur-
rent physical state as it concerned anonymous healthy controls. 
Sensitivity and specifi city of 80.6% and 97.1% respectively was achieved when the 
entire double cross-validatory evaluation was repeated for the data of week 2. The 
latter evaluation, through use of replicate measurements within the double cross-
validation, is likely to provide the more realistic assessment of true error rates and 
appears to better represent possible diagnostic potential as will be discussed further 
in this paper.
Although previous studies have reported similar high classifi cation results for 
various solid tumours, we prefer evaluation through a thorough study design and 
double cross-validation of classifi cation as proposed in this study.[3-6;12;22;23] As 
a great variety of different discriminating peaks for the same malignancy have been 
described,[3;4;24] caution with proteomic data has been stressed before.[7;8] The dis-
crepancies in discriminating protein profi les, found by different research groups, lead 
to serious concerns regarding biological variations and technological reproducibility 
issues. Therefore, we used a standardised and well-documented sample collection 
and a thorough study design, matching biological variables and pre-analytical condi-
tions.[16] Still, patient samples from all stages of CRC were equally distributed over 
the different target plates, as was the male/female ratio between the two groups, 
excluding these factors as a discriminator in the detection classifi er. Unfortunately 
there was signifi cant difference in age; the control group being younger than the 
CRC patients. Ideally, the control group should consist of age-matched symptom-free 
individuals undergoing a colonoscopy showing no aberrations. However, due to the 
nature of the intervention, ethical legislation and the increasing disease burden with 
ageing this is diffi cult to realize in clinical practice. Notwithstanding, we performed 
an analysis to examine the differences in intensity of most discriminating peaks 
based on age, gender and sample age. In the present study there was no signifi cant 
contribution of one of these factors on the most discriminating peaks of our clas-






A source of bias may be the presence of batch effects, such as day-to-day varia-
tion or plate-to-plate variation. The presence of batch effects is unavoidable and 
– rather than to eliminate them from the design – a better approach is to account 
for and accommodate these effects, in such a way that they do not lead to errors 
of artifi cially induced group separation. Consequently, we randomly distributed the 
available samples from each group across the batches such that proportions were 
equal across batches within group. The so-called randomised block design ensured 
that the batch effect – if it materialised – would not induce an artifi cial between-
group effect.[14;15] 
A crucial point of discussion in the evolving fi eld of clinical proteomics is valida-
tion of classifi cation.[9;25] Given the sample size achievable within the experiment, 
use of a separate (possibly set-aside) validation set was precluded. The other prob-
lem is ‘predictive optimisation’. However, as evaluation of predictive performance 
of the classifi er is our primary focus, it is crucial that calibration is not carried out 
on the same data used for validation, which in turn would require an additional 
tuning set. Again, this would greatly increase the burden of collecting suffi cient 
samples. For these reasons, other studies often carry out predictive optimisation on 
the full data in practice - which results in optimistically biased error rate evaluations, 
particularly with high-dimensional data such as in mass spectrometry proteomics.[26] 
As we have already suggested, another option is to reduce the available calibration 
data prior to optimisation, so as to set aside data, both for a training and validation 
set. However, this ‘solution’ is not as innocent as would appear at fi rst sight, since it 
typically reduces the calibration set beyond the point of what is needed for reason-
able calibration. Once more, this is particularly the case in high-dimensional cases 
such as clinical proteomics, where samples of malignancies are relatively diffi cult to 
obtain. Both problems may be avoided by carrying out a double-cross-validatory ap-
proach, which avoids the need for separate test and validation sets to yield unbiased 
error rate estimates. The double validatory aspect of the procedure results from the 
fact that the discriminant rule constructed to classify the left-out data was optimised 
through a secondary cross-validatory evaluation within the fi rst cross-validatory layer 
(i.e. full cross-validation again on each ‘leftover’ set after removal of an observa-
tion). In this manner, we are able to integrate predictive optimisation and predictive 
unbiased validation in the same procedure, without loss of data – which is a crucial 
requirement to get realistic estimates of error rate with high-dimensional data while 
reducing the risk of overfi tting.[27] Although the principle is sound and understood, 
this procedure has until recently not been applied in practice due to the considerable 
computational cost and (algebraic) complexity of the method. 
Our classifi er is based on Fisher linear discrimination, which has been derived and 
may be justifi ed based on a variety of principles of inference, such as maximization 
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of the between-group separation relative to within-group error in the two-group case 
or the likelihood principle for normally distributed within-group populations. The 
methodology has been amply studied and has been established as reliable and robust 
form of classifi cation and discriminant analysis. Furthermore, Fisher discrimination 
does not require an assumption of within-group normal dispersion.[21;28;29] Hastie 
et al. contains an up-to-date account of many new applications that demonstrate 
the continuing success of the approach.[18;21;28-30] Much similar and confi rma-
tory experience has accumulated in related fi elds of application, which identifi es 
this classifi cation method as most reliable in high-dimensional analysis.[19;31] For 
proteomic mass spectra, principal components are attractive as it provides a means 
of non-parametrically smoothing and pooling information across peaks. 
The controversy about the use of protein profi les as a pattern diagnostic without 
analysis of the diagnostic biomarkers remains to be solved for its clinical applica-
tion. Identifi cation and functional analysis of these discriminating proteins/peptides 
might render new insights on tumour development and environmental responsive-
ness, which could eventually be translated in new diagnostic and prognostic insights 
for the clinician. Unfortunately, little success has been booked so far in assigning 
reproducible discriminating biomarkers.[12;25] Though this study showed two most 
discriminating mass values of MALDI-TOF based protein profi ling analysis to be low 
molecular weight fragments, we have not identifi ed these potential biomarkers yet. 
In the present study we used patterns of proteomic signatures from high dimen-
sional mass spectrometry data to generate a diagnostic classifi er for the detection 
of CRC. To our knowledge, this is the fi rst double cross-validatory study in a ran-
domised block design in this fi eld of research. Although independent validation 
would strengthen the observations and follow up studies are now underway, we ob-
tained maximal reliability in classifi cation in this study while maintaining protection 
against overfi tting. Due to the relatively small sample size we have chosen to use our 
entire dataset for a within-study validation to avoid optimistic biased (error) misclas-
sifi cation rates. To assess the performance of our classifi er a further independent 
validation study will be necessary. In addition, in future studies the specifi city of dis-
criminating protein profi les for colorectal cancer have to be assessed in comparison 
with other cancer types. Nevertheless, we are currently able to detect CRC accurately 
on the basis of differences in actual information in the serum protein profi les with 
a rigorously standardised approach and exclusion of batch effects. Thus, although 
introduction in a routine clinical setting may take longer than originally hoped for, 
this study is an initial proof for a successful evolution of the potentially great use of 







Fisher linear discriminant analysis may be defined as assigning an observation to the group for which the 
smallest within-group distance 1( ) ( ) ( )TgD g gx x x is found for the corresponding observed 
feature vector ( ,..., )1 p= x xx  with respect to the gth group (g=1,2 here, for either cases or controls), where p 
is the dimensionality of the problem, g denotes the population within-group sample mean for the gth group 
and  is the (common) within-group dispersion matrix.  We may estimate the population means through the 
within-group sample means. When the dimensionality of the problem is greater than the sample size, as is the 
case in this problem, the observed within-group pooled covariance matrix S will typically not be of full rank 
and hence special measures are called for before we can apply the above paradigm in this context. This can be 
achieved through an initial principal components decomposition of the observed within-group pooled 
covariance matrix TS = Q Q , where Q  and 1( ,..., )rdiag  are the matrices of principal 
component weightings and variances respectively (r is the rank of the pooled covariance matrix). We then re-
estimate the within-group covariance matrix by only retaining the first k components only: 
T
(k) (k) (k) (k)S = Q Q , which account for most of the variation in the spectra. The discriminant rule may now 
be expressed as assigning an observation to the group for which we observe the smallest sample estimate 
1
( )( ) ( ) ( )
T
g g gkD x x x S x x . 
In the two-group case, this is also equivalent to least-squares regression analysis using the Moore-Penrose 
inverse of the pooled covariance matrix when k=r (all components kept, also known as shortest least squares 
regression), or else is equivalent to so-called shrunken least-squares regression.20,21 When choosing k<r, the 
choice may be made through appeal to a (cross-) validatory evaluation of the performance of the respective 
possible choices for the parameter k. The above methodology has been described and compared to other 
methods in the recent paper by Mertens18, which shows this method to be competitive in the closely related 
high-dimensional setting for classification with microarrays. Much similar and confirmatory experience has 
accumulated in related fields of application, which identifies this classification method as reliable and stable in 
high-dimensional analysis, as has been described by Stone and Jonathan, among others.19,31 
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Chapter 5
Mass Spectrometry Proteomic 
Diagnosis: Enacting the Double 
Cross-Validatory Paradigm
B.J. Mertens, M.E. de Noo, R.A.E.M. Tollenaar, A.M. Deelder, 







This paper presents an approach to the evaluation and validation of the diagnostic 
potential of mass spectrometry data in an application on the construction of an ‘early 
warning’ diagnostic procedure. Our approach is based on a full implementation and 
application of double cross-validatory calibration and evaluation. It is a key feature 
of this methodology that we can jointly optimize the classifi ers for prediction while 
simultaneously calculating validated error rates. The methodology leaves the size 
of the training data nearly intact. We present application to data from a designed 
experiment in a colon-cancer study. Subsequent to presentation of results from the 
double cross-validatory analysis, we explore a post-hoc analysis of the calibrated 
classifi ers to identify the markers that drive the classifi cation.
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INTRODUCTION 
There is currently much interest in application of mass spectrometry for the con-
struction of new diagnostic proteomic approaches for the early detection of disease. 
This is particularly the case in oncology, where there is need for new and reliable 
diagnostic tests. In this paper, we discuss the problem of ascertaining the presence of 
discriminatory information in mass spectra of serum samples in a case-control study 
for the detection of colorectal cancer. In other words, we describe -in essence -an 
early-stage feasibility study for subsequent construction of a diagnostic test based on 
proteomic mass spectra. A crucial objective of such research is to provide informa-
tion which allows researchers to make informed decisions as to the continuation of 
the research effort (which may involve experiments of much greater cost and com-
plexity in comparison to the fi rst-stage evaluation). Hence, it is essential to get a fully 
validated and unbiased assessment of predictive error rates that may be achieved, 
based on the proteomic data. At the same time, in a high-dimensional setting such as 
mass spectrometry, it is desirable that construction of the diagnostic classifi er would 
involve calibration of the predictive potential of the allocation rule itself. 
Mass spectrometry proteomics, sample size and clinical science 
In problems such as these and related settings (e.g.: microarray diagnostics, ch-
emometric discriminant studies), a key diffi culty is often the collection of a suf-
fi cient number of samples. In oncology applications this may tend to happen, due 
to logistical and ethical reasons. Our example is a typical one, as our study is a 
fi rst-stage evaluation within the context of an academic center, which has a typical 
patient population with more advanced disease. This limits the number of patients 
available for research. On the other hand, clinicians and biomedical researchers 
who wish to explore application of proteomic mass spectrometry for the construc-
tion of new diagnostic procedures, will be interested fi rst to get an indication of 
whether there is information in the spectra to allow groups to be separated and what 
the likely error rates of misclassifi cation will be. This is particularly the case since 
ethical review boards (or funding authorities) are not inclined to give permission 
for large-scale collaborative trials between hospitals, which would ease the patient 
recruitment problem, without preliminary evidence from smaller within-center trials. 
Both these reasons may conspire to cause proteomic studies to be of small sample 
size initially. 
Classical statistics will often use a separate validation set to optimize a chosen 
diagnostic classifi er for prediction fi rst. Assessment of the rule is then carried out 
on yet another test set, which must often be set-aside from the available data [1]. 






training set left over may be too small to allow researchers to apply this paradigm 
fully. In this paper, we present a double cross-validatory approach which allows for 
simultaneous predictive calibration and assessment of the allocation rule, without 
(substantial) reduction of the size of the calibration data. 
Mass spectrometry data 
The experiment and data discussed and analysed in this paper are derived from 
a MALDI-TOF (Matrix Assisted Laser Desorption Ionisation Time-Of-Flight) mass 
spectrometer (Ultraflex TOF/TOF, Bruker Daltonics, equipped with a SCOUT ion 
source which was operated in linear mode). The spectrometer produces a sequence 
of intensity readings for each sample on an ordered set of contiguous bins in the 
m/z range from 960 to 11,160 Dalton. Bin sizes (length) of the unprocessed spectra 
gradually increase with increasing m/z values, ranging from 0.07 Dalton at the lower 
end of the mass/charge scale up to 0.24 Dalton at the upper end of the scale. This 
gives intensity readings on a fi xed grid of 4483 bins within the mass-charge range 
across all samples. We refer to an earlier paper by our group for detailed information 
on experimental setup and measurement protocols.[2] 
We will discuss the essential aspects of the study design fi rst, followed by a de-
scription of the discriminant method and the double cross-validatory approach to 
joint predictive estimation (calibration) and validation of the allocation rule, which 
allows for validated error rate evaluation. Subsequent to description of the meth-
odological approach, we consider application to the colon cancer data and present 
a post hoc exploratory data analysis to interpretation of the results. While we will 
focus on our example to structure the discussion, the issues apply quite generally to 
similar problems in proteomics and many other related problems in bioinformatics, 
chemometrics, statistical prediction and beyond. We will assume that the reader has 
some knowledge of standard leave-one-out cross-validation. 
DESIGN AND SAMPLE REPLICATION 
Design 
A characteristic problem of proteomic mass spectrometry design is the need to cope 
with the presence of what we may loosely refer to as so-called ‘batch effects’. Ex-
amples are plate-to-plate variability, day-to-day variation and so on, whose presence 
is in reality unavoidable. To accommodate these effects, we identify each plate 
by day combination as a block and employ standard randomised block design by 
randomly distributing the available samples from each group (colon cancer and con-
trols) across the blocks such that proportions are (as near as) equal within and across 
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blocks for each group. For colon cancer, we randomised samples to plates in such a 
manner that the distribution of disease stages is in approximately equal proportions 
within and across plates. The position on the plates of samples allocated to each 
plate was also randomised. Each plate was then assigned to a distinct day, which 
completes the design. Table 1 summarizes the design as executed on the fi rst week, 
which provides mass spectra on 63 colon cancer patients and 50 healthy controls. 
Table 1. Design as executed on the  rst week. A replicate of the entire experiment was run on the subsequent week using plate duplicates. 
‘Stage’ refers to the distribution of cases across the four respective disease stages.
TNM stage Plate 1 Plate 2 Plate 3 Total
Cases I 4 4 3
63
II 10 10 8
III 4 4 4
IV 4 4 4
22 22 19
Controls
17 17 16 50
Total 39 39 35 113
In our case, it was decided to carry out the experiment in a single week using three 
plates only, each of which was assigned to a consecutive day in the middle of the 
week - Tuesday to Thursday. We refer the reader to the statistical literature on design 
of experiments for further discussion and details of the issues involved, as well as 
many other examples of these basic design principles.[3-6] 
Sample replication 
We can exploit design to augment cross-validatory analysis. This is because while 
sample sizes may be small (i.e. it is diffi cult to get new independent samples), the 
amount of sample material available for each sample may be more abundant. This 
allows the introduction of so-called replicate samples into the design. Since the 
samples are pre-arranged on rectangular plates, a second ‘copy’ of any plate can 
be made provided suffi cient sample material is available from each sample. (In 
our case, suffi cient sample material was available for a second copy only). Thus, 
we can duplicate the entire design from the fi rst week and remeasure the replicate 
plates through the same design on the second subsequent week, using new sample 
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)  of the associated recorded mass spectrum in the fi rst week, where 
the vector elements refer to the measured mass/charge intensities on a predefi ned 
and ordered grid of mass/charges of dimensionality p. In addition, we have for each 




, ... , x2
ip 
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replicate on the corresponding plate measured on the same day one week later. We 
may denote the associated class label from each ith observation as c(i) which takes 
value in the set of group indicators {1,...,G}, where G is the number of groups. [Note 
we will drop use of the suffi xes 1,2 when the context makes clear to which week 
the data relates.] Unfortunately, due to a technical malfunction which occurred on 
the last day of the second week the replicate measurements from the third plate are 
unavailable. As a consequence we only have available the 78 replicates from the fi rst 
2 plates in week 2 for further analysis. 
INTEGRATED CALIBRATION AND VALIDATION FOR CLASSIFICATION BY 
DOUBLE CROSS-VALIDATION 
We restrict attention to double cross-validated linear discrimination for joint calibration 
and validation.[7] First we discuss shrinkage-based estimation and the need for it in 
linear discrimination. Then we explain the double cross-validatory implementation. 
Linear classi cation and shrinkage estimation methodology 
We base classifi cation on Fisher linear discrimination. There is voluminous literature 
on the method, which is well established in the applied sciences, such as biology and 
medicine.[1;8-10] An article by Hastie et al. contains an up-to-date account of many 
new applications which demonstrate the continuing success of the approach.[1] 
Fisher linear discriminant allocation may be defi ned as assigning a new observa-






is minimal, where g denotes the group indicator with g є {1,...,G}, µ
g
the popula-
tion means and Σ the population within-group dispersion matrix which is assumed 
equal across groups. In practice, the population means and dispersion matrix will 
be unknown and hence must be estimated from the data. In a high-dimensional 
problem such as in mass spectrometry proteomics, this leaves us with a diffi culty 
in estimating the dispersion matrix as we will typically not be able to achieve a full 
rank estimate. 
Mass Spectrometry Proteomic Diagnosis: Enacting the Double Cross-Validatory Paradigm 79
At the risk of some oversimplifi cation of the discussion, there are basically two 
ways in which we may remedy the problem so that the above methodology may 
again be applied. The fi rst is through either selection or construction (or a combina-
tion of both) of a set of features which is reduced in dimensionality, while capturing 
most of the variability in the data. In essence, this is the approach which is currently 
applied in most of the mass spectrometry proteomics literature. Typical examples are 
found in papers by Baggerly, Yasui, Sauve and Morris, among others.[11-14] We do 
not consider this approach to be fundamentally flawed for mass spectrometry pro-
teomic data. On the contrary, it is self evident that mass spectra consist of mixtures of 
possibly overlaid intensity peaks corresponding to substances present in the analyte. 
Thus, to elucidate this structure (fi rst) is in principle of interest. 
The alternative is not to select in the fi rst instance, but instead explicitly utilize the 
correlations which are induced between intensities on the mass-charge bins through 
the associated discretisation of the continuous signal (peaks). The simplest approach 
is through principal components decomposition [15], which has a long history of 
successful application in classical spectroscopy such as in near infrared spectroscopy 
for example Krzanowski et al. [16] 
Within this approach, we leave the dimensionality of the data intact and instead 
introduce a regularised estimation of the dispersion matrix to cope with the singular-
ity of the sample dispersion matrix, based on the component decomposition. We ex-
plore two distinct forms of regularization, both of which may be expressed in terms 
of the spectral decomposition of the ‘observed’ (or sample) pooled dispersion matrix 
S = QΛQT where Q and Λ = diag (λ1, ..., λr) are the matrices of principal component 
weights (or loadings) and variances respectively, with λ1 > ...> λr > 0 respectively 
(r is the rank of the pooled covariance matrix). The within-group covariance matrix 

















 denotes the corresponding reduced matrix of 
component loadings. The associated linear discriminant allocation rule hence assigns 
observations to the group for which the smallest sample-based distance estimates 
g 




 (x - 
g
)T 
are observed, with 
g
the sample group means for g є {1, ... G}. In the two-group case, 
this is also equivalent to least-squares regression analysis using the Moore-Penrose 






as shortest least squares regression), or else (k<r) is equivalent to so-called shrunken 
least-squares regression.[8;17] Alternatively, we may employ ridge regularization 
S(γ) = Q[(1 − γ)Λ + γI]QT ,
where 0<γ≤ 1 is the ridge regularization or ‘tuning’ parameter, in which case the 
sample distance measures are (x - 
g
) S-1
(λ) (x - g)
T. 
Double cross-validatory estimation and validation 
Application of the above described classifi cation approaches still require choice of 
the tuning parameters k or γ involved. As we are specifi cally interested in an evalu-
ation of predictive performance of any diagnostic allocation rule, it becomes crucial 
that any optimization -such as the choice of the tuning parameters - does not take 
place on the same data used for validation. On the other hand, predictive tuning is 
clearly highly desirable if diagnosis is of interest, so we would not wish to base the 
choice of tuning parameters on the full calibration data itself (and thus effectively 
drop predictive tuning from the analysis), but use a truly validatory choice instead. 
This implies we either set aside a so-called separate ‘tuning set’ from the avail-
able calibration data prior to validation of predictive performance itself or appeal 
to some form of cross-validation. Good predictive optimization or tuning becomes 
particularly important in a high-dimensional setting, such as proteomics, as it pro-
vides an opportunity to safeguard model choice against over-fi tting (in other words: 
over-interpreting the data). Meanwhile, even if we were able to effectively choose 
good tuning parameters, the predictive performance (in our case essentially the 
error rates) of any implied allocation rule should again be validated, which again 
introduces a need for yet another set-aside validation set or cross-validation. 
We may solve both problems by carrying out a so-called double cross-validatory 
approach, which avoids the need to introduce separate test (tuning) and valida-
tion sets. The method has been fi rst proposed and investigated by Stone[7] and 
integrates predictive optimization and unbiased validated error rate estimation in a 
single validatory procedure. While the principle of the methodology is sound and 
well described, this procedure has until recently not been applied in practice due 
to the considerable computational cost and (algebraic) complexity of the method.
[18] This paper describes a fi rst full implementation in the related setting of discrimi-
nant allocation on microarray data. Other papers by our group give further details 
on computational background, application for leave-one-out in spectroscopy and 
further references.[19;20] 
Similar to with ordinary leave-one-out cross-validation, double cross-validation 
removes each individual (sample) in turn from the data, after which the discriminant 
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rule is fully recalibrated (and optimised for prediction) on the leftover data and using 
the same procedure in each case. The resulting classifi cation rule is then applied to 
the left-out datum to obtain an unbiased allocation for this sample. This procedure 
is then repeated across all individuals and for each person separately, after which 
misclassifi cation rates are calculated on the basis of the thus validated classifi ca-
tions. The double-validatory aspect results from the fact that the discriminant rule 
constructed to classify each left-out datum is optimised through a secondary cross-
validatory evaluation within the fi rst cross-validatory layer (i.e. full cross-validation 
again on each ‘leftover’ set after removal of an observation). In this manner, we are 
able to combine predictive optimization and predictive unbiased validation in the 
same procedure, without loss of data -which is an important requirement to get 
realistic estimates of error rate with high-dimensional data.
APPLICATION AND EVALUATION 
Preprocessing of mass spectra 
Some pre-processing can be benefi cial when it removes variation from the data 
which does not relate to the group separation and might obscure an existing group 
separation. We describe the pre-processing steps carried out prior to the double 
cross-validatory classifi cation analysis. 
First, we calculated for each sample the average intensity within each bin across 
the four mass spectra from the associated spots on the target plate. Then, we aggre-
gated contiguous bins on the m/z scale, such that the new aggregated bin size spans 
approximately one Dalton at the left side of the spectrum and gradually increases 
to a width of approximately 3 Dalton at the right hand side. For each of these new 
aggregated bins, we calculated for each spectrum the associated aggregate intensity 
by summing the intensities across the bins being aggregated. Subsequently, spectral 
baseline was removed from each of the thus aggregated spectra separately using an 
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) denotes the ordered sequence of baseline corrected 
m/z intensity values for the ith sample at this stage of preprocessing. We then correct 
the spectrum for the typical intensity and variability across the spectrum by calculat-
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preprocessing procedure proposed by Satten et al , although our cruder version does 






of each spectrum, where α is a real constant. We chose α = 100. The main purpose 
of the log-transform is to ensure numerical stability of calculations. The above pre-
processing steps were applied for each sample and within each week separately, 




from the fi rst and second weeks. It 
is important to stress that the preprocessing of the data of any ith sample does not 
involve use of any information based on the remaining samples {k|k ≠ i}, nor of the 
duplicate replicate measured spectrum of the same sample on another week. This 
is an important requirement to ensure the validity of the cross-validatory evaluation 
described subsequently. 
Double cross-validatory error rates 
First, we restrict ourselves to the data from the fi rst week. Table 2 displays the esti-
mated recognition rates and performance measures from an analysis of the fi rst week 
data (leftmost 3 columns). All of the estimates are based on double cross-validation. 
We used the average of sensitivity (Se) and specifi city (Sp) as our estimate of the 
total recognition rate (T), which implies we assume prior class probabilities to equal 
0.5. A threshold of 0.5 was also used to assign observations on the basis of the a-
posteriori class probabilities within the cross-validatory calculations. B denotes the 
Brier distance defi ned 
B = 1  ∑
i
  





) is the double cross-validated predicted a-posteriori class prob-
ability for the correct class c(i) for each ith sample and n is the total sample size. 
Likewise, AUC is a double cross-validation estimate of the area under the empirical 
ROC curve defi ned as 
AUC = 1   ∑
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i 






where G1 and G2 refer to the sample index labels for samples from the fi rst and 
second group respectively. Use of the threshold at 0.5 is appropriate and suffi cient 
for an evaluation of diagnostic potential only. Application in e.g. a screening type 
application would require a more careful choice of prior probability, which is how-
Mass Spectrometry Proteomic Diagnosis: Enacting the Double Cross-Validatory Paradigm 83
ever a subtly different and also subsequent research question and not the focus of 
this paper. 
The rightmost three columns of the table refers to a repetition of this entire double 
cross-validatory exercise, which replaces each sample feature vector x1
i
 with the 
corresponding replicate measurement x2
i
 immediately prior to classifi cation of that ith
sample (i.e. replacing the feature vectors with the data from week 2 in the outermost 
layer (only!) of the double cross-validatory calculation). Crucially and importantly, 
construction of the corresponding discriminant rule for the classifi cation of each such 
ith sample in the internal ‘calibration’ layer of the double cross-validatory procedure 
does of course remain based on the data from week 1. Note that as the replicate data 
from the third plate are not available, these results are based on the double cross-
validated predictions for the remaining 78 replicate samples from week 2 only.













Figure 1: Mean spectra for each group separately, after preprocessing. We plot negative









[I(p(1 | xi) > p(1 | xj)) + 0.5 ∗ I(p(1 | xi) = p(1 | xj))],
where G1 and G2 refer to the sample index labels for samples from the first and second
group respectively. Use of the threshold at 0.5 is appropriate and sufficient for an evalu-
ation of diagnostic potential only. Application in e.g. a screening type application would
require a more careful choice of prior probability, which is however a subtly different and
also subsequent research question and not the focus of this paper.
The rightmost three columns of the table refers to a repetition of this entire double
cross-validatory exercise, which replaces each sample feature vector x1i with the corre-
sponding replicate measurement x2i immediately prior to classification of that i
th sample
13







Table 2. Double cross-validated classi cation results for the colon cancer data. T is the total recognition rate. Se and Sp are sensitivity and 
speci city, respectively. B is the Brier distance and AUC is the estimated area under the ROC curve.
Method First week Second week
T (Se, Sp) B AUC T (Se, Sp) B AUC
Moore-Penrose S(r) 92.6 (95.2, 90.0) 0.0618 97.6 94.4 (91.7,97.1) 0.0600 97.4
PCA Selection S(κ) 92.6 (95.2, 90.0) 0.0606 97.3 88.8 (80.6,97.1) 0.0914 96.8
Moore-Penrose Euclidian S(r)   λ (r) = I (r) 89.4 (88.9,90.0) 0.0829 96.0 87.2 (86.1,88.2) 0.0770 97.0
PCA Selection Euclidian S(κ)   λ(κ)  = I (κ) 88.7 (87.3, 90.0) 0.0865 96.0 90.0 (88.9,91.2) 0.0795 97.0
Ridge S(r) 92.0 (95.2,88.0) 0.0602 98.4 95.8 (91.7,100.0) 0.0469 97.9
At fi rst sight, the Moore Penrose implementation (top line of the table, both weeks 
one and two) would seem to be the best performing and most consistent method. 
In week 1, Moore-Penrose, PCA-selection (both using the Mahalanobis distance) 
and ridge estimation perform equally well, but there seems to be an increase in 
error rate for week 2 for both the PCA-selection and ridge implementation. The 
Euclidean distance based implementations are worse in the evaluation on the fi rst 
week, but recognition rates are consistent across both weeks when compared to the 
other methods. These results should be interpreted with some caution and require 
some explanation. First of all, the ‘plain’ Moore-Penrose is leave-one-out only as 
it does not involve choice of shrinkage or data reduction parameter (k or λ). The 
deterioration of the PCA-selection implementations is partly due to the uncertainty 
in estimating the shrinkage terms or choice which is introduced by the double-cross-
validatory estimation. For the ridge implementation, performance is comparable to 
that from Moore-Penrose in week 1, which is not surprising since the chosen ridge 
shrinkage parameter λ< 0.0001 for most observations. The effects of uncertainty 
in the determination of the shrinkage term become particularly apparent for PCA-
selection using Mahalanobis distance (second line in the table) in week 2. The two 
Euclidean distance based implementations on the other hand seem more consistent 
across both weeks. The reason is that component selection is much more stringent 
for these two implementations, which selects only the fi rst 2 components for nearly 
all observations (with exception of two observations out of 113 for which only the 
fi rst principal component is retained). This explains the reduced performance but 
also the greater consistency of the classifi cation results. It is precisely because of this 
reason that these results (from the Euclidean based implementations) are more cred-
ible and may well turn out to be more repeatable if the classifi er were applied in the 
future to data from a new repeat experiment. For comparison, component selection 
in the Mahalanobis distance based PCA implementation is much less stringent and 
selects (k = 23 for 53 observations, k = 28 for 28 observations and the remainder of 
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the samples uses even more components). There is thus some evidence of insuf-
fi cient shrinkage for this method, and similarly for the ridge implementation. 
Investigating bias: a permutation exercise 
We have proposed double cross-validatory integrated estimation and assessment of 
statistical diagnostic rules on the basis of the argument that it should protect against 
optimistically biased evaluations. We may check this property by ‘removing’ the class 
labels c(i) from the samples i є {1, ... ,n}, randomly permute and then reassign them 
to the samples. We then carry out the double cross-validatory procedure again for 
any of our classifi cation methods. Repeating this procedure several times will give an 
indication of the biases involved, as the typical recognition rate -for example -should 
equal 50% across a large number of permutations for an unbiased method. 
Table 3. Permutation-based evaluation of double cross-validatory calculations for linear discrimination using principal component selection. 
DBCV refers to the actual double cross-validatory results (see table 2). q2:5 and q97:5 are the 2.5 and 97.5 percentiles. B is the Brier distance 
and AUC is the estimated area under the ROC curve.
Permutation results
Measure DBCV median q 2.5 q 72.5
Misclassi cation rate 7.4 50.0 36.3 72.7
AUC 97.3 49.4 24.8 64.2
B 0.0606 0.324 0.200 0.446
Table 3 shows results from such an exercise for the pca-selection based algorithm 
across more than 600 such permutations. The results, both for misclassifi cation rate 
as we fi nd median rates and areas of 50% exactly. Table 3 also includes 95% con-
fi dence intervals for the permutation-based performance measures. These give an 
indication of the variability which can be expected with purely random data and 
can be compared with the actually observed double-cross-validation results in our 
study (second column of the table). Clearly, the distance between the validated mea-
sures actually observed and even the extreme bounds of the random permutation 
confi dence intervals is considerable, demonstrating the presence of discriminating 
information in the mass spectra. 
Data reduction and post-hoc exploratory analysis 
We wish to get an indication of which markers drive the classifi cation. To explore 
these aspects, we can complement the double cross-validatory analysis with post-
hoc exploratory analyses. We consider two analyses, the fi rst of which is based on 






bins which together account for most of the variation in the spectra. The second 
explores the linear discriminant weights from a post-hoc fi t on the full data. 
Data reduction 
Initialize I = {1,...,p} as the ordered set of bin indices and V = {v1,...,vp} the associated 













/n is the sample mean and j is the 
bin index number. Calculate the constant vref = q
0.95
(V ) as the 95% percentile of all 
p bin variances. Now initialize the bin selection set B as the set containing the bin 
indicator j for which the maximum variance vj is observed in the set V . Initialize 
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 |j є B}), 
i :1, ... ,n. Defi ne cor(a, b) to be the coeffi cient of correlation between two vectors 
a and b. 
Now run the following algorithm. Now run the following algorithm.
{Start of outer loop}
{Start of inner loop}
Set k=1, I = I − {j} and V = V − {vj}
Now iterate the following procedure until termination.
Calculate ρlower = cor(mi,x[j−k]) and ρupper = cor(mi,x[j+k])
If ρlower > 0.9 and ρupper > 0.9 then
1. Add j − k and j + k to the bin selection set: B = {j − k} ∪B ∪ {j + k}.
2. Update the means mi,i : 1, . . . , n.
3. Remove indices j − k and j + k from the index set I, such that





Now select the bin index j for which vj = max(V ).
If vj > vref then
Update the index set B = B + {j} and likewise Xs and m.
Go to {Start of inner loop}
Else End algorithm.
The algorithm identifies a set of ‘clusters’ of bins. There is no assumption on either
shape of the signal or of monotonicity involved (a single cluster may span mixture of
underlying peaks). Running this algorithm on the data from the first week finds the
set of indices B that corresponds to the bins which account for most of the variation in
the data. Applying this to our data results in a subset of 330 bins (in 32 bin clusters -
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The algorithm identifi es a set of ‘clusters’ of bins. There is no assumption on either 
shape of the signal or of monotonicity involved (a single cluster may span mixture of 
underlying peaks). Running this algorithm on the data from the fi rst week fi nds the 
s t f indices B that corresponds to the bins which account for most of the variation 
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in the data. Applying this to our data results in a subset of 330 bins (in 32 bin clus-
ters -but note it is possible that we visit the same contiguous region of bins several 
times). Repeating the entire double cross-validatory procedure using the principal 
component selection shrinkage procedure on this reduced set yields recognition 
rates as described in table 4, which are not inconsistent with those from the full 
double cross-validatory evaluation shown in table 2. (Note however, ”double-cross” 
error rates from this algorithmic approach will be biased as they are based on feature 
selection from the full data.) 
Table 4. Results from re-running double cross-validatory calculations after bin-selection for the colon cancer data (week 1 data only). T is the total 
recognition rate. Se and Sp are sensitivity and speci¯city respectively. B is the Brier distance and AUC is the estimated area under the ROC curve.
Method T (Se,Sp) B AUC
PCA-selection S(κ) 90.0 (92.1, 88.0) 0.0807 96.5
PCA-selection Euclidisch S(κ)   λ(κ)  = I (κ) 89.0 (92.1, 86.0) 0.0824 95.4
Post-hoc data exploration 
The second aspect which is of interest is a post-hoc exploration of the (linear) 
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 are the two sample group means (for cases and controls).
[9;17] An appropriate and convenient way to summarize the information contained 
in these coeffi cients is via the associated correlations of the measured intensities for 













 is the standard deviation at the jth bin and s
g
the standard 
deviation of class indicators. We will base this investigation on the linear discrimi-
nant fi t using the Euclidean distance on the fi rst two principal components (use S
(k)
, 




), as the double validatory assessment of this classifi er clearly 
identifi es the fi rst 2 components as containing the discriminatory information. 
At this point, we can carry out the analysis starting from a linear discriminant fi t 
based on the full data. Alternatively, we may equally well base the evaluation on a 
recomputation of the linear discriminant fi t on the reduced data described in previ-
ous subsection (in both cases we use the data from the fi rst week). Figure 2 (middle 
section) shows a plot of the correlation coeffi cients, subsequent to data reduction 
(previously described selection of 330 bins, but of course now using all 113 samples 
from the fi rst week). We only show results within the m/z region between 1200 and 
2200 Dalton, as the correlations are effectively zero in the remainder of the m/z 
range. Evidently, this immediately implies that the separating information is to be 
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Figure 2: Discriminant correlation coefficients ρj = sxjβj/sg of observed intensity values
with the class indicators in the m/z range from 1200 up to 2200 Dalton. We have plotted
the first two principal components above these correlations for visual comparison and
interpretation. Below the correlations, we plot mean spectra per group (i.e., the vectors
x1 and x2, as in figure 1). The y-axis is only relevant to the correlation coefficient, while
we have vertically offset and rescaled both components and mean spectra to aid visual
comparison across the m/z range.
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Figure 2. Discriminant correlation coe  cients ρj = sxj βj /sg of observed intensity values with the class indicators in the m/z range from 1200 up 
to 2200 Dalton. We have plotted the  rst two principal components above these correlations for visual comparison and interpretation. Below the 
correlations, we plot mean spectra per group (i.e., the vectors x1 and x2, as in  gure 1). The y-axis is only relevant to the correlation coe  cient, 
while we have vertically o set and rescaled both components and mean spectra to aid visual comparison across the m/z range.
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We note that the picture shown is virtually indistinguishable by eye from that 
which results from an analysis of the full data (not shown to save space). The 
reason for this is that the data reduction restricts attention to the dominant sources 
of variation, which is not very different from what is achieved through principal 
component reduction. Immediately above the correlation coeffi cients graph, fi gure 
2 displays the fi rst two principal components (vertically offset and rescaled to aid 
visual interpretation) and again based on the reduced data. In this case, the distinct 
bin subsets selected by the previous data reduction step are clearly visible in the 
two components, and display the characteristic ‘peaks’ we would expect to identify. 
Disjoint neighbouring bin sets are connected with straight lines. The thus calculated 
components are a close approximation to those which would result from an analysis 
of the full data, as we should expect (results not shown). As for the correlation coef-
fi cients, any conclusions are therefore identical whether we use the reduced data or 
not, although the data reduction step perhaps makes the component plot easier to 
‘read’. At the bottom of the graph we give the mean spectrum again for each group 
separately and from the original data within the m/z range of interest, as shown in 
fi gure 1 also, along the complete m/z range. 
From this graphical analysis, it is clear how the linear discriminant correlation coef-
fi cients identify two major discriminating contributions, the fi rst of which is centered 
at 1467.7 Dalton and the second at 1867.7 Dalton. Furthermore, the correlations 
have opposite signs at these locations, which would indicate that the discriminating 
information can be summarised through a contrast effect between corresponding 
measured intensities in the spectra. An investigation of the principal components 
plots above learns that the contribution at 1467.7 Dalton is primarily accounted for 
by the fi rst component, which also already contains the contrast with intensities 
recorded at 1867.7 Dalton. This contrast is then further amplifi ed by the second 
component which identifi es a second orthogonal source of variation relative to the 
fi rst component, centered predominately at the already identifi ed peak at 1867.7 Dal-
ton. Note how each component identifi es several other smaller contributions, which 
could also be of interest for further investigation. Comparing these graphs with the 
within-group mean spectra, the resemblance with the principal components plots at 
the top of the fi gure are striking and would suggest that the fi rst component may 
be primarily explained through variation within the control group at 1467.7 Dalton. 
Likewise, the second component accounts for a substantial intensity peak at 1867.7 
Dalton within the colon cancer group. 
To investigate this further, fi gure 3 provides scatter plots of cases and controls 
versus the fi rst 2 components (left plot) and between intensities at 1467.7 and 1867.7 
Dalton respectively (right plot). The resemblance between both graphs is striking as 
















































Figure 3: Scatter plots distinguishing cases (o) from controls (+). On the left we plot
the second versus the first principal component. The right plot shows intensity values
at 1867.2 m/z versus those at 1467.7 m/z.
applies to the principal components scatter plot, which confirms our interpretation of
the data in figure 2. Figure 4 provides a concise summary graphical illustration of the
results. We calculate the contrast (difference) for all 113 individuals participating in
the study between the measured intensities at 1467.7 and 1867.7 Dalton and display the
differences in a dotplot using distinct plotting symbols for cases and controls respectively,
which demonstrates the separation between both groups.
For further discussion of the clinical background, study rationale, setup, execution
and interpretation of results from a substantive clinical perspective, we refer to (Noo
2006) and subsequent papers from these authors.
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applies to the principal components scatter plot, which confirms our interpretation of
the data in figure 2. Figure 4 provides a concise summary graphical illustration of the
results. We calculate the contrast (difference) for all 113 individuals participating in
the study between the measured intensities at 1467.7 and 1867.7 Dalton and display the
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and interpretation of results from a substantive clinical perspective, we refer to (Noo
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Figure 3. Scatter plots distinguishing cases (o) from controls (+). On the left we plot the second versus the  rst principal component. The right 
plot shows intensity values at 1867.2 m/z versus those at 1467.7 m/z.
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we can see, an increase in intensity at 1467.7 Dalton separates controls from cases. 
Similarly, an increase in intensity at 1867.7 Dalton separates cases from controls. The 
same interpretation applies to the principal components scatter plot, which confi rms 
our interpretation of the data in fi gure 2. Figure 4 provides a concise summary 
graphical illustration of the results. We calculate the contrast (difference) for all 113 
individuals participating in the study between the measured intensities at 1467.7 and 
1867.7 Dalton and display the differences in a dot plot using distinct plotting sym-
bols for cases and controls respectively, which demonstrates the separation between 
both groups. 
For further discussion of the clinical background, study rationale, setup, execution 
and interpretation of results from a substantive clinical perspective, we refer to (Noo 
2006) and subsequent papers from these authors. 
DISCUSSION 
Double validatory analysis 
Use of a separate validation or test set is often precluded in high dimensional prob-
lems, due to sample size restrictions. In our case, this arises because the experiment 
was carried out in an academic medical center, which implies (colon cancer) cases 
are restricted to a maximum of about 50 patients yearly and with more advanced 
disease. Selection of appropriate control samples may be more diffi cult still, even if 
we use surrogate serum samples -as in this experiment. Larger numbers of cases may 
be recruited by setting up multi-center trials and using longer recruitment periods. 
However, researchers may need some justifi cation in the form of a small feasibility 
study before setting up such complex trials. It is in such situations that double cross-
validatory analysis can be most useful to help researchers make the maximum use 
of the scarce data available. The other option of reducing the available calibration 
data prior to optimization of any discriminant rule by setting aside data (perhaps for 
both a ‘predictive tuning’ as well as ‘validation’ set) is not as innocent as appears 
at fi rst sight. This is because it will often reduce the calibration set beyond what is 
−1 −0.5 0 0.5 1 1.5
contrast between intensities at m/z 1467.7 and m/z 1867.7
Figure 4: Plot of the contrasts (differences) between intensities at 1467.7 m/z and 1867.7
m/z across all observations, using distinct plotting symbols for each group: cases (o) and
controls (+).
5 Discussion
5.1 Double validatory analysis
Use of a separate validation or test set is often precluded in high dimensional problems,
due to sample size restrictions. In our case, this arises because the experiment was carried
out in an academic medical center, which implies (colon cancer) cases are restricted to
a maximum of abo t 50 patients yearly and with more advanced disease. Selection of
appropriate control samples may be more difficult still, even if we use surrogate serum
samples - as in this experiment. Larger numbers of cases may be recruited by setting up
multi-center trials and using longer recruitment periods. However, researchers may need
some justification in the form of a small feasibility study before setting up such complex
trials. It is in such situations that double cross-validatory analysis can be most useful to
help researchers make the maximum use of the scarce data available. The other option
of reducing the available calibration data prior to optimization of any discriminant rule
by setting aside data (perhaps for both a ‘predictive tuning’ as well as ‘validation’ set)
is not as nnocu us as appears at first sight. This is because it will often reduce the
calibration set beyond what is needed for reasonable calibration. Moreover, reducing the
size of the calibration data changes the condition of the estimation itself. To put this
simply: we are not only reducing the data by setting-aside data from the calibration
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Figure 4. Plot of the diferences between intensities at 1467.7 m/z and 1867.7 m/z across all observations, using distinct plotting symbols for 






needed for reasonable calibration. Moreover, reducing the size of the calibration data 
changes the condition of the estimation itself. To put this simply: we are not only 
reducing the data by setting-aside data from the calibration set, but also changing the 
discriminant problem itself. This is again particularly the case in high-dimensional 
cases such as in proteomics where the problem will typically be ill-conditioned. 
The approach we have described in this paper avoids these diffi culties through 
application of double cross-validation to combine the two aspects of predictive op-
timization and validation. Subsequent to this basic evaluation of the discrimina-
tory potential of the spectral data, a more exploratory analysis can be carried out, 
provided we are carefully to interpret results cautiously without contradicting the 
primary validated evaluation. We discuss a number of issues related to application 
of (double) cross-validation. 
Full validation 
One potential cause for concern is whether double cross-validation precludes the 
need for a completely separate validation set entirely. Is ‘double-cross’ also ‘full’ vali-
dation? The simple answer to this question is that it can not be, as any form of cross-
validation must typically always remain ‘within-study’ validation and there can be 
factors beyond our knowledge which have influenced the study results. Good scien-
tifi c practice requires that we replicate results in a separate repeat study. This caution 
applies particularly to the defi nition of the case and control group, as the impact of 
systematic effects due to measurement can be minimised through use of randomised 
block design. Repeat studies may help to detect such problems. Note however, that 
these criticisms would also have applied to the standard practice of using within-
study set-aside test and validation sets. Meanwhile, double cross-validation should 
give reasonable protection against overfi tting and unbiased estimates of error rate at 
the time of study. Double-cross represents the maximum usage we can make of the 
data for joint predictive optimization and validation within a single experiment. Even 
when separate test and validation sets are available however, researchers may still 
be interested to compare the thus validated re-search fi ndings with those from a fully 
double cross-validated analysis on the combined data in order to evaluate whether 
the greater sample size would have allowed for better calibrations -possibly because 
of improved detection of the smaller signal sources in the spectra.[23] More gener-
ally, we could speculate where the validation process should stop. Typically, the 
performance of any decision rule or classifi er has a tendency to ‘decay’ over time. To 
assess this, subsequent experiments are needed to verify the estimated error rates. 
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What classi er are we evaluating? 
Two related questions to the previous discussion are ‘What classifi er does double 
cross-validation evaluate?’ and ‘How to assign a new observation?’. Indeed, each 
observation has its own classifi er in the double cross-validatory evaluation. This 
seems to run counter to the intuition that we calibrate a discriminant rule fi rst and 
only then evaluate. In that case, the estimated error rate is taken as a reflection of the 
diagnostic abilities of that particular classifi er and the allocation of a new sample is 
immediate. There is however no logical inconsistency here. Double cross-validation 
estimates the error rate we would get ‘if we were to apply leave-one-out’ on the 
whole data. Once we know what the error rate is, we may choose the specifi c 
classifi er (choice of k or λ in our case) for allocation of future samples (if required) 
through application of ordinary leave-one-out on the whole data (this is in line with 
the discussion presented by Mervin Stone.[7] With double cross-validation, there are 
however other options to allow allocation of new samples which have not yet been 
discussed in the literature. In our case for example, we may use the mode of the 
number of components selected (k) across all samples and then re-estimate the dis-
criminant model with this choice from the full data. More adventurous still, we could 
retain each of the n classifi cation rules which are calibrated within the double-cross 
procedure and use this ensemble (of classifi ers) for allocation of any future new 
observation x. This could be done by calculating the associated a-posteriori class 
probabilities p
i 
(g|x), for each i є {1, ... ,n} and g є {1, ... ,G}, where p
i
is obtained from 
the discriminant model calibrated in the double-cross procedure when the ith datum 
has been removed from the data (in the outer shell of the double-cross procedure). 
Classifi cation may then be based on the mean across these n a-posteriori class prob-
abilities for any gth class. We will not pursue these options further in this paper. 
Validation and the future of (statistical) proteomics 
Rigorous emphasis on validation and proper design can help to establish long-term 
credibility for proteomic research and more general bioinformatics applications. 
The double-cross approach with randomised block design described in this paper 
represents one contribution towards this goal. Many other steps may however be 
taken to enhance the quality of such research studies. One example is to promote 
use of ‘truly’ separate validation sets, as obtained from subsequent separate and ad-
ditional sampling from the population of interest and measurement through identical 
protocols as applied in the fi rst study. In practice, this will be particularly relevant 
for those studies which indicate potential from the fi rst within-study verifi cation of 
diagnostic ability. Editors of scientifi c journals can also contribute much to inspire a 
conservative attitude by careful scrutiny of the papers presented for publication. Per-






to which validatory evaluation did (or should) contribute to the research fi ndings 
presented. This may also prevent mistakes from slipping through the net. Although 
this may cause considerable annoyance in some cases when we face the diffi cul-
ties of establishing results in the short term, but may enhance scientifi c credibility 
of (proteomic) research as a whole in the long run. Results from the present study 
show that, with good designed experimentation, these precautions need not form 
insurmountable obstacles. 
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With a lifetime risk currently estimated one in nine, breast cancer is among the most 
common diagnosed malignancies and remains a leading cause of cancer-related mor-
bidity and mortality. Proteomic expression profi ling generated by mass spectrometry 
has been suggested as a potential tool for the early diagnosis of cancer and other 
diseases. The objective of our study was to assess the feasibility of this approach for 
the discrimination of breast cancer patients from healthy individuals.
Experimental design
In a randomised block design pre-operative serum samples obtained from 77 breast 
cancer patients and 29 controls were used to generate high-resolution MALDI-TOF 
protein profi les. The median age of the patient group and control group was respec-
tively, 57.2 years and 50.0 years. All available 106 samples from both groups were 
randomly distributed across 3 plates in roughly equal proportions. The MALDI-TOF 
spectra generated using C8 magnetic beads assisted mass spectrometry (Ultrafl ex, 
Bruker Daltonics, Germany) were smoothed, binned and normalised after base-
line correction. After pre-processing of the spectra, linear discriminant analysis with 
double cross-validation, based on principal component analysis, was used to classify 
the protein profi les.
Results
A total recognition rate of 99%, a sensitivity of 100% and a specifi city of 97.0% for 
the detection of breast cancer were shown. The area under the curve of the clas-
sifi er was 98.3%, which demonstrates the high, signifi cant separation power of the 
classifi er. The fi rst 2 principal components account for most of the between-group 
separation. 
Conclusions
Double cross-validation showed that classifi cation could be attributed to actual infor-
mation in the protein profi les rather than to chance. Although preliminary, the high 
sensitivity and specifi city indicate the potential usefulness of serum protein profi les 
for the detection of breast cancer. 
MALDI-TOF Serum Protein Pro ling for the detection of breast cancer 99
INTRODUCTION
With a lifetime risk currently estimated one in nine, breast cancer is among the most 
common diagnosed malignancies and remains a leading cause of cancer-related mor-
bidity and mortality. Although the precise pathways of tumour genesis remain poorly 
defi ned, it appears that most invasive breast cancers arise from gene alterations that 
result in an initial transformation of normal breast tissue to in situ carcinoma.[1] 
Currently, mammography remains the most important diagnostic tool, although MRI 
and ultrasonography are used in case of impairment of the latter diagnostic results.
[2] However, up to 20% of new breast cancers are not detected or visible on a mam-
mogram.[3] Prognosis and selection of therapy may be infl uenced by the age and 
menopausal status of the patient, Bloom-Richardson stage, histological and nuclear 
grade of the primary tumour, oestrogen-receptor (ER) and progesterone-receptor 
(PR) status, measures of proliferative capacity, and HER2/neu gene amplifi cation.
[4] Currently, serum tumour markers play no role of importance in the diagnosis of 
breast cancer due to a lack of sensitivity and specifi city. 
Proteomic expression profi les generated with mass spectrometry have been sug-
gested as potential tools for the early diagnosis of cancer and other diseases. After 
the initial ‘hype’ of biomarker detection on the basis of multiple low-molecular-
weight serum proteins stringent demands have been proposed on both study design 
and experimental procedures for proteomic profi ling.[5-11] Subsequently, several 
studies appeared showing the importance of standardised protocols and homogene-
ity of subject groups and especially validation of the classifi cation method.[12-16] 
This study aims to live up to all these demands.
Since no serum biomarker is currently known to reliably detect breast cancer, the 
present study was designed to test and validate whether serum protein profi les gen-
erated with mass spectrometry could be indicative of the presence breast cancer.
MATERIAL AND METHODS
Subjects
Serum samples were obtained from a total of 77 patients one day prior to surgery for 
a breast disease. All surgical specimens were histologically examined and if malig-
nant, the extent of tumour spread was assessed by TNM classifi cation. All stages of 
breast cancer were present in the patient group. The median age of the patient group 
was 57.2 years (range 32.6-90.3). Patients were included from October 2002 till July 






median age of the healthy symptom-free control group was 50.0 years (25.9-76.7). 
The 29 controls were included in November and December 2004 (Table 1). 
Serum samples
Informed consent was obtained from all patients and the study was approved by the 
Medical Ethical Committee of the LUMC. All samples were collected and processed 
following a standardised protocol: all blood samples were drawn while the patients 
or healthy controls were seated and non-fasting. The samples were collected in a 
10 cc Serum Separator Vacutainer Tube (BD Diagnostics, Plymouth, UK) and centri-
fuged 30 min later at 3000 rpm for 10 minutes. The serum samples were distributed 
into 1 ml aliquots and stored at -70 ºC. After thawing on ice the serum samples were 
randomised over different 96-well microtitration racks (Matrix) and then stored at 
-70ºC until the experiment.
Study design
We used a randomised blocked design to avoid any potential batch effects.[17;18] 
All the available 106 samples from both groups were randomly distributed across 
3 plates in roughly equal proportions (Table 2). For breast cancer, the distribution 
of stadia across plates was again in random fashion and in approximately equal 
proportions (Table 3). The position on the plates of samples allocated to each plate 
was randomised as well. Each plate was then assigned to a distinct day. Analysis was 
carried out on 3 consecutive days, Tuesday to Thursday, processing a single plate 
each day. 
Table 1. Patient characteristics.
Patients Controls
n = 78 29
Age (mean) 56.6 49.9
 (range) 36.2-90.3 25.9-76.7
Table 2. Distribution and randomisation of serum samples of colorectal cancer patients with di erent TNM stage before and after the MALDI-
TOF experiment. The distribution of stadia across plates was performed randomly random fashion and approximately equal proportions.
Plate 1 Plate 2 Plate 3 Total
Breast cancer 26 26 26 78
Controls 11 9 9 29
Total 37 35 35 107
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Isolation of peptides and protein pro ling
The isolation of peptides from serum was performed using the C8 magnetic beads 
based hydrophobic interaction chromatography (MB-HIC) kit from Bruker Daltonics 
(Bremen, Germany) mainly according to manufacturers instructions, adapted for 
automation on a 8-channel Hamilton STAR® pipetting robot (Hamilton, Martinsried, 
Germany) as previously described by our group. Each sample was spotted in quadru-
plicate on a MALDI AnchorChip™. Matrix Assisted Laser Desorption Ionisation Time-
Of-Flight (MALDI-TOF) mass spectrometry measurements were performed using an 
Ultrafl ex I TOF/TOF instrument (Bruker Daltonics, Bremen, Germany) equipped 
with a SCOUT ion source, operating in linear mode. Ions formed with a N2 pulse 
laser beam (337 nm) were accelerated to 25 kV. With this specifi c serum preparation 
peptide/protein peaks in the m/z range of 960 to 11,169 Dalton were measured. 
Data processing and statistical analysis
All unprocessed spectra were exported from the Ultrafl ex in standard 8-bit binary 
ASCII format. They consisted of approximately 45,000 mass-to-charge ratio (m/z) 
values, covering a domain of 1.160 - 11,600 Dalton. To increase robustness, the 
average of four spots was used to represent one serum sample. Subsequently, we 
lightly smoothed, binned and normalised the spectra after baseline correction. Fully 
validated classifi cation error rates were estimated based on a classical Fisher linear 
discriminant analysis through complete double cross-validatory joint estimation and 
assessment of class predictions as previously described.[19]
Table 3. Distribution and randomisation of serum samples of breast cancer group over the three MS target plates.
Stage Plate 1 Plate 2 Plate 3 Total
DCIS 5 4 3 12
I 6 6 8 22
IIA 7 8 3 18
IIB 4 6 4 14
IIIA 1 2 4 5
IIIB 1 0 2 3
IIIC 1 0 2 3







 Three different randomised target plates were successfully measured on three con-
secutive days in the middle of the week. Figure 1 shows a raw data spectrum, 
directly obtained from the MALDI-TOF mass spectrometer. Before pre-processing 
and further analysis a mean spectrum of each sample was calculated over all four 
spots that were measured for each sample. The above-described pre-processing 
steps resulted in a sequence of 4483 normalised m/z values ranging from 1160 to 
11,600 Dalton, for each individual. One sample from the breast cancer group was 
excluded from analysis due to its poor quality spectra.
Double cross-validatory analysis and evaluation carried out on the protein spectra 
correctly classifi ed 28 of 29 controls as non-cancer. All breast cancer patients were 
correctly classifi ed as malignant (Table 4). These validated results yield a total recog-
nition rate of 98.2%, a sensitivity of 100% and a specifi city of 97.6% for the detection 
of breast cancer. To analyze the actual discriminative power of the classifi er, we pro-
duced an ROC-curve (again based on the double cross-validatory classifi cation prob-
abilities), visualizing the performance of the two-class classifi er in fi gure 2. The AUC 








Figure 1.   
Figure 1. MALDI-TOF spectrum of a breast cancer patient after peptide isolation with C8 magnetic beads. On the Y-axis the relative intensity is 
shown. The mass to charge ration (m/z) is demonstrated on the X-axis in Dalton.
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[24.8, 64.2]. As both median recognition rates and AUC’s equal 50%, there is thus no 
substantial evidence of bias remaining within the cross-validatory calculation.
We then proceeded to a post hoc exploration of the classifi cation model. In the 
present study the fi rst two principal components provided most of the between-
group separation. Figure 3 shows a plot of the correlation coeffi cients, with the class 
indicator, which can be calculated from the linear discriminant weightings in the 
region between 1.160 and 11,600 Dalton.[20;21] As illustrated, the classifi cation is 
achieved primarily through a contrast in peak intensities between the fi rst and sec-
Table 4. Double cross-validatory classi cation of serum samples. A positive test results assigns subjects to the breast 
cancer (BC) group and a negative to the controls. In the horizontal plane the actual histologically con rmed diagnosis 
is stated.
Test results for detection of BC
Neg Pos Total
Controls 77 0 77







Figure 2. ROC-curve for the double cross-validated two-group classi er. The true positive recognition rate (sensitivity) is demonstrated on the 












Figure 3. Correlation coe  cients of two  rst principal components with the class indicator. The correlation coe  cients were calculated from the 
linear discriminant weightings. The negative correlation of the  rst peak is an indicator for the control group and the positive correlation of the 




o  Patient group
+  Control 
Figure 4. Scatter plot of the  rst two principle components on basis of which the classi cation patient-control group was made.
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ond principal component. This can also be seen in the scatter plot shown in fi gure 
4: low intensities at the fi rst peak for cases separates cases from controls. Likewise, 
a small contribution for controls at the second peak separates controls from patients. 
To illustrate these results further, we can simply calculate the contrast between the 
two peak intensities directly across all subjects and construct a simple one-dimen-
sional summary of the data, as shown in the histogram displayed in fi gure 5, which 
shows overlapping histograms of this (ad hoc) contrast for each group separately. 
The separation is clearly visible. We also quantifi ed the signifi cance of this difference 
by performing a two-sample Student t-test on this contrast, (p<0.0001). 
DISCUSSION
This study underlines the potential of serum protein profi ling for the detection of 
breast cancer. We were able to classify breast cancer patients and healthy individuals 
very accurately based upon information in MALDI-TOF serum spectra. The classifi er, 
calibrated and validated on spectra of the entire dataset demonstrated a sensitivity 
and specifi city of 100% and 97.6% respectively. Only one subject from the control 
 




Difference in most discriminating peaks 
Figure 5. Histogram showing the di erence between the normalized intensities of the two most discriminating “peaks” (bins). The X-axis shows 






group was misclassifi ed in the malignant group (Table 4). Moreover, with a lifetime 
risk of one in nine, it might even be the case that one of 29 control subjects cur-
rently is developing or carrying the disease. Unfortunately, since the control group 
consisted of anonymous symptom-free subjects it was impossible to retrieve the 
current physical state. All patients with various stages of breast cancer were correctly 
classifi ed, including DCIS patients. The fact that all DCIS patients are recognised in 
the cancer group, adds to its possible future applicability as a tool for early detection. 
If these results are validated, future studies could be performed to screen women at 
high risk for breast cancer by both mammography and serum protein profi ling.[22] 
In that way the positive predictive value of the proteomic pattern approach could 
be assessed. Further, efforts have to be made to correlate different stages of breast 
cancer with serum protein profi les because this may contribute better prognostica-
tion and may eventually lead to more individualised treatment. Obviously, validation 
and suffi cient sample size are once again of paramount importance for the reliability 
and its potential in a clinical setting.
We favour a thorough and stringent study design and double cross-validation of 
our classifi cation model.[19] We feel that the use of standardised serum collection 
and mass spectrometry protocols, as advocated in various studies, has lifted serum 
protein profi ling to a more reliable level.[12;13;16;23] To avoid the most common pit-
falls in clinical proteomics sample collection, pre-analytical conditions and biological 
variables were in the present study matched for both groups and were rigorously 
standardised. The location of blood collection, i.e. the outdoor clinic for controls and 
the surgical ward for the patient group showed no infl uence on serum protein pro-
fi les (data not shown). Furthermore, patient samples from all stages of breast cancer 
were randomly distributed over three different target plates, excluding these factors 
as a discriminator in the current classifi er. Ideally, the control group should consist 
of precisely age-matched individuals undergoing a mammography showing no aber-
rations. However, in practice this is diffi cult to realize, due to ethical and logistical 
issues. Notwithstanding, we performed an analysis to examine the differences in 
intensity of most discriminating peaks based on age. In the present study there was 
no signifi cant contribution of one of these factors on the most discriminating peaks 
of our classifi cation model (data not shown).
Regarding the bioinformatic and statistical approach of these high dimensional 
data there were two main points to consider: avoiding batch effects and validation 
of the classifi cation model. To avoid observational bias, a randomised block design 
was used as an additional precaution. The randomised block design ensured that 
no batch effects were introduced and excluded artifi cial between-group separations.
[17;18] Another recurrent topic of debate in serum protein profi ling is validation of 
the classifi cation model.[11;24] Consensus is achieved that, ideally, discriminating 
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protein profi les for the detection of a certain malignancy should be validated using 
an independent dataset. In the current phase of this study, the use of an independent 
validation set was excluded since the relatively small sample size did not allow this. 
Until a larger sample set is obtained, we advocate the use of a double cross valida-
tion of classifi cation. This procedure avoids the need for separate test and validation 
sets to yield unbiased error rate estimates. The double validatory aspect of the 
procedure results from the fact that the discriminant rule constructed to classify the 
left-out data was optimised through a secondary cross-validatory evaluation within 
the fi rst cross-validatory layer.[19;25]
The classifi cation between cancer and non-cancer was mostly performed using 
the fi rst two principal components, corresponding to two most discriminating peaks. 
Identifi cation and functional analysis of these discriminating proteins/peptides might 
render new insights on tumour development and environmental responsiveness, 
which could eventually be translated in new diagnostic and prognostic insights 
for the clinician. Until nowadays, little success has been booked in assigning re-
producible discriminating biomarkers.[14;24] Though this study showed two most 
discriminating mass values of MALDI-TOF based protein profi ling analysis to be 
low molecular weight fragments, we have not identifi ed these potential biomarkers 
yet. Some have argued that low molecular weight proteins in serum, the serum 
peptidome, is nothing but aspecifi c biological trash and therefore does not yield 
any reliable biomarkers in the currently technically available mass range.[26-28] 
However, very recently Villanueva et al. published a study in which they proposed 
that although discriminating peptides do indeed belong to well known coagulation 
and complement pathways, their patterns or signatures do most certainly indicate 
the presence of cancer.[29] This study showed that most of the cancer-type specifi c 
biomarker fragments were generated in patient serum by enzymatic cleavage at 
previously known endoproteage cleavage sites after the blood sample was collected.
[30] They postulated that these cancer-specifi c low molecular weight proteins in 
the serum peptidome are an indirect snapshot of the enzyme activity in tumour 
cells. We support to their hypothesis that discriminating serum protein profi les are a 
compilation of surrogate markers for the detection and classifi cation of certain types 
of tumours. 
In conclusion, the present study demonstrated that patterns of proteomic signa-
tures from high dimensional mass spectrometry data can be used as highly reliable 
diagnostic classifi ers for the detection of breast cancer. With the double crossvalida-
tory study in a randomised block design we obtained maximal reliability in classifi ca-
tion while maintaining protection against overfi tting. Surely, independent validation 






extremely high sensitivity and specifi city of the present study are highly promising 
for a new diagnostic approach in breast cancer. 
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With over 1 million new cases in the world each year, breast cancer is the common-
est malignancy in women and comprises 18% of all female cancers. Proteomic ex-
pression profi ling generated by mass spectrometry has been suggested as a potential 
tool for the early diagnosis of cancer. The objective of our study was to assess and 
validate the feasibility of this approach for the detection of breast cancer.
Methods
In a randomised block design pre-operative serum samples obtained from 63 breast 
cancer patients and 73 controls were used to generate high-resolution MALDI-TOF 
protein profi les as a calibration set. The median age of the patient and control group 
was respectively, 52 (20-81) and 57 years (39-87). The MALDI-TOF spectra generated 
using WCX magnetic beads assisted mass spectrometry (Ultrafl ex) were smoothed, 
binned and normalised after baseline correction. After pre-processing of the spectra, 
linear discriminant analysis with double cross-validation, based on principal compo-
nent analysis, was used to classify the protein profi les. Consequently, the classifi er 
constructed on the fi rst 2 plates was applied on the spectra of an independent 
validation set. This validation set consisted of serum samples from 29 breast cancer 
patients and 38 controls. The median age was 59 years (26-87) and 57 years (24-71) 
for the patient and control group respectively.
Results
Double cross-validatory analysis carried out on the protein spectra of the calibration 
set yielded a total recognition rate of 86%, a sensitivity of 88% and a specifi city of 
84% for the detection of breast cancer within the calibration set. The AUC of this 
classifi er was 90.3%. When this classifi er was applied on the spectra of the inde-
pendent validation set a total recognition rate of 80.9%, a sensitivity of 72% and a 
specifi city of 89% were found.
Conclusions
The use of a randomised block design, but mainly an independent validation set 
proves that discriminating protein profi les can be detected between breast cancer 
patients and healthy controls. Although further validation in larger series and iden-
tifi cation of the discriminating proteins must be achieved, the high sensitivity and 
specifi city indicate that serum protein profi les could be an option for the detection 
of breast cancer.
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INTRODUCTION
With over 1 million new cases in the world each year, breast cancer is the com-
monest malignancy in women and comprises 18% of all female cancers. In 2005, 
breast cancer caused 502,000 deaths (7% of cancer deaths; almost 1% of all deaths) 
worldwide.[1] Despite increasing incidence rates, annual mortality rates from breast 
cancer have decreased over the last decade (2.3% per year from 1990 to 2002).[2] 
The effect of reduction due to early diagnosis of breast cancer has been outlined 
with patients’ data by the Surveillance, Epidemiology, and End Results program in 
a competing-risk analysis calculating probabilities of death from breast cancer and 
other causes according tot stage, race and age at diagnosis.[3] 
Currently, mammography remains the most important diagnostic tool in women 
with breast tissue that is not dense, although MRI and ultrasonography are used in 
case of impairment of the latter diagnostic results.[4] In many countries mammog-
raphy is used as a population based screening in woman older than 50 years. The 
effect of breast screening in terms of breast cancer mortality reduction persists after 
long-term follow-up. A recent meta-analysis of seven randomised trials concluded 
that there was a 15-20% reduction in risk of death from breast cancer in women 
attending mammography.[5] However, up to 20% of new breast cancers are not 
detected or visible on a mammogram.[6] 
Prognosis and selection of therapy may be infl uenced by the age and menopausal 
status of the patient, Bloom-Richardson stage, histological and nuclear grade of the 
primary tumour, oestrogen-receptor (ER) and progesterone-receptor (PR) status and 
HER2/neu gene amplifi cation.[7] Currently, serum tumour markers play no role of 
importance in the diagnosis of breast cancer due to a lack of sensitivity and specifi c-
ity. 
Proteomic expression profi les generated with mass spectrometry have been 
suggested as a potential tool for the early diagnosis of cancer and other diseases. 
Although promising results have been shown in classifying cancer studies based 
on biomarker detection with multiple low-molecular-weight serum proteins[8-11] 
stringent demands have been proposed on both study design and experimental pro-
cedures for proteomic profi ling.[12-14] Subsequently, several groups have stressed 
the importance of standardised protocols and homogeneity of subject groups and 
especially validation of the classifi cation method.[15-19] Since no serum biomarker 
is currently available to detect breast cancer, the present study was designed to test 
and validate whether serum protein profi les generated with mass spectrometry could 








Serum samples were obtained from a total of 111 patients one day prior to surgery for 
breast disease. All surgical specimens were histological examined and if malignant, 
the extent of tumour spread was assessed by TNM classifi cation. Next to invasive 
stages of breast cancer, ductal carcinoma in situ (DCIS) samples were present in the 
patient group. The control group consisted of 92 healthy female volunteers. Patients 
and controls were included from October 2002 till July 2006 in our center. 
In the calibration set the mean age of the patient group and control group was 
52 (20-81) and 57 years (39-87) respectively. In the validation set the mean age was 
59 years (26-87) and 57 years (24-71) for the patient and control group respectively 
(Table 1).
Serum samples 
Informed consent was obtained from all subjects and the study was approved by the 
Medical Ethical Committee of the LUMC. All samples were collected and processed 
following a standardised protocol: all blood samples were drawn from non-fasting 
patients or healthy controls while they were seated. The samples were collected in a 
8.5 cc Serum Separator Vacutainer Tube (BD Diagnostics, Plymouth, UK) and centri-
fuged 30 min later at 3000 rpm for 10 minutes. The serum samples were distributed 
into 0.5 ml aliquots and stored at -70ºC. After thawing on ice the serum samples were 
randomised over different 96-well microtitration racks (Matrix, Hudson, USA) and 
then stored at -70ºC until the experiment.
Study design 
We used a randomised blocked design to avoid any potential batch effects.[20;21] All 
the available samples from both groups were randomly distributed across 3 plates 
in roughly equal proportions (Table 2). For breast cancer, the distribution of disease 
stages across plates was again in random fashion and in approximately equal pro-
Table 1. Patient characteristics.
Calibration set Validation set
Patients Controls Patients Controls
N= 73 63 38 29
Age (median) 52 57 57 59
(range) 20-81 39-87 26-87 24-71
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portions (Table 3). The position on the plates of samples allocated to each plate was 
randomised as well. Each plate was then assigned to a distinct day. Analysis was car-
ried out on 3 consecutive days, Tuesday to Thursday, processing a single plate each 
day. During the fi rst two days, a calibration set with serum samples from 73 breast 
cancer patients and 63 controls was used to generate high-resolution MALDI-TOF 
protein profi les. The last day of the experiment, an independent validation set with 
serum samples from 38 breast cancer patients and 29 controls was measured.
Isolation of peptides and protein pro ling 
The isolation of peptides from serum was performed using magnetic beads based 
weak cation exchange chromatography (MB-WCX) kit from Bruker, mainly accord-
ing to the manufacturers instructions, and adapted for automation on a 8-channel 
Hamilton STAR® pipetting robot (Hamilton, Martinsried, Germany). Magnetic beads 
with WCX-functionality (MB-WCX) were divided in 10 µl -aliquots in a 96-well mi-
crotiter plate, which was placed on the magnetic beads separation device (MPC®-
auto96, Dynal, Oslo, Norway), with the magnet down. MB-WCX binding solution 
Table 2. Distribution and randomisation of serum samples of breast cancer patients and controls over the 3 MS target plates. Plate 1 and 2 were 
used as a calibration set, while plate 3 was used as a validation set. 
Plate 1 Plate 2 Plate 3 Total
Breast cancer 36 37 38 111
Controls 30 33 29 92
Total 66 70 67 203
Table 3. Distribution and randomisation of all di erent stages of breast cancer over the 3 MS target plates. Plate 1 and 2 were used as a 
calibration set, while plate 3 was used as a validation set. 
Stage Plate 1 Plate 2 Plate 3 Total
DCIS 3 7 7 17
I 12 14 14 40
IIA 11 11 6 28
IIB 5 3 7 15
IIIA 3 1 2 7
IIIB 1 1 2 4
IIIC 1 0 0 1






(10 µl) and 5 µl serum sample were added to the beads and carefully mixed using 
the mixing feature of the robot. The sample was incubated for 5 minutes and the 
magnet was lifted, followed by a 30s waiting interval to settle the magnetic beads. 
The supernatant was removed and the magnet was lowered again. The magnetic 
beads were washed three times with MB-WCX washing solution (also provided with 
the kit) lifting and lowering the magnet as needed. The peptides were eluted from 
the beads using 10 µl elution solution (from the kit). Stabilization buffer was added 
(10 µl) and 2 µl of the stabilised eluate was transferred to a fresh 384-well microtiter 
plate (Greiner). Fifteen µl of α-cyano-4-hydroxycinnamic acid (0.3 g/l in ethanol: 
acetone 2:1) was added to the 2 µl eluate in the 384-well microtiter plate and mixed 
carefully. One microliter of this mixture was spotted in quadruplicate on a MALDI 
AnchorChip™ (Bruker Daltonics, Bremen, Germany).
Data processing and statistical analysis
To increase robustness, the average of four spots was used to represent one se-
rum sample. All unprocessed spectra were exported from the Ultrafl ex in standard 
8-bit binary ASCII format. They consisted of approximately 32,670 mass-to-charge 
ratio (m/z) values, covering a domain of 960 - 11,168 Dalton. The high-resolution 
spectra were fi rst lightly smoothed and then, due to the quadratic nature of the TOF-
equation, binned using a linear function of the time scale, resulting in bin widths 
of approximately 0.4 Dalton at the beginning of the spectrum and 1.4 Dalton at the 
end at the mass/charge scale. Subsequently, we normalised the spectra after base-
line correction. In the calibration set, classifi cation error rates were estimated and 
validated based on a classical Fisher linear discriminant analysis through complete 
double cross-validation as previously described.[24] This double cross-validated clas-
sifi er was then applied on the validation set. This set was pre-processed using the 
exact same procedure as the calibration set. Using the estimated parameters from the 
calibration set, each sample in the validation set was assigned to the group for which 
the probability was highest. The error rates are based on sensitivity and specifi city 
values, assuming a prior class probability of 0.5 for each group. 
RESULTS
Three different randomised target plates were successfully measured on three con-
secutive days in the middle of the week. Figure 1 shows a raw data spectrum, 
directly obtained from the MALDI-TOF mass spectrometer. For further analysis, we 
fi rst calculated the mean spectrum of each sample across all four spots that were 
measured for each sample, after pre-processing. The above-described pre-processing 
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steps resulted in a sequence of 11,205 normalised m/z values ranging from 960 to 
11,168 Dalton, for each individual. 
Double cross-validatory analysis and evaluation carried out on the protein spectra 
of the calibration set (2 target plates) correctly classifi ed 56 of 63 breast cancer pa-
tients as malignant. Sixty-one of 73 controls were correctly classifi ed as non-cancer 
(Table 4a). The misclassifi ed patients in the calibration set included 1 patient with 
DCIS, 4 stage I patients, 3 with stage IIA and 4 patients with stage IIB. There was no 
correlation with hormonal status.
These double cross validated results yielded a total recognition rate of 86%, a 
sensitivity of 88% and a specifi city of 84% for the detection of breast cancer within 
the calibration set. To analyze the actual discriminative power of the classifi er, we 
produced an ROC-curve (again based on the double cross-validatory classifi cation 
probabilities), visualizing the performance of the two-class classifi er in fi gure 2. The 
AUC of the classifi er was 90.3%. To further evaluate possible bias of the double 
cross-validatory calculations, we performed a permutation exercise, which randomly 








Figure 1.   
Figure 1. MALDI-TOF spectrum of a breast cancer patient after peptide isolation with WCX magnetic beads. On the Y-axis the relative intensity is 






Table 4a. Double cross-validatory classi cation of serum samples in calibration set. A positive test results assigns subjects to the breast 
cancer (BC) group and a negative to the controls. 
Test results for detection of BC
Pos Neg Total
BC patients 61 12 73
Controls 7 56 63
68 68 136
Table 4b. Double cross-validatory classi cation of serum samples in validation set.
Test results for detection of BC
Pos Neg Total
BC patients 4 34 38







Figure 2. ROC-curve for the double cross-validated two-group classi er. The true positive recognition rate (sensitivity) is demonstrated on the 
y-axis against the false negative recognition rate (1-speci city) on the x-axis of the classi er. 
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Figure 3.  
Figure 3. Histogram showing the normal distribution for the misclassi cation rate in the permutation exercise. The X-axis shows the 




Figure 4. Correlation coe  cients of most discriminating principal components with the class indicator. The correlation coe  cients were 






double cross-validation procedure. Carrying out this procedure more than 600 times 
resulted in a median recognition rate of 49.0% with a 95% confi dence interval of 
[0.39, 0.69] as shown in fi gure 3. The median AUC was 49.7% with confi dence inter-
val of [0.28, 0.61]. As both median recognition rates and AUC’s equal roughly 50.0%, 
there is thus no substantial evidence of bias remaining within the cross-validatory 



















Figure 5. Scatter plot of the  rst two principle components on basis of which the classi cation patient-control group was made.
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clearly separated from these permutation-based null-hypothesis confi dence intervals, 
which prove the existence of discriminatory information in the spectra. 
A post hoc exploration of the classifi cation model was performed. In the pres-
ent study 8 peaks that correlated most with the two groups provided most of the 
between-group separation. Figure 4 shows a plot of the correlation coeffi cients, with 
the class indicator, which can be calculated from the linear discriminant weightings 
in the region between 960 and 11,168 Dalton. Figure 5 shows scatter plots of 4 of 
these most discriminating peaks between cases from controls.
Consequently, we applied the double cross-validated classifi er constructed on the 
fi rst 2 plates on the spectra of the independent validation set. In this set 21 of 29 
controls were correctly classifi ed as non-malignant and only 3 of 38 breast cancer 
patients were misclassifi ed, as shown in table 4b. From the 4 misclassifi ed patients 
1 had DCIS, whereas 2 patients both had stage I disease, according to their post-
operative histological report. Nevertheless, these results produce a total recognition 
rate of 80.9%, a sensitivity of 72% and a specifi city of 92% of the classifi er in an 
independent dataset.
DISCUSSION
This validation study shows that breast cancer can be detected by serum protein 
profi ling. We were able to classify breast cancer patients and healthy individuals 
accurately based upon information in MALDI-TOF serum spectra. In the calibration 
set the double cross-validated classifi er demonstrated a sensitivity and specifi city of 
88% and 84% respectively. Sixty-one out of 73 controls were correctly classifi ed as 
non-cancer. Moreover, with a lifetime risk of 1 in 9, it cannot be excluded that some 
of the control subjects currently are developing or carrying the disease. Unfortu-
nately, since the control group consisted of anonymous symptom-free subjects it was 
impossible to retrieve the current physical state. The misclassifi ed cancer patients 
had varying early stages of disease, from stage I to IIB. However, the fact that all but 
one DCIS patients was recognised in the cancer group, adds to its possible future 
applicability as a tool for early detection. 
More importantly, in the independent validation set the classifi er demonstrated a 
sensitivity and specifi city of 72% and 92% respectively. While for the misclassifi ed 
controls in the validation set the current physical state was also unknown due to 
their anonymity, the current physical state could easily be retrieved for the misclas-
sifi ed patients. Histological reports showed that one of them had DCIS and two 
of them were diagnosed with stage I disease. In this case the breast tumour had 






non-cancer group, which was confi rmed from the treatment chart at the time of 
blood collection. When this sample would have been excluded of the analysis, the 
specifi city of the classifi er would increase even more in the validation set. Especially 
this high specifi city adds to the potential of serum protein profi les to screen women 
at high risk for breast cancer, since there appears to be a low chance of false positive 
test results and unnecessary treatment will be avoided. When combined with mam-
mography the positive predictive value of the proteomic pattern approach could be 
assessed in a high risk population.[22] 
Since a potential drawback of any approach with high dimensional data is the 
tendency to discover patterns among many variables that may not be a direct re-
sult of the pathological state but rather a result of pre-analytical characteristics the 
need of an independent validation set has been stressed extensively.[14;23;24] In 
our previous studies, the use of an independent validation set was not possible 
due the relatively small sample. Therefore, until now we advocated a thorough 
and stringent study design and double cross-validation of the classifi cation model.
[24] This procedure avoided the need for separate test and validation sets to yield 
unbiased error rate estimates. However, in the current study discriminating protein 
profi les for the detection of breast cancer could be validated using an independent 
dataset. Nevertheless, the classifi er in the calibration set was constructed following 
stringent demands. Again, a randomised block design was used to avoid observa-
tional bias, ensuring that no batch effects were introduced and artifi cial between-
group separations excluded.[20;21] However, the issue clinically most relevant is the 
use of an independent validation set for the classifi cation of diseased versus healthy 
individuals. This is primarily based on a specifi c problem in the discovery-based 
research fi eld of clinical proteomics, namely overfi tting. Overfi tting may occur when 
multivariate models show apparent discrimination that is actually caused by data 
over-interpretation, and hence give rise to results that are not reproducible.[14;17;18] 
Therefore, protection against overfi tting of the classifi er was maintained by using the 
double cross validation in the calibration set. In this way, maximal reliability of the 
classifi er was obtained by this procedure. Then, the performance of the classifi er was 
tested in the independent validation set and it proved that breast cancer can indeed 
reliably be detected by discriminating protein profi les.
Obviously, other most common pitfalls in clinical proteomics such as sample col-
lection, pre-analytical conditions and biological variation were avoided.[15;16;25] 
Therefore, serum sample collection and pre-analytical factors were rigorously stan-
dardised.[19] Furthermore, subjects in both groups were matched for age, although 
age is recently shown not to bias serum peptodomics.[26] In addition, patient samples 
from all stages of breast cancer were randomly distributed over three different target 
plates, excluding these factors as a discriminator in the current classifi er. 
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Interestingly, the classifi cation between cancer and non-cancer was performed 
using more principal components than in our earlier work when C8 magnetic beads 
were used. In the present study more than 2 peaks were responsible for most on 
the between group separation. As shown in fi gure 2 and 5, these include peaks with 
1451, 1617, 5906 and 6644 m/z. Since the primary focus of this study was to assess 
and validate the feasibility of protein profi les based detection of breast cancer and 
therefore merely concentrated on pattern diagnostics, we have not identifi ed these 
potential biomarkers yet. However, the controversy about the use of protein profi les 
as a pattern diagnostic without analysis of the diagnostic biomarkers still remains to 
be solved for its clinical application. Some have argued that low molecular weight 
proteins in serum, the serum peptidome, is nothing but aspecifi c biological trash and 
therefore does not yield any reliable biomarkers in the currently technically avail-
able mass range.[27-29] Nonetheless, recently it was postulated that although dis-
criminating peptides do indeed belong to well known coagulation and complement 
pathways, their patterns or signatures do most certainly indicate the presence of 
cancer.[26] This study showed that most of the cancer-type specifi c biomarker frag-
ments were generated in patient serum by enzymatic cleavage at previously known 
endoproteage cleavage sites after the blood sample was collected.[30] Villanueva et 
al. postulated that these cancer-specifi c low molecular weight proteins in the serum 
peptidome are an indirect snapshot of the enzyme activity in tumour cells. We sup-
port their hypothesis that discriminating serum protein profi les are a compilation of 
surrogate markers for the detection and classifi cation of certain types of tumours. 
In conclusion, the present study demonstrated that serum protein profi les gener-
ated with mass spectrometry could be indicative of the presence breast cancer. In 
order to obtain most realistic estimates of the discriminating power of serum protein 
profi les a classifi er was constructed in a randomised block design. Maximal reliability 
in classifi cation was achieved through double cross-validation of the classifi er while 
maintaining protection against overfi tting. Principally the potential of proteomic sig-
natures from high dimensional mass spectrometry data as highly reliable diagnostic 
classifi ers for the detection of breast cancer was actually confi rmed in the indepen-
dent validation set. The fact that high sensitivity and specifi city could be maintained 
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There is an urgent need for new biomarkers in oncology to improve early detection, 
monitor disease outcome and fi nd targets for more individualised therapy. A fi eld 
of recent interest is clinical proteomics, which was reported to lead to high sensitiv-
ity and specifi cities for early detection of several solid tumours.[1;2] This emerging 
fi eld uses mass spectrometry based protein profi les/patterns of easy accessible body 
fl uids to distinguish cancer from none-cancer patients. This would be a solution to 
the problem that cancer is often diagnosed in late stages, when curative resection of 
the diseased organ is not possible anymore and the disease has already metastised, 
dropping survival rates dramatically. However, after the initial hype in early 2002 
critical noise has been heard on several aspects of serum proteomics. In this paper 
we describe the hopes and fears for the introduction of clinical proteomics for (early) 
detection of CRC. 
COLORECTAL CANCER
Colorectal adenocarcinoma is the third most common cancer and the fourth most 
frequent cause of death due to cancer worldwide. Worldwide almost one million 
new cases occur yearly, with 492,000 related deaths.[3] In developed countries it is 
the second most common tumour, with a lifetime risk of 5%, but its incidence and 
mortality are now decreasing.[4;5] Surgery is the cornerstone of therapy when the 
disease is confi ned to the bowel wall. This results in 70 to 80% of patients who have 
tumours that, at diagnosis, can be resected with curative intent.[6] After curative sur-
gery the fi ve-year survival rate for patients with localised disease is 90%, decreasing 
to 65% in case of metastised disease in the lymph nodes. Adjuvant radiation therapy, 
chemotherapy, or both are useful in selected patients. Classifi cation of tumours into 
pathogenetical subtypes with distinct clinical courses enables clinicians to target 
therapy. For CRC TNM staging system remains the golden standard and relies entirely 
on morphological appearance of the tumour. However, tumours with similar histo-
pathological characteristics may have different clinical outcome and responsiveness 
to therapy.[7] Therefore, more individualised treatment would benefi t the individual 
patient and avoid unnecessary morbidity. Nonetheless, early detection of CRC will 
increase survival most, in view of the fact that it is well recognised that CRC arises 
from a multistep sequence of genetic alterations that result in the transformation 
of normal mucosa to a precursor adenoma and ultimately to carcinoma. Given the 








In cancer research biomarkers are molecules that indicate the presence of cancer in 
the body. Most biomarkers are based on abnormal changes or mutation in genes, 
RNA, proteins and metabolites. Since the molecular changes that occur during tu-
mour development can take place over a number of years, some biomarkers can 
potentially be used to detect colorectal cancer early. Furthermore, they might be 
used to predict prognosis, monitor disease progression and therapeutic response. 
Gion et al. classifi ed different circulating biomarkers according to their clinical ap-
plication.[11] These candidate biomarkers however, are frequently found in relatively 
low concentrations amid a sea of other biomolecules, so biomarker research and 
possible diagnostic tests depend critically on the ability to make high sensitive and 
accurate biochemical measurements. Ideally, such biomarkers should be specifi c to 
the disease and easy accessible, such as serum, plasma or urine, increasing their 
clinical applicability.
Carcinoembryonic antigen (CEA) is the best-characterised serologic tumour marker 
for CRC. However, its use as a population based screening tool for early detection 
and diagnosis of CRC is hindered by its low sensitivity and specifi city. Fletcher 
showed that for screening purposes in a normal population, a cut-off concentra-
tion of 2.5 µg/L CEA would yield a sensitivity of 30-40%. Based on these data he 
calculated that there would be 250 false positive tests for every true positive test, 
i.e. a patient with cancer. Furthermore, 60% of the cancers would not be detected. 
The same poor sensitivity applies for diagnosis of CRC. In addition, as CEA can be 
elevated in the absence of malignancy, specifi city is also impaired.[12-15]
Faecal occult-blood testing (FOBT) is another biomarker for which clinical trials 
have shown evidence of a decreased risk of death. This approach is a non-invasive 
option that limits the need for follow-up colonoscopy to patients with evidence 
of bleeding. Neoplasms bleed intermittently, however, allowing many to escape 
detection with faecal occult-blood testing. Annual retesting is therefore necessary 
but is still insuffi cient, detecting only 25 to 50% of colorectal cancers and 10% of 
adenomas. The specifi city of FOBT is also limited by frequent false positive reactions 
to dietary compounds, medications, and gastrointestinal bleeding from causes other 
than colorectal cancer.[16-18]
A NEW DIAGNOSTIC PARADIGM: CLINICAL PROTEOMICS
In 2002 several studies discriminated patients with various cancers from healthy 
subjects on the basis of presence/absence of multiple low-molecular-weight serum 
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proteins using SELDI-TOF mass spectrometry technologies.[19-22] The authors hy-
pothesised that proteomic patterns are correlated to biological events occurring in 
the entire organism and are likely to change in the presence of disease. New types 
of bioinformatic pattern recognition algorithms were used to identify patterns of 
protein changes in order to discriminate cancer patients from healthy individuals 
with promising results. 
Petricoin and his co-workers stated that fi nding a single disease-related biomarker 
is like searching for a needle in a haystack; each entity has to be separated and 
identifi ed individually.[23;24] Moreover, they postulated that the blood proteome 
constantly changes as a consequence of the perfusion of the diseased organ add-
ing, subtracting, or modifying the circulating proteome. These differences might 
be the result of proteins being abnormally produced or shed and added to the 
serum proteome, clipped or modifi ed as a consequence of the disease process, 
or subtracted from the proteome owing to disease-related proteolytic degradation 
pathways. Therefore, protein pattern diagnostics would provide easier and more 
reliable tools for detection of cancer. The advantages of the SELDI proteomic pat-
tern approach were stressed in several papers. In addition to the high sensitivity 
and specifi city, cost-effectiveness, easy accessibility of body fl uid and especially the 
high-throughput, ultimately allowing application in future screening studies, were 
mentioned.[20;25] Next to these hopeful voices, soon critical notes were made on 
analytical reproducibility and the use of the so-called black box approach, lacking 
identifi cation of discriminating proteins. 
In the next paragraphs this paper will focus on the current status of clinical pro-
teomics research in oncology and will refl ect on pitfalls and fears in this relatively 
new area in clinical medicine: reproducibility issues and pre-analytical factors; statis-
tical issues; and identifi cation and nature of discriminating proteins/peptides.
REPRODUCIBILITY ISSUES AND PRE-ANALYTICAL FACTORS
Boguski and McIntosh were among the fi rst to argue that serum proteomics may be 
susceptible to observational biases. They stated that any confounding factor could 
conceivably cause a phenotypic response that might be confused with a specifi c 
characteristic of the disease process under study.[26] Confounding factors such as 
smoking, diet and preoperative stress, but also sample collection and quality, trouble 
a reliable and clear differentiation of a normal or malignant status. Another cause 
for concern mentioned in this study, is the sample quality and number. The authors 
favoured use of homogeneous groups with suffi cient sample size and stringent stan-






studies.[27;28] Another critical study questioned the reliability of the presence of 
statistically signifi cant signals at M/Z values less than 500, as used in one of the fi rst 
studies. Sorace et al. claimed that the presence of statistically signifi cant bands of 
low M/Z includes degradation products of higher molecular weight macromolecules 
or a matrix effect. Furthermore, this study cautioned for poor reproducibility of 
experimental conditions of chip based mass spectrometry.[29] This is also reported 
by another group, which showed the poor reproducibility of the SELDI-TOF ovarian 
cancer data. Baggerly and colleagues postulated that this could partly be contributed 
to baseline correction, poor sample features in noise regions and even a change 
of protocol mid-experiment.[30] Most importantly, the promising results that were 
reported earlier could not be reproduced and therefore stressed the importance of 
standardised approaches, stringent experimental design. Furthermore, their study 
pointed out that strong pre-processing of the protein spectra is required in order tot 
obtain reliable classifi cation results in the search for new biomarkers. 
Possible confounding factors can be categorised into three sources of variation and 
bias: biological variation, pre-analytical variation and analytical reproducibility. Bio-
logical variation, consist of both environmental and individual factors, such as race, 
age, diet, smoking, stress, general physical condition, and use of drugs, and may 
also infl uence serum protein profi les. However, at the present no data have been 
published on this source of variation. Nevertheless, in a previous study our group 
analysed pre-analytical and reproducibility issues of our MALDI-TOF approach.[31] 
The pre-analytical variations corresponded to the logistical conditions in the routine 
clinical setting; the effects of sample handling and storage. So far, only few other 
studies have reported on the effects of different serum sample preparations and the 
use of a magnetic-beads-based approach to capture and concentrate serum proteins 
for MALDI-TOF mass spectrometry.[32-34] Where Villanueva et al. mostly focused on 
infl uences of different magnetic beads capturing and its automation on the reproduc-
ibility of serum protein profi les, Baumann and co-workers mainly studied pre-ana-
lytical variation of sample handling. In table 1, different results of sample handling 
experiments of the above mentioned studies are summarised. For clinical studies the 
use of two freeze/thaw cycles is recommended by 3 out of 4 manuscripts. This in 
mainly due to logistical reasons, such as the ´standard´ for centralised sample col-
lection in large hospitals. The point all authors agreed on is the infl uence of sample 
handling, i.e. the time venous blood is left to stand before serum centrifugation. This 
aspect appears to account for the largest effect on serum or plasma protein profi les. 
Consequently, standardised sample collection and a well documented population are 
recommended in all performed studies. Standardised protocols should be used from 
the point of sample collection, sample handling, storage and freezing of the samples. 
Although the importance of homogeneity and uniformity within sample groups must 
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once again be stressed, variation of such factors can not totally be excluded in a 
clinical setting. In all, when these recommendations are strictly followed and both 
clinical and analytical factors are controlled, we think that the methodology can be 
standardised to a level which allows application as a tool in biomarker discovery. 
STATISTICAL ISSUES
As in all research with high dimensional data, two practical realities constrain the 
analysis of mass spectra in proteomics. The fi rst is the ‘curse of dimensionality’: 
the number of features characterizing these data is in the thousands or tens of 
thousands. The second is the ‘curse of dataset sparsity’: the number of samples is 
limited. Somorjai et al. showed the infl uences of these two curses on classifi cation 
outcomes. Both the sample per feature ratio, which should be 5 to 10 ideally, and 
feature selection are pivotal importance for reliable classifi cation and biological op-
timal relevance.[35;36] 
Previous to any feature selection or classifi cation, raw mass spectra have to be 
submitted to so-called pre-processing. During this process noise of protein/peptide 
mass spectra is reduced and spectra are normalised. Furthermore, smoothing, bin-
ning and baseline correction are also performed during pre-processing of the data. 
Currently, there is a lot of discussion between several groups on how to establish 
the best method, because data pre-processing is extremely important. There are 
complex interactions between baseline subtraction, normalization, noise estimation, 
and peak identifi cation, and therefore these steps should not be considered in isola-
tion.[31;37-40]
Another recurrent topic for debate is the bioinformatic approach and statistical 
analysis of protein spectra. Clinically most relevant is the issue of an independent 
validation set for the classifi cation of diseased versus healthy individuals. This is pri-
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marily based on a specifi c problem in the discovery-based research fi eld of clinical 
proteomics, namely overfi tting. Overfi tting may occur in the analysis of large datasets 
when multivariate models show apparent discrimination that is actually caused by 
data over-interpretation, and hence give rise to results that are not reproducible.
[30;41;42] The chance of overfi tting, however, can be reduced by appropriate ap-
plication of validatory estimation and assessment, such as through application of 
double cross-validation, when properly implemented.[43] Although we have shown 
this in a previous study, the general opinion is in favor performing a classifi cation 
study with independent validation. Furthermore, feature selection is also given a lot 
of attention by statisticians in the fi eld. Several experimental investigations have been 
made with different peak feature selection methods. A common approach thus far 
is analysing the data in two phases. First, the peaks in the spectra are extracted and 
quantifi ed. Secondly, a resulting matrix of peak quantifi cations is created. For more 
detailed information on this statistical matter, we refer to the literature.[37;44-46]
IDENTIFICATION AND NATURE OF DISCRIMINATING PROTEINS
The controversy about the use of protein profi les as a pattern diagnostic without 
identifi cation of the individual diagnostic biomarkers remains to be solved before 
its clinical application. Whereas the fi rst clinical proteomics studies published their 
classifi cation method mainly as a black box study, nowadays identifi cation of the 
most discriminating proteins or peptides is required for publication in most scien-
tifi c journals. Identifi cation and functional analysis of these discriminating proteins/
peptides might render new insights on tumour development and environmental 
responsiveness, which could eventually be translated into new diagnostic and prog-
nostic insights for the clinician. Unfortunately, little success has been booked so far 
in assigning reproducible discriminating biomarkers.[35;42]
Furthermore, several studies have identifi ed their discriminating peaks as compo-
nents of the coagulation cascade or complement system.[47-51] So, in contrast to the 
original refl ection that discriminating proteomic patterns would identify cancer-spe-
cifi c proteins, it appears that these potential markers belong to the normal serum and 
plasma proteome. Consequently, some investigators have argued that low molecular 
weight proteins in serum, the serum peptidome, is nothing but aspecifi c biological 
trash and therefore does not yield any reliable biomarkers in the currently technically 
available mass range.[29;52] Others have proposed that the discriminatory protein 
peaks represent acute phase reactants that are present in serum in extremely high 
concentrations.[49;53] Conversely, recently a study reported that although discrimi-
nating peptides do indeed belong to the well known coagulation and complement 
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pathways, their patterns or signatures can nevertheless indicate the presence of 
cancer. Villanueva et al. showed that most of the cancer-type specifi c biomarker frag-
ments were generated in patient serum by enzymatic cleavage at previously known 
endoprotease cleavage sites after the blood sample was collected.[54;55] They postu-
lated that the discriminating peptides originated after ex vivo proteolysis by tumour 
specifi c proteases of high abundance protein fragments primarily generated by the 
coagulation and complement enzymatic cascades. In this view, they consider these 
cancer-specifi c low molecular weight proteins in the serum peptidome an indirect 
snapshot of the enzyme activity in tumour cells. We support their hypothesis that 
proteolytic process profi les in the serum peptidome hold important information that 
may have direct clinical utility as a surrogate marker for the detection and classifi ca-
tion of certain types of tumours. Unique proteases may be shed by tumour cells or 
refl ect activity of the host immune response, which may contribute to new proteins 
such as chemokines and lymfokines. These processes result in subtle changes in 
low molecular proteomic signatures, which may ultimately be used for classifi cation 
methods in various cancers and disease in the future.[54] Proteases have been exten-
sively implicated in the development and progression of cancer.[56;57] Song et al. 
recently stated that proteolytic processing of high abundance host-response proteins 
actually amplifi es the signal of potentially low-abundance biologically active disease 
markers such as proteases. Therefore, it might be expected that more convenient and 
reliable blood proteins and peptides simply serve as an endogenous substrate pool 
for proteases as surrogate markers for the detection and classifi cation of cancer.[58]
Another recurrent topic of debate is which blood component is best used for pro-
tein profi ling and peptidome analysis. Some investigators favour the use of plasma 
because they presume that, in serum, ongoing enzymatic activity, occurring during 
clotting, is likely to cleave even proteins that are not involved in biological relevant 
pathways.[53;59] Others, however, advocate the use of serum. We support the hy-
pothesis that since the kidneys rapidly clear peptides smaller than 4 kDa which 
are in vivo generated in the circulation, the majority of peptides in blood samples 
exist from ex vivo proteolysis. This explains that low abundance proteins, including 
possible tumour markers, may be totally obscured and not retraceable during direct 
mass spectrometry. However, it has recently been shown that exogenous proteases 
are functionally measurable in serum, yet in higher concentrations than in plasma.
[54] 
Functional proteomics studies allow the investigation of environmental factors over 
time, rendering the monitoring of metabolic responses to various stimuli. Hence, 
post translational modifi cations can be studied, whereas they can not be detected 
by genomic studies. Posttranslational modifi cations changes like glycosylation of 






cell behaviour and can be detected using mass spectrometry due to characteristic 
mass shifts.[60] We expect that both phosphoproteomics and/or glycoproteomics, 
enabling study of crucial post translational modifi cations of proteins in the cancer 
pathway, will revolutionize our understanding of the function of these proteins, and 
hence render new insights for monitoring and therapy.
CLINICAL PROTEOMICS IN CRC 
So far, few protein profi ling studies have been published on the detection of CRC, 
of two were based on SELDI/TOF and one on MALDI-TOF mass spectrometry. The 
fi rst SELDI/TOF study showed seven potential biomarkers that could differentiate 
CRC patients from patients with colorectal adenoma with a sensitivity of 89% and 
specifi city of 83%. The seven potential biomarkers have a large range in mass values, 
differing from 4654 till 21,742 Da.[61] A more recent published study found 5 pos-
sible biomarkers to differentiate between healthy control subjects and CRC patients. 
For three of these potential markers they found a sensitivity and specifi city between 
65% and 90%. They reported that m/z 3100, 3300, 4500, 6600 and 28,000 were the 
most important biomarkers.[62] Our group used MALDI-TOF mass spectrometry to 
differentiate CRC patients from healthy controls. In a randomised block design pre-
operative serum samples obtained from 66 colorectal cancer patients and 50 controls 
were used to generate high-resolution MALDI-TOF protein profi les.[43] After pre-
processing of the spectra, linear discriminant analysis with double cross-validation, 
based on principal component analysis was used to classify the protein profi les. A 
total recognition rate of 92.6%, a sensitivity of 95.2% and a specifi city of 90.0% for 
the detection of CRC were shown. In our study two fi rst principal components ac-
counted for most of the between-group separation, both with a m/z between 1000 
and 2000 Da. 
Although a lot of research has been done using 2D gel electrophoresis to detect 
possible biomarkers and targets for CRC, this falls outside the scope of this paper 
since this technique can not be scaled up to a directly applicable diagnostic test. On 
the other hand, recently a screening assay based on APC protein truncation test has 
been proposed and other studies mention the potential use of protein microarrays.
[2;63-65] However, studies linking large protein expression patterns with clinical out-
come in colorectal cancer are still in their infancy. To be able to predict occurrence 
of disease, and treatment outcome, more studies on genotype-phenotype correla-
tions are needed both in sporadic and in hereditary colorectal cancer. 
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FUTURE PERSPECTIVES
The best anticancer strategies still rely on early detection followed by close monitor-
ing for early relapse so that therapies can be appropriately adjusted.[66] In addition, 
new targets for therapy are a constant subject of study in oncology. In fact, increased 
understanding of the molecular mechanisms of cancer progression may refi ne treat-
ment and management of patients. Advances in genomics and proteomics may lead 
to earlier detection of cancer and may enable a more precise classifi cation of (smaller 
subsets of) patients based on their predicted response to individual therapies. Con-
ceptually, proteomics is more suitable than genomics for novel targeted therapies, 
since most of protein biomarkers are based on aberrant protein signalling circuits 
represented by post translational modifi cations. The dynamic range of the proteome 
allows more insight in the functional state of a cell, tissue or organ over time. Be-
sides, protein profi ling and classifi cation of several components of multiple aberrant 
cell signalling cascades would be expected to predict disease behaviour better than 
just single pathways in isolation.[64] Therefore, proteomics could be expected to 
render better insight in pathogenetic mechanisms, disease progression and treatment 
response. This is of paramount importance as cancer advances dynamically and 
affects heterogeneous cell populations, either as a part of cancer or as a part of a 
tumour-host reaction.[49;67] 
Further refi nement of serum protein profi les is needed before these mass spec-
trometry based techniques become part of clinical routine. Nowadays, several stud-
ies have carefully evaluated reproducibility, automation, sample throughput and 
sensitivity of serum proteomic techniques. The fi rst problems related to these factors 
seem to have been overcome due to stringent standardised approaches as described 
earlier. However, proteomics studies still have several drawbacks: 1) current tools 
only allow narrow-range analyses, 2) identifi cation of proteins of interest remains 
cumbersome, 3) protein studies address mixtures of high complexity. Hence, due to 
the dynamic ranges of the human proteome and the lack of amplifi cation methods 
in protein studies, targeted proteomics techniques for (quantitative) identifi cation 
of low-abundant proteins have to be further investigated.[68] Another approach to 
study proteins at a functional level might be the use of array-based proteomics 
platforms. This techniques offers the potential for highly multiplex and sensitive 
analysis of serum or tumour proteins.[64] Using this direct approach of studying the 
proteomic circuitry would theoretically allow for the creation of functional signalling 
maps of cancers, even at the level of the individual patient. Regarding identifi cation 
of potential biomarkers, limitations of direct MS/MS have been stressed before as 






In the next era research in oncology will drift to more individualised medicine. 
In this view, molecular profi ling forms a welcome addition to the pathology report 
of cancer. Until now, histopathological staging and demographics have been used 
to predict disease outcome. However, we believe that protein profi ling and other 
proteomics techniques may lead to more individualised medicine and tailor made 
therapy.[69;70] At fi rst, both approaches should be used complementary instead of 
competitively.
It is unlikely that in the next decade, serum protein profi les will certainly replace 
the current gold standard colonoscopy for the diagnosis of CRC. Nevertheless, we 
hypothesise that MALDI-TOF based serum protein profi les, once validated in inde-
pendent studies, could be used as selection criteria for the more invasive and time 
consuming diagnostic colonoscopy (Figure 1). Eventually, with the present debate 
on screenings programs for colorectal cancer in several countries, clinical proteom-
ics may replace and surpass the use of faecal occult-blood testing (FOBT). When in 
independent validation studies sensitivity and specifi city remain about 90% protein 
profi ling might even replace FOBT, since this approach has a lower specifi city and 
a number of disadvantages. Non-bleeding tumours and more relevant, polyps and 
adenomas can not be detected using FOBT, whereas we expect to realise this with 
serum protein profi ling within the next decade.[17;18]
So, although the current reality may not have kept pace with previous expectations 
and the translation from bench to beside is more laborious than initially thought, 
there is supporting evidence for the potential great use of clinical proteomics in 
oncology. Particularly, when efforts for technical innovations to further increase sen-




















Figure 1.  Flow chart of possible clinical application of MALDI-TOF 
Figure 1. Flow chart of possible clinical application of MALDI-TOF
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tive methods for protein identifi cation on alternations are developed. In combination 
with the use and set-up of well-defi ned cases with well documented serum banks, 
including not only CRC samples, but also infl ammatory disease and polyps, serum 
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Kanker van de dikke darm is een van de meest voorkomende vormen van kanker in 
de westerse wereld. In Nederland worden er jaarlijks circa 10.000 nieuwe patiënten 
gedocumenteerd, terwijl er wereldwijd bijna 900.000 nieuwe gevallen per jaar wor-
den gemeld. Over het algemeen geldt dat hoe eerder de diagnose gesteld wordt, hoe 
groter de kans dat een curatieve resectie mogelijk is en dus de kans op een betere 
overleving. Helaas wordt kanker van de dikkedarm vaak pas in een laat stadium ge-
diagnosticeerd en behandeld, met als gevolg een relatief slechte prognose. Daarom 
bestaat er een dringende behoefte aan een weinig invasief, specifi ek onderzoek dat 
de diagnose reeds in een vroeg ziektestadium stelt, waardoor de behandeling eerder 
gestart en tevens beter op het individu toegespitst kan worden.
De gouden standaard voor de diagnostiek van primaire colorectale tumoren is de 
colonoscopie. Afgezien van het invasieve karakter en de voor patiënten onprettige 
darmvoorbereiding zijn ook de kosten en tijd een beperkende factor om deze me-
thode grootschalig te gebruiken in bijvoorbeeld een bevolkingsonderzoek. Naast de 
colonoscopie wordt tot op heden de concentratie van het eiwit CarcinoEmbryonic 
Antigen (CEA) in het bloed gebruikt als diagnostische marker voor de aanwezigheid 
van colorectale tumoren, vooral tijdens de follow-up. Echter als diagnostische test 
voor het detecteren van primaire darmtumoren heeft CEA een lage sensitiviteit van 
44% en specifi citeit van 88%. Door deze matige betrouwbaarheid is de techniek niet 
geschikt voor vroegdiagnostiek toepassing op grote schaal, laat staan voor screenings 
doeleinden. Daarentegen is na resectie van de primaire tumor het verloop van de 
CEA spiegel wel een betrouwbare indicator voor de ziektestatus. Een relatief nieuwe 
screeningstechniek voor dikke darmkanker is de Fecale Occulte Bloed Test (FOBT), 
een test die spoortjes bloed aantoont in de ontlasting. Het is een non-invasieve tech-
niek die de noodzaak voor follow-up colonoscopie limiteert. Een nadeel is echter dat 
tumoren die intermitterend bloeden, aan detectie door FOBT kunnen ontsnappen. 
Bovendien is de specifi citeit van de test beperkt doordat er frequent foutpositieve 
uitslagen optreden als gevolg van dieet (rauw vlees), medicatie en andere oorzaken 
van gastro-intestinale bloeding dan darmkanker.
Recapitulerend is er momenteel geen gebruiksvriendelijke diagnostische test met 
voldoende hoge sensitiviteit en specifi citeit om de ziekte in een vroeg stadium op te 
sporen. Nochtans is er grote behoefte aan gevoelige technieken om tumormarkers 
te identifi ceren, waarmee detectie van zowel primaire tumoren als recidiverende 
ziekte of metastasen in een vroeg stadium mogelijk wordt. Hierdoor kan er eerder 
tot behandeling van tumor(recidief) of metastasen worden overgegaan, wat tot een 
betere overleving zal leiden.
In hoofdstuk 1 wordt een introductie gegeven over een nieuwe en gevoelige 
techniek, proteomics genaamd; een zich snel ontwikkelend onderzoeksveld dat ten 






organisme in kaart te brengen. Na het afronden van het humane genoomproject 
is het mogelijk geworden om een groot aantal van deze eiwitten te identifi ceren. 
Proteomics is gebaseerd op de separatie en visualisatie van complexe eiwitmeng-
sels. Zo kunnen eiwitten die een veranderd expressiepatroon vertonen, worden 
opgespoord en in verband worden gebracht met de aanwezigheid van een tumor. 
Deze discriminerende eiwitprofi elen kunnen als diagnostische of prognostische test 
gebruikt worden, of zelfs targets vormen voor nieuwe behandelingsstrategieën. De 
meeste clinical proteomics studies binnen de oncologie richten zich op het detec-
teren van verschillen in eiwitexpressie in serummonsters tussen gezonde proefper-
sonen en patiënten met een maligniteit. Deze techniek werd in 2002 voor het eerst 
toegepast bij de detectie van ovariumcarcinoom. Deze studie was, afgezien van de 
veelbelovende resultaten voor de opsporing van een solide tumor, erg vernieuwend 
door het gebruik van patroonherkenning van meerdere eiwitten zonder dat deze 
geïdentifi ceerd waren, een zogenaamde black box methode. Deze aanpak kreeg al 
snel navolging en ook de resultaten van detectie van prostaat en longkanker waren 
zeer veelbelovend in volgende studies. 
De eiwitprofi elen worden gemeten met behulp van massaspectrometrie, een 
veelzijdige techniek die gebruikt kan worden voor identifi catie, kwantifi ceren en 
profi lering van isotopen, moleculen en molecuulcomplexen in kleine hoeveelheden 
van chemische en biologische mengsels. In een massaspectrometer worden indi-
viduele eiwitten van het serummonster in de gasfase geïoniseerd. Daarna worden 
de gevormde ionen versneld in een zeer precies geregeld elektrisch veld en in een 
vluchtbuis afgeschoten. De ionen worden vervolgens gescheiden op basis van hun 
massa/ ladingsverhouding (m/z) waarna de detectie volgt. Na de detectie wordt een 
massaspectrum gegenereerd als grafi ek, waarin de intensiteit (Y-as) van iedere m/z 
(X-as) wordt weergegeven.
Na initiële positieve reacties op de veelbelovende resultaten van het gebruik van 
eiwitprofi elen als patroonherkenning voor de aanwezigheid van een tumor, kwam 
er in de internationale literatuur kritiek op de reproduceerbaarheid en betrouwbaar-
heid van de massaspectrometrie. De vraag was of de classifi catieresultaten, die op 
basis van de eiwitprofi elen een individu aan de kanker of gezonde groep toewees, 
vertroebeld zouden worden door andere factoren. Verschil in experimentele om-
standigheden en individuele variaties werden aangewezen als potentiële co-factoren 
op eiwitprofi elen. Indien de eiwitprofi elen inderdaad zo gevoelig zouden zijn voor 
variaties in bloedafname, opslag, voorbewerking van het serum en het massaspec-
trometrie experiment, dan zou de eventuele klinische toepasbaarheid voor de toe-
komst drastisch afnemen. 
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Hoofdstuk 2 is een overzicht van de verschillende vormen van translationeel 
onderzoek die onze onderzoeksgroep verricht naar colorectale tumoren en kan als 
inleiding van het proteomics onderzoek gelezen worden. 
Om te verifi ëren of de eiwitprofi elen inderdaad onderhevig zijn aan variatie door 
externe factoren onderzochten wij in hoofdstuk 3 van dit proefschrift de reprodu-
ceerbaarheid van onze methode en de invloed van verschillende logistieke preana-
lytische variaties de serum eiwitprofi elen. Om zoveel mogelijk de reële klinische 
situatie na te bootsen, werden er experiment gedaan met verschil in tijd tussen 
afdraaien van de bloedbuis tot serum, verschil in afname tijdstip over de dag en het 
uitvoeren van meerdere vries -en dooicycli met een serummonster. Uit de resultaten 
van deze experimenten bleek dat de tijd dat het bloed staat voordat het serum wordt 
gecentrifugeerd de grootste variatie op serum eiwitprofi elen heeft. Er was een te ver-
waarlozen invloed van het afnametijdstip op de dag en ook het aantal vries -en dooi 
cycli, mits kleiner dan 4, had weinig invloed op de variatie van de massaspectra. 
Een ander belangrijk aspect voor de praktische bruikbaarheid van een toekomstige 
serumtest voor de detectie van colorectale tumoren, is de invloed van maaltijden 
op de eiwitprofi elen. Als klein onderdeel van de experimenten naar de invloed 
van preanalytische variatie vergeleken wij tevens eiwitprofi elen van een individu in 
nuchtere toestand en na maaltijden. Hierin was echter geen verschil te vinden en 
daarmee werd geconcludeerd dat dit geen invloed heeft op de serum eiwitprofi elen. 
De gehele studie was één van de eerste studies die de reproduceerbaarheid van de 
eigen methodiek onderzocht en op basis van deze resultaten een gestandaardiseerde 
aanpak voor alle verdere studies aanbeval. Het belang van het gebruik van een 
uniforme en goed gedocumenteerde populatie en een gestandaardiseerd afname 
protocol voor de serummonsters werd in alle studies onderstreept. Mits aan deze 
voorwaarden wordt voldaan, kan met behulp van discriminerende eiwitprofi elen 
betrouwbare classifi catie resultaten geboekt worden in het kankeronderzoek.
In hoofdstuk 4 en 5 wordt ingegaan op de resultaten die met behulp van dezelfde 
aanpak verkregen zijn om op basis van discriminerende serum eiwitprofi elen on-
derscheid te maken tussen patiënten met dikke darmkanker en gezonde controles. 
Hierbij voldeed elk geselecteerd serummonster aan het in hoofdstuk 3 opgestelde 
standaardprotocol. Naast de variatie in biologische en preanalytische factoren, is de 
statistische analyse een ander belangrijk onderwerp van discussie in de internatio-
nale literatuur. De eiwitspectra vormen hoogdimensionale data en brengen hierdoor 
direct enkele praktische bezwaren met zich mee. Gezien het hoge aantal datapunten 
per spectrum is voor een betrouwbare analyse een groot aantal monsters nodig. 
Daarnaast is het voor de opzet van de studie van belang dat de verschillende groepen 
binnen een experiment in dezelfde proporties aanwezig zijn. Echter de belangrijkste 






is het gebruik van een aparte training en validatie set in een klinische studie van 
groot belang. Het classifi catiemodel wordt berekend in een zogeheten trainingstest 
door te zoeken naar discriminerende eiwitprofi elen die het beste een verschil maken 
tussen de gezonde en de zieke groep. Vervolgens wordt in een validatie set met 
onafhankelijke patiënten en gezonde controles het classifi catiemodel getoetst en de 
sensitiviteit en specifi citeit van dit model berekend. Dit classifi catiemodel is een ei-
witprofi el waarvan de identiteit van de discriminerende eiwitten (pieken) onbekend 
is. Als aanvulling op deze black box benadering kan met behulp van dezelfde mas-
saspectrometer worden overgegaan op identifi catie van de discriminerende eiwitten. 
Er is nog veel onderzoek noodzakelijk alvorens er consensus bereikt kan worden 
over de optimale statistische en bioinformatica benadering van de hoogdimensionale 
data binnen de clinical proteomics studies.
Tot op heden is er slechts een summier aantal klinische studies verschenen die met 
clinical proteomics een maligniteit betrouwbaar hebben opgespoord. Het grootste 
manco tot op heden is dat de resultaten niet in een ander laboratorium bevestigd 
kunnen worden, maar ook dat de validatie van het eigen classifi catiemodel vaak 
te wensen over laat. Om dit en bovengenoemde valkuilen te vermijden heeft onze 
groep een zeer strikt opgezette classifi catie studie uitgevoerd voor de detectie van 
colorectale tumoren. Hoofdstuk 4 beschrijft de resultaten van het onderzoek naar de 
detectie van colorectale tumoren op basis van discriminerende eiwitprofi elen. Hier-
toe werden 66 patiënten met alle ziekte stadia, inclusief stadium IV patiënten met tot 
de lever beperkte metastasen, en 50 anonieme gezonde controles geïncludeerd. De 
monsters werden vervolgens gerandomiseerd, maar in gelijke proporties per groep 
over 3 platen verdeeld en op 3 achtereenvolgende dagen met de massaspectrometer 
gemeten. Dit leverde een zogeheten ‘randomised block design’ op, waarmee wij 
geprobeerd hebben om de classifi catieresultaten zo min mogelijk te beïnvloeden 
met experimentele of batcheffecten. Voor de statistische analyse hebben wij lineaire 
discriminantie gebruikt om een optimale scheiding te krijgen tussen beide groepen. 
In verband met het relatieve kleine aantal monsters dat voldeed aan het standaard 
inclusie en afname protocol, was het gebruik van een onafhankelijke validatieset 
niet mogelijk in deze studie. Daarom hebben wij gebruik gemaakt van een methode 
die maximaal betrouwbare resultaten oplevert binnen de mogelijkheden van een 
interne validatie. Met deze zogeheten dubbele kruisvalidatie van de eiwitprofi elen 
toonden de resultaten een sensitiviteit van 95% en een specifi citeit van 90% voor 
het de detectie van colorectale tumoren. De oppervlakte onder de ROC-curve voor 
deze test bedroeg 97% en toont hiermee de signifi cantie van het onderscheidend 
vermogen van de test aan. Het gebruik van dubbele kruisvalidatie binnen de dataset 
en de grote oppervlakte onder de ROC-curve tonen aan dat het classifi catiemodel 
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op daadwerkelijke informatie in de spectra en niet op toeval berust. De statistische 
achtergronden hiervan worden in hoofdstuk 5 beschreven. 
Dezelfde studie opzet, massaspectrometrie en statistische analyse is gebruikt in 
hoofdstuk 6, waar eiwitprofi elen van patiënten met mammacarcinomen werden 
vergeleken met die van gezonde controles met dezelfde gemiddelde leeftijd. Ook 
deze studie toonde veelbelovende resultaten voor de detectie van mammacarcimo-
nen, met een sensitiviteit van 100% en een specifi citeit van 97%. De discriminerende 
eiwitpieken werden andermaal in de laag moleculaire massa range gevonden, maar 
in andere correlaties dan bij de studie beschreven in hoofdstuk 3. Belangrijk echter 
was wederom de optimaal mogelijke betrouwbare classifi catie en het uitsluiten van 
zoveel mogelijk verstorende factoren. Identifi catie van deze pieken was ten tijde van 
het onderzoek nog niet volledig mogelijk, maar dit zal binnen afzienbare tijd wel 
gerealiseerd worden. 
In hoofdstuk 7 wordt het bewijs geleverd dat discriminerende eiwitprofi elen 
ook in een onafhankelijke validatieset op zeer betrouwbare wijze gebruikt kunnen 
worden voor de detectie van borstkanker. Het is de eerste proteomics studie die in 
een gerandomiseerde en onafhankelijke patiëntengroep (in een validatieset) deze 
veelbelovende resultaten laat zien.
In hoofdstuk 8 wordt een overzicht gegeven over de stand van zaken van cli-
nical proteomics binnen de oncologie en worden de toekomstige bevindingen en 
verwachtingen binnen het veld besproken. Hoewel clinical proteomics pas in de 
kinderschoenen verkeert, lijkt deze methode te kunnen bijdragen aan de urgente 
zoektocht naar nieuwe biomarkers binnen de oncologie. De eerste kinderziektes, de 
reproduceerbaarheid en preanalytische variaties, lijken overwonnen en maken be-
trouwbare classifi catiestudies mogelijk mits er volgens strikte standaardprotocollen 
met een homogene groep patiënten en sera gewerkt wordt. De samenstelling van de 
populatie blijft veel aandacht vragen om een maximale uniformiteit te waarborgen 
en zoveel mogelijk externe co-factoren te vermijden. Er is nog veel werk te ver-
richten aan de statistische benadering van klinische studies op basis van proteomics. 
Een ander punt van aandacht is de identiteit van de discriminerende eiwitten. De 
identiteit van de eiwitten zou kunnen leiden tot een beter begrip van pathomecha-
nisme van het ontstaan van colorectale tumoren, maar ook targets voor nieuwe be-
handelingen kunnen vormen. Er zijn hypothesen dat deze discriminerende eiwitten 
niet specifi ek voor de tumor zelf zijn, maar veelal acute fase eiwitten en afkomstig uit 
de complement- of stollingscascade. Momenteel wordt dit door meerdere groepen 
onderzocht. Dit is immers ook essentieel voor het bepalen van de specifi citeit van 
de eiwitprofi elen per verschillend type solide tumor. Hoewel er in de eerste jaren al 
veelbelovende resultaten zijn geboekt met vroegdetectie van kanker met behulp van 






plaats kan vinden. Dit proefschrift is echter een kleine stap in de juiste richting en 
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